



Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices – a cluster randomised controlled trial (PANDAs) in General Practice

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001469
Article Type:	Research
Date Submitted by the Author:	03-Jul-2012
Complete List of Authors:	Mathers, Nigel; University of Sheffield, Academic Unit of Primary Medical Care Ng, Chirk-Jen; University of Malaya, Department of Primary Care Medicine Campbell, Michael; University of Sheffield, SCHARR Colwell, Brigitte; University of Sheffield, Academic Unit of Primary Medical Care Brown, Ian; Sheffield Hallam University, Centre for Health and Social Care Research Bradley, Alastair; University of Sheffield, Academic Unit of Primary Medical Care
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	General practice / Family practice, Patient-centred medicine
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE, PRIMARY CARE

SCHOLARONE™
Manuscripts

Title:

Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices – a cluster randomised controlled trial (PANDAs) in General Practice.

Authors

Nigel Mathers¹ MD. PhD. FRCGP.

Chirk-Jenn Ng² MD. PhD.

Michael J Campbell³ BA. MSc. PhD. CStat.

Brigitte Colwell⁴ BA.

Ian Brown⁵ BSc. PhD. RN.

Alastair Bradley⁶ MB ChB. LLB. MRCP.

¹ Professor of Primary Medical Care, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

² Associate Professor, Department of Primary Care Medicine, Faculty of Medicine Building, University of Malaya, 50603 Kuala Lumpur Malaysia.

³ Professor of Medical Statistics, School of Health and Related Research, University of Sheffield, 30 Regent Street, Sheffield S1 4DA, UK.

⁴ Research Associate, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

⁵ Senior Lecturer, Centre for Health and Social Care Research, Sheffield Hallam University, Montgomery House, 32 Collegiate Crescent, Sheffield, S10 2BP, UK.

1
2
3 ⁶ NIHR In-Practice Training Fellow, Academic Unit of Primary Medical Care, University of
4
5 Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU,
6
7 UK
8
9

10
11 Corresponding Author: Professor Nigel Mathers, Academic Unit of Primary Medical Care,
12
13 University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road,
14
15 Sheffield S5 7AU. Email: n.mathers@sheffield.ac.uk
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE FOCUS:

- Does the use of the PANDAs decision aid in general practice improve decision quality and glycaemic control in people who are making treatment choices about their type 2 diabetes mellitus (T2DM) treatment, including whether or not to start insulin?

KEY MESSAGES:

- Patient decision aids provide evidence-based information about treatment options, help patients to clarify their values and guide them systematically to make an informed decision.
- The use of the PANDAs decision aid by doctors and nurses in usual NHS general practice with people who have T2DM and are making treatment choices reduces decision conflicts and improves knowledge, realistic expectations and patients' involvement in decision making.
- HbA1c levels were reduced in both groups at six months when compared to baseline (0.24% controls and 0.37% intervention) with a non-significant mean difference between the two groups of 0.351, $p=0.117$).

STRENGTHS AND LIMITATIONS

- This study was underpowered to detect a minimally, clinically important difference in glycaemic control between the two groups due to slow recruitment.
- There was no blinding in this study due to the nature of the intervention which may have influenced the outcome assessment.
- This was a pragmatic trial and there may have been variations in how the decision aid was used in different General Practices which may have diluted the effect of the study.

Abstract

Objective

To determine the effectiveness of a patient decision aid (PDA) to improve decision quality and glycaemic control in people with diabetes making treatment choices using a cluster RCT.

Design

A cluster randomised controlled trial.

Setting

49 general practices in UK randomised into intervention (n=25) and control (n=24).

Participants

General Practices: Inclusion criteria: > 4 medical partners; list size > 7000; and a diabetes register with > 1% of practice population. 191 Practices assessed for eligibility, 49 Practices randomised and completed the study.

Patients: People with T2DM taking at least two oral glucose-lowering drugs with maximum tolerated dose with an HbA1c greater than 7.4% (IFCC HbA1c >57mmol/mol) or advised in the preceding six months to add or consider changing to insulin therapy. Exclusion criteria: currently using insulin therapy; difficulty reading or understanding English; difficulty in understanding the purpose of the study; visual or cognitive impairment or mentally ill. 182 assessed for eligibility, 175 randomised to 95 intervention and 80 controls, 167 completion and analysis.

Intervention

Brief training of clinicians and use of PDA with patients in single consultation.

Primary Outcomes

Decision quality (decisional conflict scores, knowledge, realistic expectations and autonomy) and glycaemic control (glycosolated haemoglobin, HbA1c).

Secondary Outcomes

Knowledge and realistic expectations of the risks and benefits of insulin therapy and diabetic complications.

Results

Intervention Group: lower total decisional conflict scores (17.4 v 25.2, $p<0.001$); better knowledge (51.6% v 28.8%, $p<0.001$); realistic expectations (risk of ‘hypo’, ‘weight gain’, ‘complications’; 81.0% v 5.2%, 70.5% v 5.3%, 26.3% v 5.0% respectively, $p<0.001$); and were more autonomous in decision making (64.1% v 42.9%, $p=0.012$).

No significant difference in the glycaemic control between the two groups.

Conclusions

Use of the PANDAs decision aid reduces decisional conflict, improves knowledge, promotes realistic expectations and autonomy in people with diabetes making treatment choices in general practice.

ISRCTN Trials Register Number 14842077

Data sharing statement: There are no additional data available

Introduction

Diabetes mellitus is a growing health problem in England with a total of 2.4 million people (5.5% of population) living with the disease in 2011.¹ Diabetes currently accounts for 10% of all NHS expenditure.² However, overall diabetes control is less than satisfactory. In 2008/2009, 67% of people with T2DM achieved a glycosolated haemoglobin (HbA1c) of less than 7.5% (IFCC HbA1c 58 mmol/mol).³

The UK Prospective Diabetes Study (UKPDS) has established the importance of maintaining good blood glucose control in patients with T2DM. For every 1.0% increase in HbA1c, there is an increase, in risk, of 14% for myocardial infarction, 21% for diabetes-related deaths and 37% for micro-vascular complications.⁴ In the same study, it was reported that only 25% were able to achieve good glycaemic control with monotherapy after 9 years of the trial. Most patients will require combination therapy, including insulin, 5-10 years after diagnosis.⁵

Currently, the NICE guidelines recommend a combination of metformin and insulin secretagogues in those who have inadequate blood glucose control with monotherapy. In those in whom dual therapy has been unsuccessful, either insulin or a thiazolidinedione should be added to optimise glycaemic control.³ Frequently, this poses a clinical dilemma for both patients and healthcare providers; both parties need to agree which next treatment option to pursue and this includes whether or not to start insulin therapy. However, patients may be fearful of needles and the side effects of insulin (e.g. hypoglycaemia); they need to acquire new skills; change their daily routine and address the challenge of glucose monitoring.⁶ Similarly, doctors may be hesitant to prescribe insulin due to their own lack of relevant skills, time pressures, and a fear of increasing the risk of side effects.^{7 8} In this category of patients,

1
2
3 the decision making process is a complex one. Studies have shown that patients usually make
4
5 decisions based on emotions such as trust, rather than on the information given by their
6
7 healthcare providers.⁹ For their part, doctors do not necessarily follow evidence-based
8
9 guidelines¹⁰ and it was in this context that the PANDAs decision aid was developed to
10
11 facilitate shared decision making between clinicians and patients when making decisions
12
13 about the treatment of their diabetes at this stage of their illness. The development of the
14
15 PANDAs decision aid will be described elsewhere.
16
17
18
19

20
21 Patient decision aids are tools that provide evidence-based information about treatment
22
23 options, help patients to clarify their values and guide them systematically to make an
24
25 informed decision. Patient decision aids have been shown to improve knowledge, realistic
26
27 expectations, value-decision concordance and patient involvement in decision making.¹¹
28
29
30

31
32 The primary research question was “Does the use of the PANDAs decision aid improve
33
34 decision quality in patients with T2DM who are making a decision whether or not to start
35
36 insulin in general practice?”
37
38
39

40
41 The study focussed on people with T2DM who had poor glycaemic control (HbA1c
42
43 >7.4mmol/l or IFCC HbA1c >57 mmol/mol) and who, despite receiving optimal oral glucose
44
45 lowering therapy, required "step-up" treatment. A cluster randomised controlled trial was
46
47 carried out to evaluate the clinical effectiveness of the decision aid on decision quality and
48
49 glycaemic control.
50
51
52
53
54
55
56
57
58
59
60

Methods

The setting for this study was general practices in Sheffield, Rotherham and Doncaster with recruitment being undertaken through the National Institute for Health Research Primary Care Research Network (PCRN) and the Cutler Group of South Yorkshire Research Practices. The recruitment of practices and patients began in 2008 and the data collection ended in 2011.

Practices were invited to take part by postal invitation following a publicity campaign using a modified viral marketing technique involving sequential non-specific PANDAs post cards ('PANDAs are coming') to 'pique' interest, followed by increasingly informative flyers (Figure 1).¹²

The inclusion criteria for general practices were: > 4 medical partners; list size > 7000; and a diabetes register with > 1% of practice population. The participating general practices were asked to screen their computerised diabetes register for eligible patients with T2DM (aged > 21 years). The inclusion criteria were: people with T2DM who were taking at least two oral glucose-lowering drugs with maximum tolerated dose and had a latest HbA1c greater than 7.4% (IFCC HbA1c >57mmol/mol) or had been advised in the preceding six months to add or consider changing to insulin therapy. The exclusion criteria were: patients who were currently using insulin therapy; had difficulty reading or understanding English; had difficulty in understanding the purpose of the study; had visual or cognitive impairment and were mentally ill.

The patients were contacted by a letter from their general practitioners (GPs) and invited to participate in this study. If they agreed, they were sent details of the study (including the

1
2
3 information sheet) and asked to attend an appointment at their regular practice where consent
4
5 to the study was obtained by the researchers. Practices were incentivised to take part in the
6
7 trial, receiving a nominal payment to cover legitimate expenses.
8

9 10 **Randomisation and concealment:**

11 This was a pragmatic trial and all eligible and willing practices were randomly allocated by
12
13 computer to two groups: the intervention group used the PANDAs decision aid when making
14
15 the specified treatment choices and the control group delivered usual care. Each practice was
16
17 considered a cluster and all patients within the cluster received either the intervention or usual
18
19 care. The practices were the units of randomisation, since it would have been difficult to
20
21 allocate two patients in the same practice to different arms of the trial. Blinding of the
22
23 intervention and assessment of the process measures were not feasible in view of the nature
24
25 of the intervention studied. A statistician generated the random allocation sequence while a
26
27 secretary who was not involved in the research study assigned participants to either the
28
29 intervention or control groups. A researcher and a research nurse enrolled the participants
30
31 into the study.
32
33
34
35
36
37
38

39 **Intervention and control groups**

40 The doctors and/or the nurses who were primarily involved in the diabetes care of the
41
42 practice attended a short training session lasting between one to two hours on how to use the
43
44 PANDAs decision aid. The training topics covered included the principles of shared decision
45
46 making, the importance and clinical effectiveness of decision aids, the evidence for various
47
48 treatment options for poorly controlled T2DM and essential skills in risk communication.¹³
49
50 The patient participants were given the PANDAs decision aid (Table 1) by the researcher to
51
52 read and complete prior to the consultation in the waiting room. This was followed by the
53
54
55
56
57
58
59
60

1
2
3 consultation with the GP or the practice nurse facilitated by the use of the PANDAs decision
4
5 aid.

6
7 In the control group, the GP and the practice nurse did not receive any training and the
8
9 PANDAs decision aid was not used. The GPs or the nurses conducted a normal consultation
10
11 with the patient.
12
13

14
15
16 Table 1: Content of the PANDAs decision aid

17
18 The PANDAs Decision Aid contains the following information in line with the
19
20 International Patient Decision Aid Standards criteria:

- 21
22 1. Information about the insulin and other treatment options
23 ▪ Reasons for starting insulin
24 ▪ The procedure of insulin injection
25 ▪ Common concerns about insulin
26 ▪ Treatment options: Make no change; lifestyle modification; insulin therapy
27 2. Present probabilities of outcomes
28 ▪ The advantages and disadvantages of each option were described in words,
29 numbers and pictures ('smiley faces')
30 3. Patient value clarifications
31 ▪ A list of patients' values about the advantages and disadvantages of insulin
32 therapy
33 4. Structured guidance
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Outcome measures and follow-up

Primary outcome measure:

The primary outcome measures were decisional conflict based on the Decisional Conflict Scale score,^{14 15} (immediate) used as an indicator of decision quality and glycaemic control (glycosolated haemoglobin, HbA1c) at six months.

Secondary outcome measures:

1
2
3 Knowledge and realistic expectations of the risks and benefits were assessed by asking the
4 patients to indicate their perceived chance of experiencing the side effects of insulin therapy
5 and diabetic complications.
6
7
8

9
10
11 Operational definitions of the secondary outcome measures were agreed as (1) knowledge:
12 about the treatment option that is most effective in reducing blood glucose level and diabetic
13 complications; (2) realistic expectations: a self-reported chance of experience hypoglycaemia,
14 gaining weight and developing complications; (3) preference option: preferred treatment
15 options of initiate insulin, adhere more to diabetes advice more regularly or make no change;
16 (4) participation in decision making: using the Control Preference Scale scores and (5) regret:
17 using the Regret Scale scores.
18
19
20
21
22
23
24
25
26
27
28

29 The secondary measures were other decision quality indicators (knowledge of treatment
30 options, realistic expectation, preference option, proportion undecided, participation in
31 decision making); duration of consultation; and outcome of decision making (regret and
32 persistence with the chosen option).
33
34
35
36
37

38 The practice provided the baseline and six-month follow up data. Baseline data comprised:
39 practice and clinician profile, patients' socio-demography, diabetes profile (duration,
40 complication, prescription, glycaemic control), comorbidities (e.g. hypertension, coronary
41 artery disease, dyslipidaemia, chronic kidney disease); and previous T2DM education.
42
43
44
45
46

47 Immediate post-intervention data collected were: decision quality indicators and duration of
48 consultation. Six-month data comprised: HbA1c, regret score and persistence with the
49 decision.
50
51
52
53
54

55 56 **Instruments:** 57 58 59 60

Decisional conflict scale (DCS)

The DCS measures personal perceptions of (a) uncertainty in choosing options; (b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making; and (c) effective decision making such as feeling the choice is informed, value-based, likely to be implemented and expressing satisfaction with the choice. It was derived from the decisional conflict construct.¹⁶ The traditional 16-item DCS with five response categories was used in this study. There are five subscales: ‘uncertainty subscale’; ‘informed subscale’; ‘values clarity subscale’; ‘support subscale’; and ‘effective decision subscale’.¹⁴ The DCS has been shown to be reliable and is correlated with the constructs of knowledge, regret and discontinuance, and has the ability to discriminate between those who make and delay decisions. Scores lower than 25 are associated with implementing decisions while scores exceeding 37.5 are associated with decisional delay or feeling unsure about implementation.¹⁵

Control preference scale (CPS)

The CPS measures the preferred or actual role in decision making.¹⁷ It consists of five items: two represents active or patient controlled role; one a shared or collaborative role; and two items represent a passive or practitioner controlled role. It has proven validity and reliability in both general public and patients with medical conditions.^{17 18} A recent study found a good inter-rater reliability and good agreement between self and researcher ratings on Control Preference Scale.¹⁹

Regret scale

This scale measures ‘distress or remorse after a (health care) decision’. It is a five-item scale with five responses (1 strongly agree to 5 strongly disagree). Regret is measured at a point

1
2
3 where the respondent can reflect on the effects of the decision that has been made. A score of
4
5 0 means no regret while a score of 100 means high regret. The regret scale correlates with
6
7 satisfaction with the decision, decisional conflict and overall quality of life.²⁰
8
9

10 11 **Sample size and statistical analysis (HbA1c)**

12
13 Assuming an intraclass correlation coefficient of 0.047 for HbA1c²¹ and a cluster sample
14
15 size of 5 patients per practice, with 80% power and 5% (two-sided) significance, 160 patients
16
17 in each group are required to allow the detection of 0.5% (SD 1.5%) difference in HbA1c.²²
18
19

20
21 The total number of Practices required, therefore, was estimated to be 64. When using the
22
23 total DCS score as the primary outcome measure and using a similar method to calculate
24
25 sample size, the total number of participants needed was 86 and the total cluster size was
26
27 estimated to be 17. We aimed for the larger sample size for the design of this study.
28

29
30 The outcome variables, were treated as continuous and we used multiple regressions with
31
32 generalised estimating equations (GEE) and exchangeable correlation to allow for clustering.
33

34
35 Multiple logistic regression with GEE was used for binary outcomes in the secondary
36
37 analysis. If a patient in the intervention arm refused to use the decision aid, they were still
38
39 included in the intervention group for analysis and were analysed according to the intention-
40
41 to-treat principle.
42
43
44

45 **Results**

46 47 48 49 **Study practices profile (Table 2)**

50
51
52
53
54
55
56
57
58
59
60

Forty-nine general practices were recruited into the study. The practices in both arms of the study were well matched in terms of mean list size, mean diabetes list size, mean number of partners and practice nurses and mean Index of Multiple Deprivation Scores.

Table 2 Study practice profile (mean and range)

	Intervention	Control
Number of Practices	25	24
List Size	7,510 (3,129-20,900)	7,325 (1,974-13,500)
People with diabetes	350(96-912)	356 (143-634)
No of partners	5 (1-13)	5 (2-10)
No of practice nurses	3 (1-6)	3 (1-5)
IMD* score	30.35 (range 8.9 - 59.5)	30.20 (range 6.5 - 55)

*Index of Multiple Deprivation

Participants

182 patients were assessed for eligibility, of whom seven were excluded for not meeting the inclusion criteria (n=5), or declined to participate (n=2). 175 patients were randomised, of whom 95 were allocated to the intervention group and 80 to the control group. Six participants in the intervention group were lost to follow-up (3 died, 1 moved away and 2 withdrew their consent), and 2 participants in the control group were also lost to follow-up (1 died and 1 moved away). The results from 167 participants were analysed (89 interventions and 78 controls) (Figure 2).

Table 3 compares the socio-demographic and clinical profiles of patients between intervention and control groups. The mean age of the patients was 64.6 years (range 39 – 87). The patients in the intervention group and control group were broadly similar except that the patients in the intervention group were older and more likely to have coronary heart disease. In both groups the patients were more likely to consult nurses for diabetes related conditions than a doctor (mean number of consultations with nurses and GPs were 2.03 and 1.15 respectively). The mean length of the initial consultation for patients, when entering the

study, in the intervention and control groups was 15.31 and 16.95 minutes respectively (mean difference 1.67min, 95% CI 0.93 to 4.27 mins).

Table 3. Baseline patient socio-demographic and clinical information of the intervention and control groups (mean and range unless otherwise stated)

	Intervention	Control
Socio-demographic profile		
Number	95	80
Demography		
Age (years)	66 (39 – 82)	62 (42 – 87)
Male (%)	50 (52%)	46 (57%)
Duration of education (years) (SD)	12.22 (4.83) (8 – 45*)	11.49 (2.74) (2 – 22)
Ethnicity white (%)	85 (89.5%)	71 (88.8%)
Clinical profile		
Duration of diabetes (years) (SD)	8.4(4.1)(1 – 25)	7.07(3.83) (1 – 16)
HbA1c (IFCC HbA1c mmol/mol) in past 12 months (%) (SD)	8.6 {70}(1.9) (7.4 – 13.1){57-120}	8.8 {73}(0.98) (7.5 – 11.5){58-102}
Number with diabetic complications (%)		
Coronary Heart Disease	29/93 (31.1)	13/80 (16.2)
Peripheral vascular disease	3/93 (3.22)	3/80 (3.75)
Stroke	8/93 (8.6)	5/80 (6.25)
Retinopathy	20/93 (21.5)	10/80 (12.5)
Nephropathy	5/93 (5.37)	10/80 (12.5)
Neuropathy	5/93 (5.37)	3/80 (3.75)
Number with co-morbidities (%)		
Hypertension	58/93 (62.3)	43/80 (53.75)
Dyslipidaemia	52/93 (55.9)	38/80 (47.5)
Health Service Utilisation		
Number of diabetes-related visits to the general practice in the past 6 months (SD)		
General Practitioners	0.92 (1.13)	1.41 (1.68) (0–11)
Nurse	2.15 (1.84)	1.89 (1.36)
Number of diabetes-related visits to the hospital in the past six months (SD)		
Length of consultation (min)	15.31 (2 – 39)	16.95 (5 – 45)

*Self report (sic)

Decisional Conflict

The mean difference between the intervention and the control groups on the total score for decisional conflict was -7.72 (95% CI -12.5 to -2.97). The distribution of decisional conflict

sub-scores are shown in Table 4. The total and subscores for every decisional conflict domain, apart from the support sub-score, were significantly lower in the intervention group. The difference in uncertainty, informed, value clarity and effective decision subscores between the intervention and control groups remained statistically significant after adjusting for differences in age, education and gender.

Table 4: Comparison of decisional conflict scores between the intervention and control groups (0=no decisional conflict, 100=maximum decisional conflict).

Subscore	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	95% CI p value
Uncertainty	20.1 (16.6)	29.4 (20.8)	-9.29	-8.72	-14.9 to -2.53 p=0.006
Informed	18.1 (13.3)	26.0 (16.6)	-7.65	-8.69	-13.3 to -4.10 p<0.001
Values Clarity	16.7 (13.9)	26.7 (18.2)	-9.74	-9.84	-14.8 to -4.84 p<0.001
Support	17.4 (13.1)	20.8 (15.3)	-3.41	-3.66	-8.58 to 1.25 p=0.144
Effective Decision	16.1 (14.4)	23.3 (15.2)	-9.70	-9.80	-16.8 to 2.75 p=0.006
Total Score	17.4 (12.6)	25.2 (14.9)	-7.67	-7.72	-12.5 to -2.97 p<0.001

* adjusted for age, education and gender

Glycosolated Haemoglobin (HbA1c)

Table 5 shows the HbA1c levels for both the intervention and the control groups at six months. HbA1c levels reduced in both groups at six months compared to baseline (0.24% in the control group and 0.37% in the intervention group). The mean difference in the HbA1c level at 6 months between the two groups was 0.351 (95%CI -0.088 to 0.789, p=0.117) after adjusting for age, education, gender, baseline HbA1c, insulin status and clustering.

Table 5: The effect of the PANDAs decision aid on HbA1c at 6 months

Intervention	Control	Mean difference in HbA1c unadjusted	Mean difference in HbA1c adjusted*	95% CI
8.64 (SD 1.37)	8.40 (SD 1.31)	0.244	0.351	-0.088 to 0.789

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering.
P=0.117

Secondary outcomes:

Knowledge

A comparison of the proportions of patients who answered the 'knowledge' questions correctly between the intervention and the control groups showed there were more patients in the intervention group who answered the questions correctly compared to those who received 'usual care'. (Table 6)

Table 6: Secondary outcomes: Knowledge and realistic expectations (Questions answered correctly)

	Intervention Decision Aid	Control Usual Care	Unadjusted Odds Ratio	Adjusted* Odds Ratio (95% CI)	ICC	p value
Knowledge						
Number	95	80				
Which choice has the greatest chance of lowering your blood sugar?	49 (51.6%)	23 (28.8%)	2.63	1.31 (1.14 to 1.50)	0.071	<0.001
Which choice has the greatest chance of lowering your complications?	29 (30.5%)	23 (28.8%)	1.09	1.20 (0.07 to 19.05)	0.202	0.90
Realistic expectations						
If you take insulin, about how many times might you experience 'hypos' in a year?	77/95 (81.0%)	4/75 (5.2%)	77	[^]	-	<0.001*
If you take insulin, about how much more weight might you gain in a year?	67/95 (70.5%)	4/75 (5.3%)	42.5		-	<0.001*
Out of 100 people like you	25/95 (26.3%)	4/80 (5%)	[^]		-	<0.001*

1
2
3 who take
4 insulin, how
5 many may get
6 complications in
7 five years?

8
9 ⁺ adjusted for clustering, insulin initiation, age, gender and education level

10 [^] Numbers answering correctly in the control group were too few to control for
11 clustering.

12 ^{*} Chi-squared p value
13

14 15 16 **Realistic expectations**

17
18 Patients who used the decision aid had significantly more realistic expectations about the side
19 effects of insulin therapy compared to those who did not (Table 6). Almost all patients in the
20 intervention group, compared to those of the control group, knew correctly their risk of
21 hypoglycaemia (81.0% vs 5.2%, $p < 0.001$) and weight gain (70.5% vs 5.3%, $p < 0.001$). More
22 people knew their risk of complications in the intervention group if they were to take insulin,
23 although most still got it wrong (26.3% vs 5.0%, $p < 0.001$).
24
25
26
27
28
29
30
31
32
33

34 35 **Preferred option**

36 Table 7 shows that the preferred choices of patients in the intervention and control groups
37 were similar after consultation.
38
39
40
41

42 Table 7: Preferred choices of patients in intervention and control groups post-
43 consultation
44

	Make No Change	Follow the diabetes advice more regularly	Start insulin	I am not sure	Total
Control	33 (42.3.8%)	29 (37.1%)	9 (11.5%)	7 (9%)	78
Intervention	32 (34.7%)	38 (41.3 %)	17 (18.4%)	5 (5.4%)	92
Total	65	67	26	12	170

45
46
47
48
49
50
51
52
53 $(X^2_3 = 2.88, p = 0.410)$
54
55
56
57

58 59 **Proportion undecided** 60

Table 8 shows that patients in the intervention group were over 3 times more likely to change from undecided to decided than in the control group, although, this was not statistically significant ($P=0.15$).

Table 8: Comparison of the proportion of patients who remained undecided between the intervention and control group immediately after intervention

	Intervention	Control	OR	95%CI
Undecided - preconsultation	23/95	14/80		
Undecided – post-consultation	8/95	9/80		
Odds in favour of changing: decided after and undecided before/undecided after and decided before	18/3*	11/6	3.27	0.69 to 16.3 (p=0.15)

*this means 18 patients changed from undecided to decided in the intervention group and 3 moved in the opposite direction. In the control group the corresponding numbers were 11 and 6

Participation in decision making

There were significant differences in patients' decision making role between the intervention and control groups ($p=0.012$ Chi square) (Table 9). It may be seen that a smaller proportion of patients in the intervention group described their decision about their diabetes treatment as "passive" or "collaborative".

Table 9: Decision making roles of patients in the intervention and control groups, post consultation with their doctor/nurse

	How did you make your decision about your diabetes treatment? (n = 169)			
	Passive	Collaborative	Autonomous	Total
Control	16 (21%)	28 (36%)	33 (43%)	77 (100%)
Intervention	8 (9%)	25 (27%)	59 (64%)	92 (100%)

($X^2=8.9$, $df=2$, $p=0.012$)

However, patients in the intervention arm were more likely to demonstrate autonomy in their decision making about their treatment compared to the control group (64% compared to 43%). Further analysis showed that an individual patient was 1.23 (95% CI 1.05 to 1.44, $p=0.008$) times more likely to make an 'autonomous' decision using the PANDAs decision aid when the intervention and control groups are compared, allowing for age and gender.

Regret and persistence with decision

Table 10 shows that there was no difference at 6 months in the regret scale, but that patients in the intervention group were rather more likely to persist with their chosen option.

Table 10: Comparison of the decision Regret Score and persistence with chosen option between the intervention and usual care groups after six months

	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	p value
Regret Score	44.63	44.57	0.06	0.22 (-2.48 to 2.93)	0.872
Persistence with chosen option	68.1%	56.3%	1.65 [†]	1.17 [^] (1.00 to 1.36)	0.041

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering

[†]Crude odds ratio

[^]Adjusted odds ratio

Discussion

The PANDAs decision aid was designed to facilitate decision making between clinicians and their patients with T2DM who were taking at least two oral glucose-lowering drugs at maximum tolerated dose, had a high HbA1c level and were considering future treatment options including the introduction of insulin. Its evaluation was based on the IPDAS recommendations²³ and the use of the ODSF Framework.²⁴ The PANDAs trial provides good

1
2
3 evidence not only for the clinical effectiveness of decision aids in usual NHS general practice
4
5 but also for the utility and feasibility of use by both nurses and doctors. In addition, the
6
7 PANDAs decision aid itself and its use were both effective and acceptable to people with
8
9 diabetes making treatment choices during clinical consultations.
10

11 12 13 14 **Decision quality**

15
16 The findings from the PANDAs trial support the results of other studies which have evaluated
17
18 the clinical effectiveness of decision aids^{11 14} in demonstrating an improvement in decision
19
20 quality when a decision aid is used in clinical consultations.
21
22

23
24
25 Decisional conflict scores, for example, when adjusted for age, education and gender were
26
27 significantly lower in the intervention group post consultation when compared to the controls,
28
29 apart from the support sub-score. It is interesting to note that the support sub-score in the
30
31 intervention group was not significantly lower than the control group - this may be the result
32
33 of a 'ceiling effect' since patients in both the intervention and control groups may already
34
35 have been receiving very good diabetes care from their general practices.
36
37
38

39
40
41 Other indicators of decision quality used in the study also demonstrated an improvement
42
43 when PANDAs was used in consultations – there was, for example, a highly significant
44
45 difference in the knowledge of people which particular treatment choice had the greatest
46
47 chance of lowering blood sugar in those who used the decision aid - although this was not the
48
49 case when the chance of insulin in lowering complications was considered - here no
50
51 difference in knowledge was observed. Some patients believe that insulin itself causes
52
53 complications as a result of misperception^{25 26} and this may explain why knowledge did not
54
55 improve in the intervention group. However, highly significant differences were observed
56
57
58
59
60

1
2
3 between the intervention and control groups in all the three domains of realistic expectations
4
5 ['hypos', weight gain and complications] supporting the notion that the PANDAs decision
6
7 aid ensured that people were fully informed about the potential risks of each option when
8
9 making their treatment choices.
10

11
12
13
14 As far as autonomy was concerned, patients in the intervention arm were more likely to make
15
16 an autonomous decision using PANDAs when the intervention and control groups were
17
18 compared allowing for both age and gender. This is consistent with the findings of other
19
20 studies.^{27,28}
21
22

23
24
25 These findings of an improvement in decision quality when a decision aid is used in clinical
26
27 consultations in other conditions and contexts are also supported by a large number of other
28
29 studies.^{22,29}
30
31

32 33 34 **Decisional Outcomes**

35
36 The glycaemic control improved in both groups six months after the intervention although no
37
38 significant difference in glycaemic control was observed between the two groups. Some GPs
39
40 in the study expressed concern at the start of the trial that glycaemic control could deteriorate
41
42 in some patients in the intervention group as a result of them choosing not to start insulin.
43
44

45 However, this was clearly not the case as may be seen from these data.
46

47 Treatment decisions made using a decision aid should, of course, be ones that are both
48
49 informed and value-based, and the PANDAs intervention was focussed on the process of
50
51 decision making rather than the outcomes of those decisions. It is therefore important to note
52
53 that PANDAs was not designed to persuade people to start treatment with insulin but to help
54
55
56
57
58
59
60

1
2
3 them make an informed treatment decision which was consistent with their values and
4
5 wishes.
6
7

8
9
10 Indeed, there was reduced decisional conflict within the intervention group compared to the
11 control and the decisions which were made were far more likely to be autonomous in nature
12 rather than passive. Participants in the intervention group were also significantly more likely
13 to persist with their chosen option at 6 months. This supports the hypothesis that people who
14 use a decision aid such as PANDAs are more likely to make an informed and value-based
15 decision and are therefore more likely to persist with their treatment choice. Concordance
16 with agreed treatment is, in turn, more likely to lead to better health outcomes and quality of
17 life.
18
19

20
21
22 No significant difference was observed on the regret scale scores and although people in the
23 intervention group were over three times more likely to change from undecided to decided
24 [ie come to a treatment decision after their consultation] in the control group, this difference
25 was not statistically significant.
26
27

28
29
30 Finally, no significant difference was observed in the preferred choices [ie the treatment
31 decision they came to] of the two groups although a higher proportion of people in the
32 intervention group did choose to initiate insulin. However it is important to note that the use
33 of a decision aid is not intended to produce a particular outcome but to support the patient
34 making a treatment choice based on their knowledge and values. These findings are also
35 consistent with current understanding of the anticipated decisional outcomes when a decision
36 aid such as PANDAs is used in clinical consultations to make treatment choices.²⁹
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Impact on Clinical Practice

The results of the PANDAs trial demonstrate that the use of the decision aid in usual general practice by both practice nurses and GPs, provided the patient has the opportunity to complete their individualised decision aid prior to their consultation, does not require significant additional consultation time. Given the potential benefits of improved adherence to treatment choices and an improved therapeutic relationship between clinicians and their patients, this is likely to make the use of the decision aid acceptable to all parties in general practice, although, its use may require some initial ‘investment’ in consultation time. In particular, both clinician and patient satisfaction with their consultations, as well as the healthcare provided and received, are both likely to be increased. A further potential advantage is that the decision aid could be used by other clinical members of the primary care team (eg healthcare assistants) potentially increasing the consultation time available to doctors and nurses for other patients. However, the efficient use of the decision aid in consultations may in part be attributed to the familiarity of the clinicians with the decision aid as a result of the brief training clinicians received at entry to the trial. In addition, this may also be due to the process by which the decision aid was developed with the active involvement of both clinicians and people with diabetes to ensure that it was as ‘user friendly’ as possible. This involvement of users in the development of the decision aid and a process evaluation of its use in the consultation by both parties will be described elsewhere.

Health service utilisation

The PANDAs trial was a pragmatic one reflecting the reality of primary care diabetes clinics which are mainly run by practice nurses. The mean number of consultations with the nurses,

1
2
3 for example, was greater than the mean number of consultations with the GPs and within the
4
5 intervention group patients were more likely to use the PANDAs decision aid with the
6
7 practice nurse than the GP. At baseline the distribution of the mean number of diabetes
8
9 related general practice visits was different in the intervention and control groups with the
10
11 practice nurses providing more clinical care to people with diabetes in the former reflecting
12
13 different patterns of care in the different practices.
14
15

16 17 18 **Patient decision aids** 19

20
21
22 The PANDAs decision aid is one of the few decision aids which focus on decision making in
23
24 chronic diseases, which take place over several consultations. According to the latest
25
26 Cochrane Decision Aid Inventory, 10 decision aids have been developed for diabetes.²⁹ Four
27
28 decision aids focus on insulin treatment, of which two are for children, one for adults
29
30 deciding on premixed insulin and one for insulin initiation in T2DM (PANDAs decision aid).
31
32 However, unlike PANDAs, none have been developed for making treatment decisions about
33
34 glycaemic control.
35
36
37
38
39

40
41 Although decision aids have positive effects on many aspects of the decision making process,
42
43 there remains a large gap in the literature on how decision aids fare “in the real world”.
44
45 O’Cathain and Thomas (2004) conducted a pragmatic trial of decision aid in a maternity ward
46
47 and found that health professional were not making use of the available decision aids,
48
49 although they reported that they approved of them. The reasons for not using them included
50
51 ‘disagreement’ with the available decision aids, lack of resources, perceived patients’
52
53 reluctance to participate and unwillingness to change their “routine care”.³⁰ O’Donnell,
54
55 Cranney et al, classified the barriers to the use of decision aids in the clinical situation under
56
57
58
59
60

1
2
3 three categories – the nature of the decision aid itself, the attitudes of patients and healthcare
4 professionals and organisational barriers such as institutional culture and commitment, time
5 constraint and costing.³¹
6
7
8
9

10
11 A number of authors have proposed various strategies to facilitate such use of decision aids in
12 different clinical settings.³² The effectiveness of these proposed strategies has not yet been
13 formally evaluated. The PANDAs trial however found the decision aid to be highly
14 acceptable to both clinicians and people with diabetes in NHS general practice – a detailed
15 process evaluation of its use can be found elsewhere. This report identifies some of the key
16 challenges to its widespread implementation in NHS general practice.
17
18
19
20
21
22
23
24
25
26

27 However, most studies of decision aids have not shown an increase in the level of satisfaction
28 with the decision making process or the decision itself. This may be another example of the
29 ‘ceiling effect’ whereby the satisfaction with the service or consultation was already high
30 before the intervention. It has also been observed that people tend to report satisfaction after
31 they have made the decisions because they tend to “rationalise” and adapt quickly to
32 uncertain events.³³ Moreover, the effect of decision aids on quality of life and health
33 outcomes indicators which are commonly used in health technology assessments, have yet to
34 be proved. More plausible intermediate outcomes, such as concordance with treatment and
35 health service utilisation, could be used as alternative indicators to evaluate the use of
36 decision aids.
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 General practice is a unique healthcare setting where multidisciplinary teams provide holistic,
52 comprehensive and continuity of care to people in the community. Practitioners usually have
53 an established relationship with their patient and an appreciation of their medical and
54
55
56
57
58
59
60

1
2
3 psychosocial background as well as their associated multi-morbid conditions. This puts them
4
5 in a very good position to advise patients on their treatment options. The use of decision aids
6
7 to facilitate treatment choices in general practice fits well with the adoption of a Care
8
9 Planning model for long-term conditions. This model of care, developed by the Diabetes UK
10
11 Year of Care Programme and recently adopted as a professional standard by the RCGP, is a
12
13 good way of ensuring that patients with diabetes are both fully informed and fully involved in
14
15 decisions about their care by supporting their “empowerment” and facilitating the
16
17 “activation” of people with long-term conditions.^{34,35}
18
19

20 21 22 23 **Implications for research and clinical practice**

24
25 For the use of patient decision aids, such as PANDAs, in routine clinical practice to become
26
27 the accepted norm, the new GP clinical commissioning groups will need to be aware of the
28
29 benefits of the use of such aids to ensure that decision aids become a professional standard in,
30
31 for example, newly commissioned pathways for a long-term condition such as diabetes.
32
33 Investment will also be necessary for the development and the continuing evaluation of
34
35 decision aid use, as well as for the training of all members of the multidisciplinary team in the
36
37 importance and in the practical use of decision aids in primary care. Both the patient’s
38
39 experience and patient/clinician satisfaction with the care received and provided is likely to
40
41 be much improved if this professional standard is adopted by commissioning groups.
42
43
44
45
46

47 48 **Conclusions**

49
50 The use of the PANDAs decision aid by health care professionals in usual NHS clinical
51
52 practice with T2DM patients who are making treatment choices in general practice improves
53
54 decision quality by reducing decisional conflict, improving knowledge and promoting
55
56 realistic expectations but has no demonstrable effect on glycaemic control.
57
58
59
60

1
2
3 Patient autonomy however is strengthened by the use of the decision aid and longer term
4 clinical outcomes are likely to be improved. A larger trial of the PANDAs decision aid will
5 be necessary to determine if biomedical parameters are improved when the decision aid is
6 used in normal NHS practice.
7
8
9
10

11 12 13 14 **Strengths and limitations of this study**

15
16 The study failed to achieve its planned sample size as a result of recruitment difficulties. The
17 reasons for this were the increase in availability of new oral and injectable glucose lowering
18 drugs which were not available at the start of the project, significant staff changes in 2008/9
19 and the reluctance of practices to participate in the study because of a potential H1N1 flu
20 pandemic in summer 2009. As a result each practice was only able to identify 3-5 eligible
21 patients for inclusion in the trial. It proved impossible to secure a funded time-extension to
22 the study and as a result recruitment ceased at 175 participants. This meant that the study was
23 underpowered to detect a difference of 0.5% in HbA1c between the two groups. The original
24 recruitment period was 12 months but because of the problems surrounding recruitment
25 outlined above, recruitment was extended to 20 months. There was also some evidence of
26 inadvertent recruitment bias with 95 participants allocated to the intervention group and 80 to
27 the control group. This is an important and well recognised consequence of a cluster RCT
28 design and is probably the result of the PANDAs practices being more likely to recruit
29 participants to the trial. There were some differences in baseline characteristics between the
30 intervention and the control and these were included in an analysis which explored how the
31 estimates of the treatment effect changed when baseline differences were controlled for.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 53 54 **Contributorship statement:**

1
2
3 **Substantial contribution to conception and design, acquisition of data or analysis and**
4
5 **interpretation of data:**
6

7 NM, CJN, MCJ, BC, AB, IB
8

9
10 **Drafting the article or revising it critically for important intellectual content:**

11 NM, CJN, MCJ
12

13
14 **Final approval of the version to be published:**

15 NM, CJN, MCJ, BC, AB, IB
16

17 NM is the guarantor.
18
19
20
21
22

23 This article presents independent research funded by the National Institute for Health
24 Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference
25 Number PB-PG- 0906-11248), ISRCTN National Trials Register Number 14842077 and the
26 Sheffield Health and Social Care NHS Foundation Trust. The views expressed are those of
27 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
28
29
30
31
32
33
34
35

36 All authors have completed the Unified Competing Interest form at
37 www.icmje.org/coi_disclosure.pdf and declare that (1) NM, CJN, MC, BC, IB, AB have
38 support from the University of Sheffield for the submitted work; (2) NM, CJN, MC, BC, IB,
39 AB have no relationships with any companies that might have an interest in the submitted
40 work in the previous 3 years; (3) their spouses, partners or children have no financial
41 relationships that may be relevant to the submitted work; and (4) NM, CJN, MC, BC, IB, AB
42 have no none-financial interests that may be relevant to the submitted work.
43
44
45
46
47
48
49
50
51
52
53

54 “The Corresponding Author has the right to grant on behalf of all authors and does grant on
55 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
56
57
58
59
60

1
2
3 Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and
4
5 any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our
6
7 licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>)."
8
9

10 11 12 13 14 **Acknowledgements**

15
16 Ethical permission to conduct the study was received from the North Sheffield Local
17
18 Research Ethics Committee (07/Q2308/53).
19

20
21 Expert specialist advice was received from Professor Simon Heller, University of Sheffield.

22
23 We thank Ms Rachel Dwyer for research support, and Dr Robert Dixon, Sheffield Care Trust,
24
25 Mr Robert Glendenning and Mr Ian Brown for managerial support.
26

27
28 Ms Sharon Hart, University of Sheffield, for administrative support.

29
30 Members of the PANDAs Advisory Group (Alicia O'Cathain, Hina Kanabar, Hugh
31
32 McCulloch, Maxine Johnson, Michelle Horspool, Mick Taylor, Sue Beveridge, Mary
33
34 MacKinnon).
35

36
37 Members of the Sheffield Diabetes UK Group
38
39

40
41 Particular thanks to all those doctors, nurses and people with diabetes for their contributions
42
43 without whom it would not, of course, have been possible to undertake the PANDAs trial.
44
45

46 47 **References**

48
49 1. Diabetes UK. Diabetes in the UK 2011/2012: Key statistics on diabetes.

50
51 <http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2011-12.pdf> (accessed
52
53 12 March 2012).
54
55
56
57
58
59
60

- 1
2
3 2. Diabetes.co.uk. Cost of Diabetes. <http://www.diabetes.co.uk/cost-of-diabetes.html>
4
5 (accessed 12 March 2012).
6
- 7 3. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: Newer
8 agents. London: NICE, 2009.
9
- 10 4. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared
11 with conventional treatment and risk of complications in patients with type 2 diabetes
12 (UKPDS 33). *Lancet* 1998;**352**:837-53.
13
- 14 5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea,
15 metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for
16 multiple therapies (UKPDS 49). *JAMA* 1999;**281**:2005-12.
17
- 18 6. Fitzgerald JT, Vijan S, Stuart N. Insulin therapy and patient attitudes at two VA centers.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Diabetes 2000;**49**:A445.
7. Lauritzen T, Scott A. Barrier to insulin therapy in type 2 diabetes: a qualitative focus group
research among patients, GPs and diabetologists. *Eur Union Gen Pract Clin J* 2002;**3**:33-40.
8. Jeavons D, Hungin AP, Cornford CS. Patients with poorly controlled diabetes in primary
care: healthcare clinicians' beliefs and attitudes. *Postgrad Med J* 2006;**82**:347-50.
9. Paling J. Strategies to help patients understand risks. *BMJ* 2003;**27**:745-8.
10. Siriwardena AN. Clinical guidelines in primary care: a survey of general practitioners'
attitudes and behaviour. *Br J Gen Pract* 1995;**45**:643-7.
11. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M,. Decision aids
for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*.
2011;Issue 10. Art. No.: CD001431.
12. Colwell, B, Mathers N, Ng, CJ, Bradley A. Improving recruitment to primary care trials:
some lessons from the use of modern marketing techniques. Debate and Analysis Paper
BJGP. [In Press]

- 1
2
3 13. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. *Science*
4
5 1981;211:453-8.
6
- 7 14. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G,. A decision
8
9 aid for women considering hormone therapy after menopause: decision support framework
10
11 and evaluation. *Patient Educ Couns* 1998;33:267-79.
12
- 13 15. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;15:25-
14
15 30.
16
- 17 16. Janis IL, Mann L. *Decision making: a psychological analysis of conflict, choice and*
18
19 *commitment*. New York: Free Press, 1977.
20
- 21 17. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res*
22
23 1997;29:21-43.
24
- 25 18. Davidson BJ, Degner LF, Morgan TR. Information and decision making preferences of
26
27 men with prostate cancer. *Oncol Nurs Forum* 1995;22:1401-8.
28
- 29 19. Kremer H, Ironson G. Measuring the involvement of people with HIV in treatment
30
31 decision making using the Control Preference Scale. *Med Decis Making* 2008;28:899-908.
32
- 33 20. Brehaut JC, O'connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E,. Validation of a
34
35 decision regret scale. *Med Decis Making* 2003;23:281-92.
36
- 37 21. Kinmonth AL, Woodcock A, Griffin S, Spiegel N, Campbell MJ, et al. Randomised
38
39 controlled trial of patient centred care of diabetes in general practice: impact on current
40
41 wellbeing and future disease risk. *BMJ* 1998;317:1202-8.
42
- 43 22. DAFNE Study Group. Training in flexible, intensive insulin management to enable
44
45 dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE)
46
47 randomized controlled trial. *BMJ* 2002;325:746-51.
48
- 49 23. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. International
50
51 Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria
52
53
54
55
56
57
58
59
60

1
2
3 framework for patient decision aid: online international Delphi consensus process. *BMJ*
4
5 2006;**333**:417-19.

6
7 24. Légaré F, O'Connor AM, Graham ID, Saucier D, Côté L, Blais J, et al. Primary health
8
9 care professionals' views on barriers and facilitators to the implementation of the Ottawa
10
11 Decision Support Framework in practice. *Patient Educ Couns* 2006;**63**:380-90.

12
13 25. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to
14
15 insulin initiation: the translating research into action for diabetes insulin starts project.
16
17 *Diabetes Care* 2010;**33**:733-35.

18
19 26. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring
20
21 psychological insulin resistance: barriers to insulin use *Diabetes Education* 2008;**34**:511-17.

22
23 27. Auvinen A, Vornanen T, Tammela TL, Ala-Opas M, Leppilahti M, Salminen P, et al. A
24
25 randomized trial of the choice of treatment in prostate cancer: design and baseline
26
27 characteristics. *BJU Int.* 2001;**88**:708-15.

28
29 28. Murray E, Davis H, Tai SS, Coulter A, Gray A, Haines A, et al. Randomised controlled
30
31 trial of an interactive multimedia decision aid on benign prostatic hypertrophy in primary
32
33 care. *BMJ* 2001;**323**:493-6.

34
35 29. Cochrane Library. Cochrane Inventory of Patient Decision Aids.
36
37 <http://decisionaid.ohri.ca/cochinvent.php> (accessed 12 March 2012)

38
39 30. O'Cathain A, Thomas, K. J. Evaluating decision aids--where next? *Health Expect*
40
41 2004;**7**(2):98-103.

42
43 31. O'Donnell S, Cranney, A., Jacobsen, M. J., Graham, I. D., O'Connor, A. M., Tugwell, P.
44
45 Understanding and overcoming the barriers of implementing patient decision aids in clinical
46
47 practice. *J Eval Clin Practice.* 2006;**12**(2):174-181.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32. O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW, Sepucha
4
5 KR, et al. Toward the 'tipping point': decision aids and informed patient choice. *Health Aff*
6
7 (*Millwood*)
8
9 2007;**26**:716-25.33.
10
11 33. O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, et al. Decision Aids
12
13 for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*
14
15 2009;Issue 3. Art. No.: CD001431.
16
17 34. Wagner EH. Chronic disease management: what will it take to improve care for chronic
18
19 illness? *Eff Clin Pract* 1998;**1**:2-4.
20
21 35. Mathers N, Roberts S, Hodgkinson I, Karet B. Care Planning: Improving the Lives of
22
23 People with Long Term Conditions. UK: Royal College of General Practitioners, 2011.
24
25 36. Campbell MK, Elbourne DR, Altman DG for the CONSORT Group. CONSORT
26
27 statement: extension to cluster randomised trials. *BMJ* 2004;**328**:702-8.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

CONFIDENTIAL

Starting Insulin Your Choice

When your diabetes tablets are not controlling your blood sugar ...

Do you need to add insulin?

This decision aid is for you if:

- You have type 2 diabetes
- Your blood sugar is not well controlled with your diabetes tablets
- Your doctor or nurse has advised you to add insulin



The
University
Of
Sheffield.

1
2
3
4 **This decision aid will guide you through the decision whether or not to start insulin. It will:**

- 5
6
7
8
9
10
11
12
13
14
- Give you information about the treatment choices you have when you blood sugar is not well controlled
 - Give you information about the advantages and disadvantages of starting insulin
 - Help you to think about what is important to you when making the decision
 - Help you find out what support you will need when making the decision
 - Help you to decide which treatment choice you prefer

15
16 **Your doctor or nurse will discuss with you about your decision after you have completed this decision aid.**

17
18
19
20 **1. Is there a need to start insulin?**

- 21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
- People with type 2 diabetes usually need insulin when their blood sugar is high despite taking tablets and having a healthy lifestyle.
 - This usually happens 5 to 10 years after the diagnosis when the body no longer produces enough insulin. The only way to have enough insulin in the body is to take insulin injections.
 - There are reasons why the blood sugar should be kept under control:
 - High blood sugar can damage your eyes, heart, kidneys, nerves and blood vessels. Damage can lead to blindness, heart attacks, kidney failure, leg amputations and strokes.
 - High blood sugar may make you feel thirsty, tired, pass urine more often, lose weight, have blurry vision, or have skin and urine infections.
 - Insulin can improve the blood sugar level and prevent the complications or stop them from getting worse. It also helps to reduce the symptoms of diabetes.
- 42
43
44

2. What happens when people take insulin?

- Insulin is added to your diabetes treatment while you continue with your tablets, diet and exercise. For most people, only one insulin injection at night is required.
- Insulin is given using an injection 'pen'. You can set the dose and press the pen to deliver the insulin through the needle into the skin of your abdomen or the outer part of your thigh.
- Every morning, you check your blood sugar with a meter.
- Your doctor or nurse will explain to you how and when to use the insulin pen and check your blood sugar. You will be followed up regularly by the doctor or nurse until you are confident in using the insulin. You can contact the nurse during working hours if you have any queries about the insulin injections.

3. What are people concerned about when they start insulin?

When people start insulin, they often worry about:

- making changes to their daily life
- the needles, the injections and the pain caused by the injections
- putting on weight
- "hypos" – hypos happens when the blood sugar is too low after taking insulin. It makes you feel dizzy, cold and sweaty. Hypos are treated with sugary drinks and food.

Your doctor or nurse will help to address your concerns.

4. How is diabetes affecting you?

Diabetes can affect people in many ways. Below are some common problems which people with type 2 diabetes may face.

Tick any that apply to you.

Have you had any of these symptoms OVER THE PAST WEEK?

- | | | |
|---|--|--|
| <input type="checkbox"/> Thirsty | <input type="checkbox"/> Tired | <input type="checkbox"/> Infections |
| <input type="checkbox"/> Passing urine more often | <input type="checkbox"/> Blurry vision | <input type="checkbox"/> Weight changes (past month) |

How would you feel if the symptoms you have now stay the same for the rest of your life?

- Delighted
- Pleased
- Mostly satisfied
- Mixed (neither satisfied nor dissatisfied)
- Mostly dissatisfied
- Unhappy
- Terrible

Which complications has your doctor or nurse diagnosed?

- | | | |
|--|---|---|
| <input type="checkbox"/> Eye disease | <input type="checkbox"/> Stroke | <input type="checkbox"/> Numbness hands/feet |
| <input type="checkbox"/> Heart disease | <input type="checkbox"/> Kidney disease | <input type="checkbox"/> Poor leg circulation |

Which of the following apply to you?

- | | | |
|--|---|----------------------------------|
| <input type="checkbox"/> High blood pressure | <input type="checkbox"/> High cholesterol | <input type="checkbox"/> Smoking |
|--|---|----------------------------------|

1
2
3 **5. Do you find it difficult to follow the diabetes advice?**

4
5 **Many people with type 2 diabetes find it difficult to follow the medical advice.**

6 How often have you been following the diabetes advice during the **PAST WEEK?**

7
8
9 **How often did you control your diet?**

10 Not at all 1-2 days 3-4 days 5-6 days Daily

11
12
13 **How often did you take your diabetes tablets?**

14 Not at all 1-2 days 3-4 days 5-6 days Daily

15
16
17
18 **How often did you exercise (e.g. walking, cycling)?**

19 Not at all 1-2 days 3-4 days 5-6 days Daily

6. What are your choices?

When people with type 2 diabetes have high blood sugar despite taking tablets, they have the following choices:

- **Make no change** and continue with your tablets and present lifestyle. You will return for a review in 3 to 6 months' time.
- **Follow the diabetes advice more regularly (diet, exercise, taking tablets)**, and wait 4 to 6 months to see if your blood sugar drops.
(Your blood sugar is unlikely to improve if you are already careful with your tablets, diet and exercise)
- **Add insulin** and continue with your tablets.

Working through the next 4 steps of this decision aid helps you decide which option to choose.

Step 1: Learn about the choices.....

To make a decision, it is important to know the advantages and disadvantages of each choice.

Choice 1: Make no change

If you make no change, your average blood sugar (HbA1c) will remain at% or higher. This is higher than the normal level of 7.4%.

If you decide to make no change to your treatment,


The advantages are:

- You keep to your daily routine
- No insulin injections
- No side effects of insulin

The disadvantages are:

- Continue to have diabetic symptoms (feeling thirsty, tired, pass urine more often, blurry vision, infections and weight changes)

Your chance of getting complications in 5 years is:

(heart disease, stroke, kidney disease, eye disease, numbness, poor circulation) 

Sticker to
go here



Choice 2: Follow the diabetes advice more regularly (diet, exercise, taking tablets)

This choice is not useful to you if:


- you are already following the diabetes advice carefully
- you are unlikely to follow the diabetes advice more regularly

If you follow the diabetes advice more regularly, your average blood sugar (HbA1c) will be%.

This is the same as your best average blood sugar level (HbA1c) in the past one year.

If you decide to follow the diabetes advice more regularly,


The advantages are:

- No insulin injections
- No side effects of insulin
- Your diabetic symptoms may improve 

The disadvantages are:

- have to make changes to your daily routine (diet, exercise, taking tablets)

Your chance of getting complications in 5 years is:

(heart disease, stroke, kidney disease, eye disease, numbness, poor circulation) 

Sticker to
go here



Choice 3: Add insulin



If you take insulin, your average blood sugar (HbA1c) will drop from% to%

If you decide to take insulin,


The advantages are:


- Your diabetic symptoms will improve 

The disadvantages are:

- Have to make changes to your daily routine
- May feel slight discomfort with the insulin injection
- Have to check your blood sugar regularly
- May put on 6 to 8 pounds in the first year 
- May have 'hypos' 3 to 5 times a year 

Your chance of getting complications in 5 years is:

(heart disease, stroke, kidney disease, eye disease, numbness, poor circulation) 



Sticker to go here

Summary of the 3 choices

Choice 1: Make no change

Average blood sugar (HbA1c) is%.

Advantages:

- Keep to your daily routine
- No insulin injections
- No side effects of insulin

Disadvantages:

- Continue to have diabetic symptoms

Your chance of getting complications in 5 years is:

Sticker to
go here

Choice 2: Follow the diabetes advice more regularly

Average blood sugar (HbA1c) is%.

Advantages:

- No insulin injections
- No side effects of insulin
- Your diabetic symptoms may improve

Disadvantages:

- Have to make changes to your daily routine and follow the diabetic advice more regularly

Your chance of getting complications in 5 years is:

Sticker to
go here

Choice 3: Add insulin

Average blood sugar (HbA1c) is%.

Advantages:

- Your diabetic symptoms will improve

Disadvantages:

- Have to make changes to your daily routine
- Slight discomfort with the insulin injection
- Have to check your blood sugar regularly
- May put on 6 to 8 pounds in the first year
- May have 'hypos' 3 to 5 times a year

Your chance of getting complications in 5 years is:

Sticker to
go here

Step 2. Thinking about what is important to you

Now you have to consider whether the advantages and disadvantages of these choices are IMPORTANT TO YOU.

Tick whether each statement is important to you.

Reasons for choosing insulin:	Yes	No
Is it important to you to reduce your blood sugar?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you to reduce your chance of getting complications?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you to reduce your diabetic symptoms?	<input type="checkbox"/>	<input type="checkbox"/>
Reasons for not choosing insulin:	Yes	No
Is it important to you not to have injections?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you not to have to check your blood sugar everyday?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you not to put on weight?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you not to have "hypos" (low blood sugar)?	<input type="checkbox"/>	<input type="checkbox"/>
Is it important to you to keep to your daily routine?	<input type="checkbox"/>	<input type="checkbox"/>
Other reason that is important to you?	Yes	No
.....	<input type="checkbox"/>	<input type="checkbox"/>

Now, think about which choice has the advantages and disadvantages that are important to you.

Which choice do you prefer? Tick one

- Make no change
- Follow the diabetes advice more regularly
- Add insulin
- Unsure

Step 3: What else do you need to help you make a decision?

Knowledge

Find out how this decision aid has helped you learn the key facts.

Tick the best answer.

	Make no change	Follow the diabetes advice more regularly	Add insulin
a) Which choice has the greatest chance of lowering your blood sugar?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
b) Which choice has the greatest chance of lowering your complications?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
If you are unsure about the answer, you can go back to the summary at page 10.			
c) If you take insulin, about how many times might you experience 'hypos' in a year?	<input type="checkbox"/> 3 to 5	<input type="checkbox"/> 6 to 8	<input type="checkbox"/> 9 to 11
d) If you take insulin, about how much more weight might you gain in a year?	<input type="checkbox"/> 3 to 5 pounds	<input type="checkbox"/> 6 to 8 pounds	<input type="checkbox"/> 9 to 11 pounds

Check your answers at the bottom of page 14.

Facts

Do you know enough about the **advantages** and **disadvantages** of each choice?

 Yes No**Values**

Are you clear about which advantages and disadvantages **matter most** to you?

 Yes No**Support**

Have you had enough **support and advice from others** to make a choice?

 Yes No**Uncertainty**

Do you feel sure about the **best choice for you**?

 Yes No

Please discuss with your doctor or nurse, if you are still unsure about the decision.

Step 4: What are the next steps?

Are you ready to make a decision? Tick one.

No, I am not ready Yes, I am ready

If you are ready to make a decision, which choice do you prefer? Tick one.

- Make no change
- Follow the diabetes advice more regularly
- Add insulin

If you decide to add insulin,

How motivated are you to do this? Not Motivated ① ② ③ ④ ⑤ Very Motivated

How confident are you that you can do this? Not Confident ① ② ③ ④ ⑤ Very Confident

List the things that might get in the way of doing this:

.....

.....

List the things that will help you to do this:

.....

.....

1
2
3 **Notes**
4

5
6 **You may want to write down:**

- 7 • Your concerns about starting insulin
- 8 • Things that you would like to discuss with your doctor, nurse and family.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35
36 **This decision aid is not intended to replace the advice of your doctor or nurse.**

37 **Content Editors:** Chirk-Jenn Ng, Nigel Mathers, Mike Campbell, Susan Beveridge, **Funded by:** National Institute for Health Research, NHS, UK

38 **Format:** Based on the Ottawa Decision Guide © 2000, A O'Connor, D Stacey. University of Ottawa, Canada 2007.

39 **Technical document:** Please contact CJ Ng at C.Ng@sheffield.ac.uk

40 Produced in 2008

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

This booklet belongs to:

Contact Details:

Academic Unit of Primary Medical Care
University of Sheffield
Samuel Fox House
Northern General Hospital
Herries Road
Sheffield
S5 7AU
United Kingdom

Tel: +44 (0)114 271 5922
Fax: +44 (0)114 271 5915
Email: C.Ng@sheffield.ac.uk

Figure 1:



review only

Figure 2:





Figure 3:





School
Of
Medicine
& Biomedical Sciences.

Practice Information Sheet

Study Title: 'PANDAs': Patient Decision Aids for Type 2 Diabetes
Protocol Ref: ZH25
Version: V6-06-08-2009

Part 1 tells you the purpose of this study and how your practice will be involved if you take part.

Part 2 gives you more detailed information about the conduct of the study.

Part 1

We would like to invite your practice to take part in a research study. This study will find out whether a patient decision booklet is useful for people with type 2 diabetes who need to make decisions about their diabetes treatment.

Before you decide whether your practice should participate, you need to understand why the research is being done and what it would involve. Please take time to read the following information carefully; talk to others about the study if you wish.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

1. What is the purpose of the study?

It is sometimes difficult for patients with Type 2 diabetes to make decisions about the treatment of their illness, especially when it involves taking additional medications or changing to another medication. Informed decision-making not only requires them to know the risks and benefits of the treatment, it also depends on how they feel and think about the treatment. Sometimes, they may not have had opportunity to discuss this information in detail with their doctor or nurse.

A Patient Decision Aid is a simple booklet which contains useful information on diabetes and its treatment. It also explores what patients feel and think about these treatments. It has been used widely to help people to make decisions about their specific illnesses, for example the menopause or a prostate problem.

So the purpose of this study is to find out whether using a patient decision aid before the GP's/Nurse's consultation will improve the quality of patients' decision-making and, eventually, their blood sugar control.

2. Why have I been invited?

Your practice is thought to have at least 1% of its practice population on a practice diabetes register.

3. Do I have to take part?

The participation of your practice is entirely voluntary and it is up to you to decide. We will describe the study and go through this information sheet with you when we visit your surgery if you invite us to do so. We will then ask you to sign a consent form to show you have agreed to take part.

4. What type of study is this?

This is a "Cluster Randomised Trial" in which practices which have consented to participate will be randomly allocated for their participating patients to be given the Patient Decision Aid or to the control group of practices in which normal diabetic practice will be followed.

5. What will happen to my practice if I take part?

If you agree to take part in this study, all GPs and one or two nurses in your practice will be given a *PANDAs* Training Package and the nurses will receive a brief training session at your practice, based on the package. If your practice has been randomised to the Patient Decision Aid, the package will be distributed immediately and this training will take place straightaway. Otherwise the package and training will be offered to your practice at the end of the study, if you wish to opt for this.

However the researchers will, before randomisation, have assisted the practice manager and nurses in how to identify eligible patients based on the following inclusion and exclusion criteria:

Inclusion criteria:

Patients with type 2 DM aged ≥ 21 who

- are taking the maximally tolerated dose of oral glucose-lowering drugs AND have a latest HbA1c $\geq 7.5\%$ throughout the last six months

OR

- have been advised to add or change to insulin therapy but declined previously AND have a latest HbA1c $\geq 7.5\%$.

Exclusion criteria:

Patients who:

- have a latest HbA1c $\geq 11\%$ unless they have previously declined insulin

- are currently using insulin therapy

- have chronic debilitating illness (including mental illness, visual or cognitive impairment)

- have difficulty understanding English or are unable to read or are without essential reading glasses at the time of consent

Your eligible patients will need to attend your normal clinic twice within six months for the purposes of the study.


1 A total of 446 people with type 2 diabetes will be invited to participate in the study
2 and up to 15 would be recruited from your practice until May 2009.


3
4 During the first visit, the researcher will go through the Participant Information Sheet
5 with patients. If they agree to participate, the researcher will ask them to sign a
6 consent form, and then to answer a questionnaire (10 minutes).

7
8
9 Depending on which treatment group your practice is put into, they will either receive
10 the Patient Decision Aid followed by a consultation with their GP/Practice Nurse or
11 just the consultation without the Patient Decision Aid. Going through the Patient
12 Decision Aid will take 15 minutes. After the consultation, all patients will be asked to
13 fill in another questionnaire (10 minutes).

14
15 During the second visit six months later, patients will be asked to answer a
16 questionnaire and a blood sample will be taken to assess their blood sugar level (5
17 minutes).

18 19 **Visit 1**



Visit 2**6. Expenses and payment**

The practice will receive £1,700 for set-up costs, including recruitment of the first consenting patient and then £50 per consenting patient thereafter, to compensate for costs of the time of all practice staff involved (practice manager, GPs, nurses and clerical officers)

At the end of the second visit, your patients will be given a £15 shopping voucher to compensate for the time they have taken to participate in this research.

7. What will the practice have to do?

A one-hour training session will be held at your practice for nurses (and GPs if they wish) on how to use the Patient Decision Aid. For practices in the intervention group this will be given immediately after the practice consents. For practices in the Control group this training will be available on request at the end of the trial.

Each practice will identify 15 eligible participants from the diabetes register and invite them to participate by telephone or mail.

Patients will attend a normal scheduled appointment at a diabetes clinic or a specially allocated appointment if the practice is willing. This appointment will, for practices in the intervention group, be after the proposed date for practice training and no later than 30 June 2009, the proposed closing date for recruitment of patients.

In the intervention group, the participants will use the Patient Decision Aid with the Nurse's assistance.

A questionnaire will be completed for each patient, but the researchers will administer that at your practice.

The GP or Nurse will then counsel the participants as in usual practice.

There will be a follow-up visit at 6-months to check the participants' HbA1c.

Your patients will be required to attend your clinic twice in six months during the study.

During their first visit, they will have to read the Patient Decision Aid, and answer a questionnaire before and after their routine consultation with the Doctor/Nurse. During the second visit, they will have to answer a questionnaire and a blood sample will be taken.

1
2
3
4
5
6
7
8
9
10
11
12

8. What is the procedure that is being tested?

We are testing the use of the Patient Decision Aid, which is a booklet containing evidence-based information about diabetes and its treatment options. It also contains questions which explore their ideas, concerns and values regarding the treatment. So far, more than 500 Patient Decision Aids have been developed in the world for various medical conditions to help patients with their decision-making. It is used to supplement GP- or nurse-led consultations .

13
14

9. What are the possible disadvantages and risks of taking part?

The Patient Decision Aid contains information about the possible side effects of different treatment options. Some people may feel anxious after reading this information. However, practice staff and/or the researchers will be able to answer any queries or concerns patients may have during and after the study.

15
16
17
18
19
20
21
22

10. What are the possible benefits of taking part?

Previous research on other medical conditions has shown that the use of Patient Decision Aids has helped people to make better-informed decisions about their treatments.

23
24
25
26
27
28
29

11. What happens when the research study stops?

The practice will continue to provide usual medical care.

30
31
32
33
34
35

12. What if there is a problem?

Any complaint about the way patients have been dealt with during the study or any possible harm they might suffer will be investigated. The detailed information on this is given in Part 2.

36
37
38
39
40
41

13. Will participation of patients in the study be kept confidential?

Yes. We will follow ethical and legal practice and all information about patients will be handled in confidence. The details are included in Part 2.

42
43
44
45
46
47

14. Is the purpose of this study educational?

Yes. Part of the data from this research will be used for a PhD study.

48
49
50
51
52
53
54
55
56
57
58
59
60

This completes Part 1.
If the information in Part 1 has interested your practice
and you are considering participation, please read the
additional information in Part 2 before making any
decision.

Part 2**15. What if relevant new information becomes available?**

Sometimes we get new information about the intervention being studied. If this happens, the researcher will tell the practice and then the study patients and discuss with them whether they should continue in the study. If patients decide not to carry on, they will be told that their care will be continued by your practice. If they decide to continue in the study, the researcher may ask them to sign an updated consent form.

If the study is stopped for any other reason, we will tell the practice and study patients. The practice will then continue the care of the study patients. The researchers will also keep practices and study patients informed of any new alternative treatment available for their diabetes care.

16. What will happen if patients don't want to carry on with the study?

Patients can withdraw from the study without giving a reason and without it affecting their care. The practice and its patients are also welcome to keep in contact with us to let us know of progress. Information already collected may still be used. Any stored blood samples that can still be identified as yours will be destroyed if you wish.

17. What if there is a problem?

If patients have a concern about any aspect of this study, they should ask to speak to the researchers who will do their best to answer their questions (Contact Brigitte Colwell/Rachel Dwyer at: 0114 271 5824/0114 226 9773 OR Professor Nigel Mathers at: 0114 271 5922). If they remain unhappy and wish to complain formally, they can do this through the NHS Complaints Procedure. Details can be obtained from the GP or the local Primary Care Trust.

In the event that something does go wrong and patients are harmed during the research and this is due to someone's negligence, then patients may have grounds for a legal action for compensation against the NHS but may have to pay their legal costs. The normal National Health Service complaints mechanisms will still be available to study patients.

18. Will patients' participation in this study be kept confidential?

Only the GP/Practice Nurse will have access to patients' medical records. All information collected will be coded and anonymised. The information we have collected as paper copies will be stored under lock and key, while the electronic data can only be accessed with a secure password. Only the researchers, sponsors, regulatory authorities and Research & Development auditors will have access to the identifiable data.

The data we collect will be used only for the purpose of this research; if data were to be used for future studies, further Research Ethics Committee approval will be sought. The data will be kept for 20 years according to the Medical Research Council guidelines.

1 All information which is collected about patients during the course of the research
2 will be kept strictly confidential, and any information about patients which leaves
3 the surgery will have their name, telephone and address removed so that they
4 cannot be recognised.
5

6 **19. Involvement of the practice**

7
8 Patients will be told that the practice has been informed about their participation
9 in this study.
10

11 **20. What will happen to any samples patients give?**

12
13 The blood sample patients give will be used to check their HbA1c as part of their
14 routine care.
15

16
17 The blood sample will be collected and sent to a standard laboratory through the
18 surgery. Only the researchers, GPs/Practice Nurse and the laboratory staff will
19 have access to the blood results. An appointment will be arranged by the practice
20 to provide feedback regarding patients' blood results.
21

22 **21. What will happen to the results of the research study?**

23
24 The results of this study will be published in medical journals. A summary of the
25 results will be sent to the practice and to study patients by post and you and they
26 will be invited to attend a public seminar.
27

28
29 Patients will not be identified in any report, publications or presentation without
30 seeking their full consent.
31

32 **22. Who is organising and funding the research?**

33
34 Sheffield Health and Social Research Consortium is the sponsor of this study and
35 the Department of Health will be funding it. Patients will be told that the practice
36 will be compensated for its costs of including them in this study.
37

38 **23. Who has reviewed the study?**

39
40 This study has been reviewed and given favourable opinion by North Sheffield
41 NHS Research Ethics Committee and scientifically reviewed by Sheffield Health
42 and Social Research Consortium as well as the Research for Patient Benefit
43 funding stream of the National Institute for Health Research. Research
44 governance approval on behalf of Sheffield Primary Care Trust has been given by
45 Sheffield Health and Social Research Consortium.
46
47

48 **24. Further information and contact details.**

49 *General Information about research*

50
51 Patients and the practice can visit the following web site to obtain more general
52 information about research:
53

54 INVOLVE – Promotes public involvement in the NHS: <http://www.invo.org.uk>
55

56 National Electronic Library for Health:
57

58
59 12071284_File000002_228009796.doc
60

1 <http://www.library.nhs.uk/trials>

2
3 *Specific information about this research project*

4
5 Ms Brigitte Colwell
6 Academic Unit of Primary Medical Care
7 University of Sheffield
8 Sam Fox House
9 Northern General Hospital
10 Herries Road
11 Sheffield
12 S5 7AU

13
14
15 Tel: 0114 2715824
16 Fax: 0114 2422136
17 Email: b.colwell@sheffield.ac.uk

18
19 *Advice to your patients as to whether they should participate*

20
21 Rachel Dwyer
22 Academic Unit of Primary Medical Care
23 University of Sheffield
24 Sam Fox House
25 Northern General Hospital
26 Herries Road
27 Sheffield
28 S5 7AU

29
30
31 Tel: 0114 2269773
32 Fax: 0114 2422136
33 Email: rachel.dwyer@sheffield.ac.uk

34
35
36 *Who should patients approach if unhappy with the study*

37
38 *The Chief Investigator:*
39 Professor Nigel Mathers
40 Academic Unit of Primary Medical Care
41 University of Sheffield
42 Sam Fox House
43 Northern General Hospital
44 Herries Road
45 Sheffield
46 S5 7AU

47
48
49 Tel: 0114 2715922
50 Fax: 0114 2422136
51 Email: n.mathers@sheffield.ac.uk

52
53 OR

54
55 Using the NHS Complaint Procedures, which you can obtain from the surgery or your
56 local NHS Primary Care Trust. You can visit the following web site for more details:

57 <http://www.nhs.uk/England/AboutTheNhs/ComplainCompliment.cmsx>



School
Of
Medicine
& Biomedical Sciences.

Participant Information Sheet

Study Title: Patient Decision Aid for Type 2 Diabetes
Protocol Ref: ZH25
Version: V3-22/04/07

Part 1 tells you the purpose of this study and what will happen to you if you take part.

Part 2 gives you more detailed information about the conduct of the study.

Part 1

We would like to invite you to take part in a research study. This study will find out whether a patient decision booklet is useful for people with type 2 diabetes who need to make decisions about their diabetes treatment.

Before you decide whether to participate, you need to understand why the research is being done and what it would involve. Please take time to read the following information carefully; talk to others about the study if you wish.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

1. What is the purpose of the study?

It is sometimes difficult to make decisions about the treatment of your illness, especially when it involves taking additional medications or changing to another medication. Informed decision-making not only requires you to know the risks and benefits of the treatment, it also depends on how you feel and think about the treatment. Sometimes, you may not have had opportunity to discuss this information in detail with your doctor or nurse.

A Patient Decision Aid is a simple booklet which contains useful information on diabetes and its treatment. It also explores what you feel and think about these treatments. It has been used widely to help people to make decisions about their specific illnesses, for example menopause or prostate problem.

Therefore, the purpose of this study is to find out whether using a patient decision aid before the GP's/Nurse's consultation will improve the quality of your decision-making and, eventually, your blood sugar control.

2. Why have I been invited?

Your GP/Practice Nurse has read through your medical notes and they found that your blood sugar is not well controlled. You might need a change in your treatment and this will involve you making a decision what you want to do to improve your blood sugar control.

A total of 446 people with type 2 diabetes will be invited to participate in the study.

3. Do I have to take part?

Your participation is entirely voluntary and it is up to you to decide. We will describe the study and go through this information sheet with you when you attend the clinic. We will then ask you to sign a consent form to show you have agreed to take part. You are free to withdraw at any time, without giving a reason. This would not affect your treatment or the standard of care you receive.

4. What type of study is this?

This is a "Randomised Trial". Sometimes we don't know which way of treating patients is best. To find out, we need to complete different treatments. We put people into groups and give each group a different treatment. The results are compared to see if one is better. To try to make sure the groups are the same to start with, patients from each practice are put into a group by chance.

5. What will happen to me if I take part?

If you agree to take part in this study, you will attend your normal clinic twice within six months. These visits, as far as possible, will coincide with your routine follow-up.


During the first visit, the researcher will go through the Participant Information Sheet with you. If you agree to participate, the researcher will ask you to sign a consent form, followed by answering a questionnaire (10 minutes).

Depending on which treatment group you are put into, you will either receive the Patient Decision Aid followed by a consultation with your GP/Practice Nurse or just the consultation without the Patient Decision Aid. Going through the Patient Decision Aid will take 15 minutes. After the consultation, you will be asked to fill in another questionnaire (10 minutes).


Six months later you will be contacted by a member of the PANDAs research team, prior to being sent a postal questionnaire for you to complete and return to us. We will also need a recent blood sugar level reading, which might mean that you will need to visit your practice to have this done.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Visit 1



Visit 2



6. Expenses and payment

When we have received your completed questionnaire, you will be sent a £15 shopping voucher to compensate for the time you have taken to participate in this research.

7. What will I have to do?

You are required to attend your clinic twice in six months during the study.

During the first visit, you will have to read the Patient Decision Aid, and answer a questionnaire before and after your routine consultation with the Doctor/Nurse. During the second visit, you will have to answer a questionnaire and a blood sample will be taken.

You should not participate in this research if you are currently involved in other drug studies, or have been in the past one-year.

8. What is the procedure that is being tested?

We are testing the use of the Patient Decision Aid, which is a booklet containing evidence-based information about diabetes and its treatment options. It also contains questions which explore your ideas, concerns and values regarding the treatment. So far, more than 500 Patient Decision Aids have been developed in the world for various medical conditions to help patients with their decision-making. It is used to supplement consultations with the doctors and nurses.

9. What are the possible disadvantages and risks of taking part?

The Patient Decision Aid contains information about the possible side effects of different treatment options. Some people may feel anxious after reading this information. However, your GP or nurse as well as the researchers will be able to answer any queries or concerns you may have during and after the study.

10. What are the possible benefits of taking part?

Previous research on other medical conditions has shown that the use of Patient Decision Aids has helped people to make better-informed decisions about their treatments.

11. What happens when the research study stops?

Your GP/Practice Nurse will continue to provide medical care for you.

1 **12. What if there is a problem?**
2

3 Any complaint about the way you have been dealt with during the study or any
4 possible harm you might suffer will be looked into. The detailed information on
5 this is given in Part 2.
6

7 **13. Will my taking part in the study be kept confidential?**
8

9
10 Yes. We will follow ethical and legal practice and all information about you will be
11 handled in confidence. The details are included in Part 2.
12

13 **14. Is the purpose of this study educational?**
14

15
16 Yes. Part of the data from this research will be used for a PhD study.
17
18
19
20
21

22 **This completes Part 1.**
23 **If the information in Part 1 has interested you and you**
24 **are considering participation, please read the additional**
25 **information in Part 2 before making any decision.**
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Part 2**15. What if relevant new information becomes available?**

Sometimes we get new information about the intervention being studied. If this happens, the researcher will tell you and discuss whether you should continue in the study. If you decide not to carry on, your care will be continued by your GP. If you decide to continue in the study, the researcher may ask you to sign an updated consent form.

If the study is stopped for any other reason, we will tell you and your GP will continue your care. We will also keep you informed of any new alternative treatment available for your diabetes care.

16. What will happen if I don't want to carry on with the study?

You can withdraw from the study without giving a reason and without affecting your care. You are also welcome to keep in contact with us to let us know your progress. Information already collected may still be used. Any stored blood samples that can still be identified as yours will be destroyed if you wish.

17. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions (Contact Ms Brigitte Colwell at: 0114 2715824 OR Professor Nigel Mathers at: 0114 2715922). If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from the GP or the local Primary Care Trust.

In the event that something does go wrong and you are harmed during the research and this is due to someone's negligence, then you may have grounds for a legal action for compensation against the NHS but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you.

18. Will my taking part in this study be kept confidential?

Only your GP/Practice Nurse will have access to your medical records. All information will be coded and anonymised. The information we have collected as paper copies will be stored under lock and key, while the electronic data can only be accessed with a secure password. Only the researchers, sponsors, regulatory authorities and Research & Development auditors will have access to the identifiable data.

The data we collect will be used only for the purpose of this research; if data were to be used for future studies, further Research Ethics Committee approval will be sought. The data will be kept for 20 years according to the Medical Research Council guidelines.

1 All information which is collected about you during the course of the research will
2 be kept strictly confidential, and any information about you which leaves the
3 surgery will have your name, telephone and address removed so that you cannot
4 be recognised.
5
6

7
8 **19. Involvement of the General Practitioner/Family doctor (GP)**

9 Your GP has been informed about your participation in this study.
10
11

12
13 **20. What will happen to any samples I give?**

14
15 The blood sample you give will be used to check for your sugar control (HbA1c).
16 This is part of your normal routine care.
17

18 The blood sample will be collected and sent to a standard laboratory through the
19 surgery. Only the researchers, GPs/Practice Nurse and the laboratory staff will
20 have access to the blood results. An appointment will be arranged by the practice
21 to provide feedback regarding your blood results.
22
23

24
25 **21. What will happen to the results of the research study?**

26
27 The results of this study will be published in medical journals. A summary of the
28 results will be sent to you by post and you will be invited to attend a public
29 seminar.
30

31 You will not be identified in any report, publications or presentation without
32 seeking your full consent.
33
34

35
36 **22. Who is organising and funding the research?**

37
38 The Sheffield Health and Social Research Consortium is the sponsor of this study
39 and the Department of Health will be funding the research. Your healthcare
40 providers will be paid for including you in this study.
41
42

43
44 **23. Who has reviewed the study?**

45
46 All research in the NHS is looked at by an independent group of people, called a
47 Research Ethics Committee to protect your safety, rights, well-being and dignity.
48 This study has been reviewed and given favourable opinion by North Sheffield
49 Local Research Ethics Committee.
50
51
52
53
54
55
56
57
58
59
60

24. Further information and contact details.

General Information about research

You can visit the following web site to obtain more general information about research:

INVOLVE – Promotes public involvement in the NHS: <http://www.invo.org.uk>

National Electronic Library for Health:
<http://www.library.nhs.uk/trials>

Specific information about this research project

Ms Brigitte Colwell
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715824
Fax: 0114 2715915
Email: b.colwell@sheffield.ac.uk

Advice as to whether you should participate

Ms Brigitte Colwell
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715824
Fax: 0114 2715915
Email: b.colwell@sheffield.ac.uk

Who you should approach if unhappy with the study

Professor Nigel Mathers
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715922
Fax: 0114 2715915
Email: n.mathers@sheffield.ac.uk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

OR

Using the NHS Complaint Procedures, which you can obtain from the surgery or your local NHS Primary Care Trust. You can visit the following web site for more details:
<http://www.nhs.uk/England/AboutTheNhs/ComplainCompliment.cmsx>

For peer review only

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Checklist of items to include when reporting a cluster randomised trial

* = addition to CONSORT <i>Modifications to checklist in italics</i>			
PAPER SECTION and topic	Item	Descriptor	Reported on Page No.
<i>TITLE & ABSTRACT</i>	1*	How participants were allocated to interventions (e.g., “random allocation”, “randomised”, or “randomly assigned”), <i>specifying that allocation was based on clusters</i>	P1
<i>INTRODUCTION</i> Background	2*	Scientific background and explanation of rationale, <i>including the rationale for using a cluster design.</i>	P6
<i>METHODS</i> Participants	3*	Eligibility criteria for participants <i>and clusters</i> and the settings and locations where the data were collected.	P7
Interventions	4*	Precise details of the interventions intended for each group, <i>whether they pertain to the individual level, the cluster level or both</i> , and how and when they were actually administered.	P8
Objectives	5*	Specific objectives and hypotheses, <i>and whether they pertain to the individual level, the cluster level or both.</i>	P6
Outcomes	6*	Report clearly defined primary and secondary outcome measures, <i>whether they pertain to the individual level, the cluster level or both</i> , and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).	P9-10
Sample size	7*	How <i>total</i> sample size was determined (<i>including method of calculation, number of clusters, cluster size, a coefficient of intraclass correlation (ICC or k), and an indication of its uncertainty</i>) and, when applicable, explanation of any interim analyses and stopping rules.	P11-13
Randomisation. Sequence generation	8*	Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification, <i>matching</i>).	P7
Allocation concealment	9*	Method used to implement the random allocation sequence, <i>specifying that allocation was based on clusters rather than individuals and clarifying whether the sequence was concealed until interventions were assigned.</i>	P7
Implementation	10	Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.	P7
Blinding (Masking)	11	Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated.	P7
Statistical methods	12*	Statistical methods used to compare groups for primary outcome(s) <i>indicating how clustering was taken into account</i> ; methods for additional analyses, such as subgroup analyses and adjusted analyses.	P11
<i>RESULTS</i> Participant flow	13*	Flow of <i>clusters and</i> individual participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of <i>clusters and</i> participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons.	P31-32
Recruitment	14	Dates defining the periods of recruitment and follow-up.	Practices: Aug 2008-Jul 2010; Patients Nov 2008-Sept 2010; Follow-up March 2011
Baseline data	15*	Baseline information for each group <i>for the individual and cluster levels as applicable</i>	P34-35
Numbers analyzed	16*	Number of <i>clusters and</i> participants (denominator) in each group included in each analysis and whether the analysis was by “intention-to-treat”. State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	P35

1 2 3 4	Outcomes and Estimation	17*	For each primary and secondary outcome, a summary of results for each group measures <i>for the individual or cluster level as applicable</i> , and the estimated effect size and its precision (e.g., 95% confidence interval) <i>and a coefficient of intracluster correlation (ICC or k) for each primary outcome</i> .	P36-7
5 6 7	Ancillary analyses	18	Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	n/a
8	Adverse events	19	All important adverse events or side effects in each intervention group.	n/a
9 10 11 12	<i>DISCUSSION</i> Interpretation	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	21-22
13	Generalisability	21*	Generalisability (external validity) <i>to individuals and/or clusters (as relevant)</i> of the trial findings.	23
14 15	Overall evidence	22	General interpretation of the results in the context of current evidence.	22



Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices – a cluster randomised controlled trial (PANDAs) in General Practice

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001469.R1
Article Type:	Research
Date Submitted by the Author:	18-Sep-2012
Complete List of Authors:	Mathers, Nigel; University of Sheffield, Academic Unit of Primary Medical Care Ng, Chirk-Jen; University of Malaya, Department of Primary Care Medicine Campbell, Michael; University of Sheffield, SCHARR Colwell, Brigitte; University of Sheffield, Academic Unit of Primary Medical Care Brown, Ian; Sheffield Hallam University, Centre for Health and Social Care Research Bradley, Alastair; University of Sheffield, Academic Unit of Primary Medical Care
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	General practice / Family practice, Patient-centred medicine
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE, PRIMARY CARE

SCHOLARONE™
Manuscripts

Title:

Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices – a cluster randomised controlled trial (PANDAs) in General Practice.

Authors

Nigel Mathers¹ MD. PhD. FRCGP.

Chirk-Jenn Ng² MBBS. MMed (Family Medicine). PhD.

Michael J Campbell³ BA. MSc. PhD. CStat.

Brigitte Colwell⁴ BA.

Ian Brown⁵ BSc. PhD. RN.

Alastair Bradley⁶ MB ChB. LLB. MRCP.

¹ Professor of Primary Medical Care, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

² Associate Professor, Department of Primary Care Medicine, Faculty of Medicine Building, University of Malaya, 50603 Kuala Lumpur Malaysia.

³ Professor of Medical Statistics, School of Health and Related Research, University of Sheffield, 30 Regent Street, Sheffield S1 4DA, UK.

⁴ Research Associate, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

⁵ Senior Lecturer, Centre for Health and Social Care Research, Sheffield Hallam University, Montgomery House, 32 Collegiate Crescent, Sheffield, S10 2BP, UK.

1
2
3 ⁶ NIHR In-Practice Training Fellow, Academic Unit of Primary Medical Care, University of
4
5 Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU,
6
7 UK
8
9

10
11 Corresponding Author: Professor Nigel Mathers, Academic Unit of Primary Medical Care,
12
13 University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road,
14
15 Sheffield S5 7AU. Email: n.mathers@sheffield.ac.uk
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE FOCUS:

- Does the use of the PANDAs decision aid in general practice improve decision quality and glycaemic control in people who are making treatment choices about their type 2 diabetes mellitus (T2DM) treatment, including whether or not to start insulin?

KEY MESSAGES:

- Patient decision aids provide evidence-based information about treatment options, help patients to clarify their values and guide them systematically to make an informed decision.
- The use of the PANDAs decision aid by doctors and nurses in usual NHS general practice with people who have T2DM and are making treatment choices reduces decision conflicts and improves knowledge, realistic expectations and patients' involvement in decision making.
- HbA1c levels were reduced in both groups at six months when compared to baseline (0.24% controls and 0.37% intervention) with a non-significant mean difference between the two groups of 0.351, $p=0.117$).

STRENGTHS AND LIMITATIONS

- This study was underpowered to detect a minimally, clinically important difference in glycaemic control between the two groups due to slow recruitment.
- There was no blinding in this study due to the nature of the intervention which may have influenced the outcome assessment.
- This was a pragmatic trial and there may have been variations in how the decision aid was used in different General Practices which may have diluted the effect of the study.

Abstract

Objective

To determine the effectiveness of a patient decision aid (PDA) to improve decision quality and glycaemic control in people with diabetes making treatment choices using a cluster RCT.

Design

A cluster randomised controlled trial.

Setting

49 general practices in UK randomised into intervention (n=25) and control (n=24).

Participants

General Practices: Inclusion criteria: > 4 medical partners; list size > 7000; and a diabetes register with > 1% of practice population. 191 Practices assessed for eligibility, 49 Practices randomised and completed the study.

Patients: People with T2DM taking at least two oral glucose-lowering drugs with maximum tolerated dose with an HbA1c greater than 7.4% (IFCC HbA1c >57mmol/mol) or advised in the preceding six months to add or consider changing to insulin therapy. Exclusion criteria: currently using insulin therapy; difficulty reading or understanding English; difficulty in understanding the purpose of the study; visual or cognitive impairment or mentally ill. 182 assessed for eligibility, 175 randomised to 95 intervention and 80 controls, 167 completion and analysis.

Intervention

Brief training of clinicians and use of PDA with patients in single consultation.

Primary Outcomes

Decision quality (decisional conflict scores, knowledge, realistic expectations and autonomy) and glycaemic control (glycosolated haemoglobin, HbA1c).

Secondary Outcomes

1
2
3 Knowledge and realistic expectations of the risks and benefits of insulin therapy and diabetic
4
5 complications.
6

7 **Results**

8
9 Intervention Group: lower total decisional conflict scores (17.4 v 25.2, $p<0.001$); better
10
11 knowledge (51.6% v 28.8%, $p<0.001$); realistic expectations (risk of ‘hypo’, ‘weight gain’,
12
13 ‘complications’; 81.0% v 5.2%, 70.5% v 5.3%, 26.3% v 5.0% respectively, $p<0.001$); and
14
15 were more autonomous in decision making (64.1% v 42.9%, $p=0.012$).
16

17
18 No significant difference in the glycaemic control between the two groups.
19

20 **Conclusions**

21
22 Use of the PANDAs decision aid reduces decisional conflict, improves knowledge, promotes
23
24 realistic expectations and autonomy in people with diabetes making treatment choices in
25
26 general practice.
27
28

29
30
31
32 **ISRCTN Trials Register Number** 14842077
33

34 **Data sharing statement:** There are no additional data available
35

36 **Funding:** Funded by National Institute for Health Research, Research for Patient Benefit.
37

38 **Competing Interests:** There are no competing interests.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Diabetes mellitus is a growing health problem in England with a total of 2.4 million people (5.5% of population) living with the disease in 2011.¹ Diabetes currently accounts for 10% of all NHS expenditure.² However, overall diabetes control is less than satisfactory. In 2008/2009, 67% of people with T2DM achieved a glycosolated haemoglobin (HbA1c) of less than 7.5% (IFCC HbA1c 58 mmol/mol).³

The UK Prospective Diabetes Study (UKPDS) has established the importance of maintaining good blood glucose control in patients with T2DM. For every 1.0% increase in HbA1c, there is an increase, in risk, of 14% for myocardial infarction, 21% for diabetes-related deaths and 37% for micro-vascular complications.⁴ In the same study, it was reported that only 25% were able to achieve good glycaemic control with monotherapy after 9 years of the trial. Most patients will require combination therapy, including insulin, 5-10 years after diagnosis.⁵

Currently, the NICE guidelines recommend a combination of metformin and insulin secretagogues in those who have inadequate blood glucose control with monotherapy. In those in whom dual therapy has been unsuccessful, either insulin or a thiazolidinedione should be added to optimise glycaemic control.³ Frequently, this poses a clinical dilemma for both patients and healthcare providers; both parties need to agree which next treatment option to pursue and this includes whether or not to start insulin therapy. However, patients may be fearful of needles and the side effects of insulin (e.g. hypoglycaemia); they need to acquire new skills; change their daily routine and address the challenge of glucose monitoring.⁶ Similarly, doctors may be hesitant to prescribe insulin due to their own lack of relevant skills, time pressures, and a fear of increasing the risk of side effects.^{7 8} In this category of patients,

1
2
3 the decision making process is a complex one. Studies have shown that patients usually make
4
5 decisions based on emotions such as trust, rather than on the information given by their
6
7 healthcare providers.⁹ For their part, doctors do not necessarily follow evidence-based
8
9 guidelines¹⁰ and it was in this context that the PANDAs decision aid was developed to
10
11 facilitate shared decision making between clinicians and patients when making decisions
12
13 about the treatment of their diabetes at this stage of their illness. The development of the
14
15 PANDAs decision aid will be described elsewhere.
16
17
18
19

20
21 Patient decision aids are tools that provide evidence-based information about treatment
22
23 options, help patients to clarify their values and guide them systematically to make an
24
25 informed decision. Patient decision aids have been shown to improve knowledge, realistic
26
27 expectations, value-decision concordance and patient involvement in decision making.¹¹
28
29
30
31

32 The primary research question was “Does the use of the PANDAs decision aid improve
33
34 decision quality in patients with T2DM who are making a decision whether or not to start
35
36 insulin in general practice?”
37
38
39
40

41 The study focussed on people with T2DM who had poor glycaemic control (HbA1c
42
43 >7.4mmol/l or IFCC HbA1c >57 mmol/mol) and who, despite receiving optimal oral glucose
44
45 lowering therapy, required "step-up" treatment. A cluster randomised controlled trial was
46
47 carried out to evaluate the clinical effectiveness of the decision aid on decision quality and
48
49 glycaemic control.
50
51
52
53
54
55
56
57
58
59
60

Methods

The setting for this study was general practices in Sheffield, Rotherham and Doncaster with recruitment being undertaken through the National Institute for Health Research Primary Care Research Network (PCRN) and the Cutler Group of South Yorkshire Research Practices. The recruitment of practices and patients began in 2008 and the data collection ended in 2011.

Practices were invited to take part by postal invitation following a publicity campaign using a modified viral marketing technique involving sequential non-specific PANDAs post cards ('PANDAs are coming') to 'pique' interest, followed by increasingly informative flyers (Figure 1).¹²

The inclusion criteria for general practices were: > 4 medical partners; list size > 7000; and a diabetes register with > 1% of practice population. The participating general practices were asked to screen their computerised diabetes register for eligible patients with T2DM (aged > 21 years). The inclusion criteria were: people with T2DM who were taking at least two oral glucose-lowering drugs with maximum tolerated dose and had a latest HbA1c greater than 7.4% (IFCC HbA1c >57mmol/mol) or had been advised in the preceeding six months to add or consider changing to insulin therapy. The exclusion criteria were: patients who were currently using insulin therapy; had difficulty reading or understanding English; had difficulty in understanding the purpose of the study; had visual or cognitive impairment and were mentally ill.

1
2
3 The patients were contacted by a letter from their general practitioners (GPs) and invited to
4 participate in this study. If they agreed, they were sent details of the study (including the
5 information sheet) and asked to attend an appointment at their regular practice where consent
6 to the study was obtained by the researchers. Practices were incentivised to take part in the
7 trial, receiving a nominal payment to cover legitimate expenses.
8
9
10
11
12

13 14 15 16 **Randomisation and concealment:**

17
18 This was a pragmatic trial and all eligible and willing practices were randomly allocated by
19 computer to two groups: the intervention group used the PANDAs decision aid when making
20 the specified treatment choices and the control group delivered usual care. We stratified the
21 practices according to the Practice list size. Each practice was considered a cluster and all
22 patients within the cluster received either the intervention or usual care. The practices were
23 the units of randomisation, since it would have been difficult to allocate two patients in the
24 same practice to different arms of the trial. Blinding of the intervention and assessment of the
25 process measures were not feasible in view of the nature of the intervention studied. A
26 statistician generated the random allocation sequence while a secretary who was not involved
27 in the research study assigned participants to either the intervention or control groups. A
28 researcher and a research nurse enrolled the participants into the study.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Intervention and control groups**

46
47 This was a complex intervention comprised three components: PDA; healthcare professional
48 training workshop; and use of the PDA in a consultation. The development of the
49 intervention was based on the UKMRC framework for the development and evaluation of
50 complex interventions¹³ and this will be reported in another study. The doctors and/or the
51 nurses who were primarily involved in the diabetes care of the practice attended a short
52
53
54
55
56
57
58
59
60

1
2
3 training session lasting between one to two hours on how to use the PANDAs decision aid.

4
5 The training topics covered included the principles of shared decision making, the importance
6
7 and clinical effectiveness of decision aids, the evidence for various treatment options for
8
9 poorly controlled T2DM and essential skills in risk communication.¹⁴

10
11 The patient participants were given the PANDAs decision aid (Table 1) by the researcher to
12
13 read and complete prior to the consultation in the waiting room. This was followed by the
14
15 consultation with the GP or the practice nurse facilitated by the use of the PANDAs decision
16
17 aid. In the control group, the GP and the practice nurse did not receive any training and the
18
19 PANDAs decision aid was not used. The GPs or the nurses conducted a normal consultation
20
21 with the patient.
22
23
24
25
26

27 Table 1: Content of the PANDAs decision aid

28
29 The PANDAs Decision Aid contains the following information in line with the
30 International Patient Decision Aid Standards criteria:

- 31
32
- 33 1. Information about the insulin and other treatment options
 - 34 ■ Reasons for starting insulin
 - 35 ■ The procedure of insulin injection
 - 36 ■ Common concerns about insulin
 - 37 ■ Treatment options: Make no change; lifestyle modification; insulin therapy
 - 38 2. Present probabilities of outcomes
 - 39 ■ The advantages and disadvantages of each option were described in words,
40 numbers and pictures ('smiley faces')
 - 41 3. Patient value clarifications
 - 42 ■ A list of patients' values about the advantages and disadvantages of insulin
43 therapy
 - 44 4. Structured guidance
- 45
46
47
48
49
50
51

52 Outcome measures and follow-up

53 Primary outcome measure:

54
55
56
57
58
59
60

1
2
3 The primary outcome measures were decisional conflict based on the Decisional Conflict
4 Scale score,^{15 16} (immediate) used as an indicator of decision quality and glycaemic control
5 (glycosolated haemoglobin, HbA1c) at six months.
6
7

8
9
10 **Secondary outcome measures:**

11 Knowledge and realistic expectations of the risks and benefits were assessed by asking the
12 patients to indicate their perceived chance of experiencing the side effects of insulin therapy
13 and diabetic complications.
14
15
16

17
18
19
20 Operational definitions of the secondary outcome measures were agreed as (1) knowledge:
21 about the treatment option that is most effective in reducing blood glucose level and diabetic
22 complications; (2) realistic expectations: a self-reported chance of experience hypoglycaemia,
23 gaining weight and developing complications; (3) preference option: preferred treatment
24 options of initiate insulin, adhere more to diabetes advice more regularly or make no change;
25 (4) participation in decision making: using the Control Preference Scale scores and (5) regret:
26 using the Regret Scale scores.
27
28
29
30
31
32
33
34
35
36
37

38 The secondary measures were other decision quality indicators (knowledge of treatment
39 options, realistic expectation, preference option, proportion undecided, participation in
40 decision making); duration of consultation; and outcome of decision making (regret and
41 persistence with the chosen option). Persistence with the chosen option is a single self-
42 reported item which the participant was asked what their treatment was six months after the
43 intervention. They were considered to be persistent with their decision if there was no change
44 in the treatment in the past six months.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The practice provided the baseline and six-month follow up data. Baseline data comprised:
4
5 practice and clinician profile, patients' socio-demography, diabetes profile (duration,
6
7 complication, prescription, glycaemic control), comorbidities (e.g. hypertension, coronary
8
9 artery disease, dyslipidaemia, chronic kidney disease); and previous T2DM education.
10
11 Immediate post-intervention data collected were: decision quality indicators and duration of
12
13 consultation. Six-month data comprised: HbA1c, regret score and persistence with the
14
15 decision.
16
17
18
19

20 21 **Instruments:**

22 23 ***Decisional conflict scale (DCS)***

24
25 The DCS measures personal perceptions of (a) uncertainty in choosing options; (b)
26
27 modifiable factors contributing to uncertainty such as feeling uninformed, unclear about
28
29 personal values and unsupported in decision making; and (c) effective decision making such
30
31 as feeling the choice is informed, value-based, likely to be implemented and expressing
32
33 satisfaction with the choice. It was derived from the decisional conflict construct.¹⁷ The
34
35 traditional 16-item DCS with five response categories was used in this study. There are five
36
37 subscales: 'uncertainty subscale'; 'informed subscale'; 'values clarity subscale'; 'support
38
39 subscale'; and 'effective decision subscale'.¹⁵ The DCS has been shown to be reliable and is
40
41 correlated with the constructs of knowledge, regret and discontinuance, and has the ability to
42
43 discriminate between those who make and delay decisions. Scores lower than 25 are
44
45 associated with implementing decisions while scores exceeding 37.5 are associated with
46
47 decisional delay or feeling unsure about implementation.¹⁶
48
49
50
51
52
53

54 55 ***Control preference scale (CPS)***

56
57 The CPS aims to measure the extent to which patients prefer or are involved in decision
58
59
60

1
2
3 making during a clinical consultation. It measures the preferred or actual role in decision
4
5 making by asking a single question which contains five items: two represents active or patient
6
7 controlled role; one a shared or collaborative role; and two items represent a passive or
8
9 practitioner controlled role.¹⁸ It has proven validity and reliability in both general public and
10
11 patients with medical conditions.^{18 19} A recent study found a good inter-rater reliability and
12
13 good agreement between self and researcher ratings on Control Preference Scale.²⁰
14
15

16 17 18 ***Regret scale*** 19

20 This scale measures 'distress or remorse after a (health care) decision'. It is a five-item scale
21
22 with five responses (1 strongly agree to 5 strongly disagree). Regret is measured at a point
23
24 where the respondent can reflect on the effects of the decision that has been made. A score of
25
26 0 means no regret while a score of 100 means high regret. The regret scale correlates with
27
28 satisfaction with the decision, decisional conflict and overall quality of life.²¹
29
30
31
32
33

34 **Sample size and statistical analysis (HbA1c)** 35

36 Assuming an intracluster correlation coefficient of 0.047 for HbA1c²² and a cluster sample
37
38 size of 5 patients per practice, with 80% power and 5% (two-sided) significance, 160 patients
39
40 in each group are required to allow the detection of 0.5% (SD 1.5%) difference in HbA1c.²³
41
42 The total number of Practices required, therefore, was estimated to be 64. When using the
43
44 total DCS score as the primary outcome measure and using a similar method to calculate
45
46 sample size, the total number of participants needed was 86 and the total cluster size was
47
48 estimated to be 17. We aimed for the larger sample size for the design of this study.
49
50

51 The outcome variables, were treated as continuous and we used multiple regressions with
52
53 generalised estimating equations (GEE) and exchangeable correlation to allow for clustering.
54
55

56 Multiple logistic regression with GEE was used for binary outcomes in the secondary
57
58
59
60

analysis. If a patient in the intervention arm refused to use the decision aid, they were still included in the intervention group for analysis and were analysed according to the intention-to-treat principle.

Results

Study practices profile (Table 2)

Forty-nine general practices were recruited into the study. The practices in both arms of the study were well matched in terms of mean list size, mean diabetes list size, mean number of partners and practice nurses and mean Index of Multiple Deprivation Scores.

Table 2 Study practice profile (mean and range)

	Intervention	Control
Number of Practices	25	24
List Size	7,510 (3,129-20,900)	7,325 (1,974-13,500)
People with diabetes	350(96-912)	356 (143-634)
No of partners	5 (1-13)	5 (2-10)
No of practice nurses	3 (1-6)	3 (1-5)
IMD* score	30.35 (range 8.9 - 59.5)	30.20 (range 6.5 - 55)

*Index of Multiple Deprivation

Participants

182 patients were assessed for eligibility, of whom seven were excluded for not meeting the inclusion criteria (n=5), or declined to participate (n=2). 175 patients were randomised, of whom 95 were allocated to the intervention group and 80 to the control group. Six participants in the intervention group were lost to follow-up (3 died, 1 moved away and 2 withdrew their consent), and 2 participants in the control group were also lost to follow-up (1 died and 1 moved away). The results from 167 participants were analysed (89 interventions and 78 controls) (Figure 2).²⁴

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Table 3 compares the socio-demographic and clinical profiles of patients between intervention and control groups. The mean age of the patients was 64.6 years (range 39 – 87). The patients in the intervention group and control group were broadly similar except that the patients in the intervention group were older and more likely to have coronary heart disease. In both groups the patients were more likely to consult nurses for diabetes related conditions than a doctor (mean number of consultations with nurses and GPs were 2.03 and 1.15 respectively). The mean length of the initial consultation for patients, when entering the study, in the intervention and control groups was 15.31 and 16.95 minutes respectively (mean difference 1.67min, 95% CI 0.93 to 4.27 mins).

56
57
58
59
60

Table 3. Baseline patient socio-demographic and clinical information of the intervention and control groups (mean and range unless otherwise stated)

	Intervention	Control
Socio-demographic profile		
Number	95	80
Demography		
Age (years)	66 (39 – 82)	62 (42 – 87)
Male (%)	50 (52%)	46 (57%)
Duration of education (years) (SD)	12.22 (4.83) (8 – 45*)	11.49 (2.74) (2 – 22)
Ethnicity white (%)	85 (89.5%)	71 (88.8%)
Clinical profile		
Duration of diabetes (years) (SD)	8.4(4.1)(1 – 25)	7.07(3.83) (1 – 16)
HbA1c (IFCC HbA1c mmol/mol) in past 12 months (%) (SD)	8.6 {70}(1.9) (7.4 – 13.1){57-120}	8.8 {73}(0.98) (7.5 – 11.5){58-102}
Number with diabetic complications (%)		
Coronary Heart Disease	29/93 (31.1)	13/80 (16.2)
Peripheral vascular disease	3/93 (3.22)	3/80 (3.75)
Stroke	8/93 (8.6)	5/80 (6.25)
Retinopathy	20/93 (21.5)	10/80 (12.5)
Nephropathy	5/93 (5.37)	10/80 (12.5)
Neuropathy	5/93 (5.37)	3/80 (3.75)
Number with co-morbidities (%)		
Hypertension	58/93 (62.3)	43/80 (53.75)
Dyslipidaemia	52/93 (55.9)	38/80 (47.5)
Health Service Utilisation		
Number of diabetes-related visits to the general practice in the past 6 months (SD)		
General Practitioners	0.92 (1.13) (0-5)	1.41 (1.68) (0–11)
Nurse	2.15 (1.84)	1.89 (1.36)
Number of diabetes-related visits to the hospital in the past six months (SD)		
Length of consultation (min)	15.31 (2 – 39)	16.95 (5 – 45)

** Self-report (this figure includes self taught continuing education outwith a formal educational programme).

Decisional Conflict

The mean difference between the intervention and the control groups on the total score for decisional conflict was -7.72 (95% CI -12.5 to -2.97). The distribution of decisional conflict sub-scores are shown in Table 4. The total and subscores for every decisional conflict domain, apart from the support sub-score, were significantly lower in the intervention group.

The difference in uncertainty, informed, value clarity and effective decision subscores between the intervention and control groups remained statistically significant after adjusting for differences in age, education and gender.

Table 4: Comparison of decisional conflict scores between the intervention and control groups (0=no decisional conflict, 100=maximum decisional conflict).

Subscore	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	95% CI p value
Uncertainty	20.1 (16.6)	29.4 (20.8)	-9.29	-8.72	-14.9 to -2.53 p=0.006
Informed	18.1 (13.3)	26.0 (16.6)	-7.65	-8.69	-13.3 to -4.10 p<0.001
Values Clarity	16.7 (13.9)	26.7 (18.2)	-9.74	-9.84	-14.8 to -4.84 p<0.001
Support	17.4 (13.1)	20.8 (15.3)	-3.41	-3.66	-8.58 to 1.25 p=0.144
Effective Decision	16.1 (14.4)	23.3 (15.2)	-9.70	-9.80	-16.8 to 2.75 p=0.006
Total Score	17.4 (12.6)	25.2 (14.9)	-7.67	-7.72	-12.5 to -2.97 p<0.001

* adjusted for clustering, insulin initiation, age, gender and education level

Glycosolated Haemoglobin (HbA1c)

Table 5 shows the HbA1c levels for both the intervention and the control groups at six months. HbA1c levels reduced in both groups at six months compared to baseline (0.24% in the control group and 0.37% in the intervention group). The mean difference in the HbA1c level at 6 months between the two groups was 0.351 (95%CI -0.088 to 0.789, p=0.117) after adjusting for age, education, gender, baseline HbA1c, insulin status and clustering.

Table 5: The effect of the PANDAs decision aid on HbA1c at 6 months

Intervention	Control	Mean difference in HbA1c unadjusted	Mean difference in HbA1c adjusted*	95% CI
8.64 (SD 1.37)	8.40 (SD 1.31)	0.244	0.351	-0.088 to 0.789

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering.
P=0.117

Secondary outcomes:**Knowledge**

A comparison of the proportions of patients who answered the 'knowledge' questions correctly between the intervention and the control groups showed there were more patients in the intervention group who answered the questions correctly compared to those who received 'usual care'. (Table 6)

Table 6: Secondary outcomes: Knowledge and realistic expectations (Questions answered correctly)

	Intervention Decision Aid	Control Usual Care	Unadjusted Odds Ratio	Adjusted ⁺ Odds Ratio (95% CI)	ICC	p value
Knowledge						
Number	95	80				
Which choice has the greatest chance of lowering	49 (51.6%)	23 (28.8%)	2.63	1.31 (1.14 to 1.50)	0.071	<0.001

your blood sugar?						
Which choice has the greatest chance of lowering your complications?	29 (30.5%)	23 (28.8%)	1.09	1.20 (0.07 to 19.05)	0.202	0.90
Realistic expectations						
If you take insulin, about how many times might you experience 'hypos' in a year?	77/95 (81.0%)	4/75 (5.2%)	75.9	^	-	<0.001*
If you take insulin, about how much more weight might you gain in a year?	67/95 (70.5%)	4/75 (5.3%)	42.5	^	-	<0.001*
Out of 100 people like you who take insulin, how many may get complications in five years?	25/95 (26.3%)	4/80 (5%)	6.8	^	-	<0.001*

* adjusted for clustering, insulin initiation, age, gender and education level

^ Numbers answering correctly in the control group were too few to control for clustering.

* Chi-squared p value

Realistic expectations

Patients who used the decision aid had significantly more realistic expectations about the side effects of insulin therapy compared to those who did not (Table 6). Almost all patients in the intervention group, compared to those of the control group, knew correctly their risk of hypoglycaemia (81.0% vs 5.2%, $p < 0.001$) and weight gain (70.5% vs 5.3%, $p < 0.001$). More

people knew their risk of complications in the intervention group if they were to take insulin, although most still got it wrong (26.3% vs 5.0%, $p < 0.001$).

Preferred option

Table 7 shows that the preferred choices of patients in the intervention and control groups were similar after consultation.

Table 7: Preferred choices of patients in intervention and control groups post-consultation

	Make No Change	Follow the diabetes advice more regularly	Start insulin	I am not sure	Total
Control	33 (42.3.8%)	29 (37.1%)	9 (11.5%)	7 (9%)	78
Intervention	32 (34.7%)	38 (41.3 %)	17 (18.4%)	5 (5.4%)	92
Total	65	67	26	12	170

($\chi^2_3 = 2.88$, $p = 0.410$)

Proportion undecided

Table 8 shows that patients in the intervention group were over 3 times more likely to change from undecided to decided than in the control group, although, this was not statistically significant ($P = 0.15$).

Table 8: Comparison of the proportion of patients who remained undecided between the intervention and control group immediately after intervention

	Intervention	Control	OR	95%CI
Undecided (pre-consultation)	23	14		
Undecided (post-consultation)	8*	9*		

Odds in favour of changing: undecided (pre) to decided (post)/ decided (pre) to undecided (post)	18/3**	11/6**	3.27	0.69 to 16.3 (p=0.15)
---	--------	--------	------	--------------------------

* This figure of 8 patients includes 5 who remained 'undecided' post consultation and includes 3 patients who moved from 'decided' pre consultation to 'undecided' post consultation. Similarly for the 9 'undecided' post consultation patients in the control group, 3 remained 'undecided' and 6 had moved from 'decided' to 'undecided'.

**This ratio means that a total of 18 patients changed from 'undecided' to 'decided' in the intervention group and that 3 moved in the opposite direction (ie a net total of 15 patients [18 – 3] had 'decided' post consultation). In the control group the corresponding numbers were 11 and 6 (ie a net total of 5 patients [11 – 6] had 'decided' post-consultation).

Participation in decision making

There were significant differences in patients' decision making role between the intervention and control groups (p=0.012 Chi square) (Table 9). It may be seen that a smaller proportion of patients in the intervention group described their decision about their diabetes treatment as "passive" or "collaborative".

Table 9: Decision making roles of patients in the intervention and control groups, post consultation with their doctor/nurse

	How did you make your decision about your diabetes treatment? (n = 169)			
	Passive	Collaborative	Autonomous	Total
Control	16 (21%)	28 (36%)	33 (43%)	77 (100%)
Intervention	8 (9%)	25 (27%)	59 (64%)	92 (100%)

($\chi^2=8.9$, df=2, p=0.012)

However, patients in the intervention arm were more likely to demonstrate autonomy in their decision making about their treatment compared to the control group (64% compared to 43%). Further analysis showed that an individual patient was 1.23 (95% CI 1.05 to 1.44, p=0.008) times more likely to make an 'autonomous' decision using the PANDAs decision aid when the intervention and control groups are compared, allowing for age and gender.

Regret and persistence with decision

Table 10 shows that there was no difference at 6 months in the regret scale, but that patients in the intervention group were rather more likely to persist with their chosen option.

Table 10: Comparison of the decision Regret Score and persistence with chosen option between the intervention and usual care groups after six months

	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	p value
Regret Score	44.63	44.57	0.06	0.22 (-2.48 to 2.93)	0.872
Persistence with chosen option	68.1%	56.3%	1.65 [†]	1.17 [^] (1.00 to 1.36)	0.041

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering

[†]Crude odds ratio

[^]Adjusted odds ratio

Acceptability

Most of the PDA users found the PDA useful. When asked about their opinion of the PDA, 83.2% (n=88), 86.3% (n=89), 86.3% (n=89) and 88.4%(n=90) thought that the PDA had helped them: to recognize that a decision needs to be made; know that the decision depends on what matters most to them; think about how involved they wanted to be in the decision; and prepare to talk to the nurse or doctor about what mattered most to them', respectively.

Discussion

The PANDAs decision aid was designed to facilitate decision making between clinicians and their patients with T2DM who were taking at least two oral glucose-lowering drugs at maximum tolerated dose, had a high HbA1c level and were considering future treatment options including the introduction of insulin. Its evaluation was based on the IPDAS recommendations²⁵ and the use of the ODSF Framework.²⁶ The PANDAs trial provides good

1
2
3 evidence not only for the clinical effectiveness of decision aids in usual NHS general practice
4
5 but also for the utility and feasibility of use by both nurses and doctors. In addition, the
6
7 PANDAs decision aid itself and its use were both effective and acceptable to people with
8
9 diabetes making treatment choices during clinical consultations.
10

11 12 13 14 **Decision quality**

15
16 The findings from the PANDAs trial support the results of other studies which have evaluated
17
18 the clinical effectiveness of decision aids^{11 15} in demonstrating an improvement in decision
19
20 quality when a decision aid is used in clinical consultations.
21

22
23
24
25 Decisional conflict scores, for example, when adjusted for age, education and gender were
26
27 significantly lower in the intervention group post consultation when compared to the controls,
28
29 apart from the support sub-score. It is interesting to note that the support sub-score in the
30
31 intervention group was not significantly lower than the control group - this may be the result
32
33 of a 'ceiling effect' since patients in both the intervention and control groups may already
34
35 have been receiving very good diabetes care from their general practices.
36
37

38
39
40 Other indicators of decision quality used in the study also demonstrated an improvement
41
42 when PANDAs was used in consultations – there was, for example, a highly significant
43
44 difference in the knowledge of people which particular treatment choice had the greatest
45
46 chance of lowering blood sugar in those who used the decision aid - although this was not the
47
48 case when the chance of insulin in lowering complications was considered - here no
49
50 difference in knowledge was observed. Some patients believe that insulin itself causes
51
52 complications as a result of misperception^{27 28} and this may explain why knowledge did not
53
54 improve in the intervention group. However, highly significant differences were observed
55
56
57
58
59
60

1
2
3 between the intervention and control groups in all the three domains of realistic expectations
4
5 ['hypos', weight gain and complications] supporting the notion that the PANDAs decision
6
7 aid ensured that people were fully informed about the potential risks of each option when
8
9 making their treatment choices.
10

11
12
13
14 As far as autonomy was concerned, patients in the intervention arm were more likely to make
15
16 an autonomous decision using PANDAs when the intervention and control groups were
17
18 compared allowing for both age and gender. This is consistent with the findings of other
19
20 studies.^{29 30}
21
22

23
24
25 These findings of an improvement in decision quality when a decision aid is used in clinical
26
27 consultations in other conditions and contexts are also supported by a large number of other
28
29 studies.^{23 31}
30
31

32 33 34 **Decisional Outcomes**

35
36 The glycaemic control improved in both groups six months after the intervention although no
37
38 significant difference in glycaemic control was observed between the two groups. Some GPs
39
40 in the study expressed concern at the start of the trial that glycaemic control could deteriorate
41
42 in some patients in the intervention group as a result of them choosing not to start insulin.
43
44 Further study is necessary to confirm this as this study did not have sufficient power to detect
45
46 the difference in glycaemic control.
47
48
49

50
51
52 Treatment decisions made using a decision aid should, of course, be ones that are both
53
54 informed and value-based, and the PANDAs intervention was focussed on the process of
55
56 decision making rather than the outcomes of those decisions. It is therefore important to note
57
58
59
60

1
2
3 that PANDAs was not designed to persuade people to start treatment with insulin but to help
4
5 them make an informed treatment decision which was consistent with their values and
6
7 wishes.
8
9

10
11 Indeed, there was reduced decisional conflict within the intervention group compared to the
12
13 control and the decisions which were made were far more likely to be autonomous in nature
14
15 rather than passive. Participants in the intervention group were also significantly more likely
16
17 to persist with their chosen option at 6 months. This supports the hypothesis that people who
18
19 use a decision aid such as PANDAs are more likely to make an informed and value-based
20
21 decision and are therefore more likely to persist with their treatment choice. Concordance
22
23 with agreed treatment is, in turn, more likely to lead to better health outcomes and quality of
24
25 life.
26
27
28
29

30
31 No significant difference was observed on the regret scale scores and although people in the
32
33 intervention group were over three times more likely to change from undecided to decided
34
35 [ie come to a treatment decision after their consultation] in the control group, this difference
36
37 was not statistically significant.
38
39
40
41

42
43 Finally, no significant difference was observed in the preferred choices [ie the treatment
44
45 decision they came to] of the two groups although a higher proportion of people in the
46
47 intervention group did choose to initiate insulin. However it is important to note that the use
48
49 of a decision aid is not intended to produce a particular outcome but to support the patient
50
51 making a treatment choice based on their knowledge and values. These findings are also
52
53 consistent with current understanding of the anticipated decisional outcomes when a decision
54
55 aid such as PANDAs is used in clinical consultations to make treatment choices.³¹
56
57
58
59
60

Impact on Clinical Practice

The results of the PANDAs trial demonstrate that the use of the decision aid in usual general practice by both practice nurses and GPs, provided the patient has the opportunity to complete their individualised decision aid prior to their consultation, does not require significant additional consultation time. Given the potential benefits of improved adherence to treatment choices and an improved therapeutic relationship between clinicians and their patients, this is likely to make the use of the decision aid acceptable to all parties in general practice, although, its use may require some initial ‘investment’ in consultation time. In particular, both clinician and patient satisfaction with their consultations, as well as the healthcare provided and received, are both likely to be increased. A further potential advantage is that the decision aid could be used by other clinical members of the primary care team (eg healthcare assistants) potentially increasing the consultation time available to doctors and nurses for other patients. However, the efficient use of the decision aid in consultations may in part be attributed to the familiarity of the clinicians with the decision aid as a result of the brief training clinicians received at entry to the trial. In addition, this may also be due to the process by which the decision aid was developed with the active involvement of both clinicians and people with diabetes to ensure that it was as ‘user friendly’ as possible. This involvement of users in the development of the decision aid and a process evaluation of its use in the consultation by both parties has been described elsewhere.³²

Health service utilisation

The PANDAs trial was a pragmatic one reflecting the reality of primary care diabetes clinics which are mainly run by practice nurses. The mean number of consultations with the nurses,

1
2
3 for example, was greater than the mean number of consultations with the GPs and within the
4
5 intervention group patients were more likely to use the PANDAs decision aid with the
6
7 practice nurse than the GP. At baseline the distribution of the mean number of diabetes
8
9 related general practice visits was different in the intervention and control groups with the
10
11 practice nurses providing more clinical care to people with diabetes in the former reflecting
12
13 different patterns of care in the different practices.
14
15

16 17 18 **Patient decision aids** 19

20
21 The PANDAs decision aid is one of the few decision aids which focus on decision making in
22
23 chronic diseases, which take place over several consultations. According to the latest
24
25 Cochrane Decision Aid Inventory, 10 decision aids have been developed for diabetes.³¹ Four
26
27 decision aids focus on insulin treatment, of which two are for children, one for adults
28
29 deciding on premixed insulin and one for insulin initiation in T2DM (PANDAs decision aid).
30
31 However, unlike PANDAs, none have been developed for making treatment decisions about
32
33 glycaemic control.
34
35

36
37
38 Although decision aids have positive effects on many aspects of the decision making process,
39
40 there remains a large gap in the literature on how decision aids fare “in the real world”.
41
42 O’Cathain and Thomas (2004) conducted a pragmatic trial of decision aid in a maternity ward
43
44 and found that health professional were not making use of the available decision aids,
45
46 although they reported that they approved of them. The reasons for not using them included
47
48 ‘disagreement’ with the available decision aids, lack of resources, perceived patients’
49
50 reluctance to participate and unwillingness to change their “routine care”.³³ O’Donnell,
51
52 Cranney et al, classified the barriers to the use of decision aids in the clinical situation under
53
54 three categories – the nature of the decision aid itself, the attitudes of patients and healthcare
55
56
57
58
59
60

1
2
3 professionals and organisational barriers such as institutional culture and commitment, time
4
5 constraint and costing.³⁴
6
7

8
9
10 A number of authors have proposed various strategies to facilitate such use of decision aids in
11 different clinical settings.³⁵ The effectiveness of these proposed strategies has not yet been
12
13 formally evaluated. The PANDAs trial however found the decision aid to be highly
14
15 acceptable to both clinicians and people with diabetes in NHS general practice – a detailed
16
17 process evaluation of its use can be found elsewhere. This report identifies some of the key
18
19 challenges to its widespread implementation in NHS general practice.
20
21
22
23

24
25 However, most studies of decision aids have not shown an increase in the level of satisfaction
26
27 with the decision making process or the decision itself. This may be another example of the
28
29 ‘ceiling effect’ whereby the satisfaction with the service or consultation was already high
30
31 before the intervention. It has also been observed that people tend to report satisfaction after
32
33 they have made the decisions because they tend to “rationalise” and adapt quickly to
34
35 uncertain events.³⁶ Moreover, the effect of decision aids on quality of life and health
36
37 outcomes indicators which are commonly used in health technology assessments, have yet to
38
39 be proved. More plausible intermediate outcomes, such as concordance with treatment and
40
41 health service utilisation, could be used as alternative indicators to evaluate the use of
42
43 decision aids.
44
45
46
47
48

49
50 General practice is a unique healthcare setting where multidisciplinary teams provide holistic,
51
52 comprehensive and continuity of care to people in the community. Practitioners usually have
53
54 an established relationship with their patient and an appreciation of their medical and
55
56 psychosocial background as well as their associated multi-morbid conditions. This puts them
57
58
59
60

1
2
3 in a very good position to advise patients on their treatment options. The use of decision aids
4
5 to facilitate treatment choices in general practice fits well with the adoption of a Care
6
7 Planning model for long-term conditions. This model of care, developed by the Diabetes UK
8
9 Year of Care Programme and recently adopted as a professional standard by the RCGP, is a
10
11 good way of ensuring that patients with diabetes are both fully informed and fully involved in
12
13 decisions about their care by supporting their “empowerment” and facilitating the
14
15 “activation” of people with long-term conditions.^{37 38}
16
17
18
19

20 21 **Implications for research and clinical practice**

22
23 For the use of patient decision aids, such as PANDAs, in routine clinical practice to become
24
25 the accepted norm, the new GP clinical commissioning groups will need to be aware of the
26
27 benefits of the use of such aids to ensure that decision aids become a professional standard in,
28
29 for example, newly commissioned pathways for a long-term condition such as diabetes.
30
31 Investment will also be necessary for the development and the continuing evaluation of
32
33 decision aid use, as well as for the training of all members of the multidisciplinary team in the
34
35 importance and in the practical use of decision aids in primary care. Both the patient’s
36
37 experience and patient/clinician satisfaction with the care received and provided is likely to
38
39 be much improved if this professional standard is adopted by commissioning groups.
40
41
42

43 **Conclusions**

44
45 The use of the PANDAs decision aid by health care professionals in usual NHS clinical
46
47 practice with T2DM patients who are making treatment choices in general practice improves
48
49 decision quality by reducing decisional conflict, improving knowledge and promoting
50
51 realistic expectations but has no demonstrable effect on glycaemic control.
52
53 Patient autonomy however is strengthened by the use of the decision aid and longer term
54
55 clinical outcomes are likely to be improved. A larger trial of the PANDAs decision aid will
56
57
58
59
60

1
2
3 be necessary to determine if biomedical parameters are improved when the decision aid is
4
5 used in normal NHS practice.
6
7

8 9 **Strengths and limitations of this study**

10 The study failed to achieve its planned sample size as a result of recruitment difficulties. The
11
12 reasons for this were the increase in availability of new oral and injectable glucose lowering
13
14 drugs (e.g. GLP1 agonists, exenatide) which were not available at the start of the project,
15
16 significant staff changes in 2008/9 and the reluctance of practices to participate in the study
17
18 because of a potential H1N1 flu pandemic in summer 2009. As a result each practice was
19
20 only able to identify 3-5 eligible patients for inclusion in the trial. It proved impossible to
21
22 secure a funded time-extension to the study and as a result recruitment ceased at 175
23
24 participants. This meant that the study was underpowered to detect a difference of 0.5% in
25
26 HbA1c between the two groups. The original recruitment period was 12 months but because
27
28 of the problems surrounding recruitment outlined above, recruitment was extended to 20
29
30 months. There was also some evidence of inadvertent recruitment bias with 95 participants
31
32 allocated to the intervention group and 80 to the control group. This is an important and well
33
34 recognised consequence of a cluster RCT design and is probably the result of the PANDAs
35
36 practices being more likely to recruit participants to the trial. There were some differences in
37
38 baseline characteristics between the intervention and the control and these were included in
39
40 an analysis which explored how the estimates of the treatment effect changed when baseline
41
42 differences were controlled for.
43
44
45
46
47
48
49
50

51 **Contributorship statement:**

52 **Substantial contribution to conception and design, acquisition of data or analysis and**
53
54 **interpretation of data:**
55
56
57
58
59
60

1
2
3 NM, CJN, MCJ, BC, AB, IB
4

5 **Drafting the article or revising it critically for important intellectual content:**
6

7 NM, CJN, MCJ
8

9 **Final approval of the version to be published:**
10

11 NM, CJN, MCJ, BC, AB, IB
12

13
14 NM is the guarantor.
15

16
17
18 This article presents independent research funded by the National Institute for Health
19 Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference
20 Number PB-PG- 0906-11248), ISRCTN National Trials Register Number 14842077 and the
21 Sheffield Health and Social Care NHS Foundation Trust. The views expressed are those of
22 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
23
24
25
26
27
28
29

30
31 All authors have completed the Unified Competing Interest form at
32 www.icmje.org/coi_disclosure.pdf and declare that (1) NM, CJN, MC, BC, IB, AB have
33 support from the University of Sheffield for the submitted work; (2) NM, CJN, MC, BC, IB,
34 AB have no relationships with any companies that might have an interest in the submitted
35 work in the previous 3 years; (3) their spouses, partners or children have no financial
36 relationships that may be relevant to the submitted work; and (4) NM, CJN, MC, BC, IB, AB
37 have no none-financial interests that may be relevant to the submitted work.
38
39
40
41
42
43
44
45
46
47
48

49 “The Corresponding Author has the right to grant on behalf of all authors and does grant on
50 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
51 Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and
52
53
54
55
56
57
58
59
60

1
2
3 any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our
4 licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>)."
5
6
7
8
9

10 11 12 **Acknowledgements**

13
14 Ethical permission to conduct the study was received from the North Sheffield Local

15
16 Research Ethics Committee (07/Q2308/53).

17
18 Expert specialist advice was received from Professor Simon Heller, University of Sheffield.

19
20 We thank Ms Rachel Dwyer for research support, and Dr Robert Dixon, Sheffield Care Trust,

21
22 Mr Robert Glendenning and Mr Ian Brown for managerial support.

23
24 Ms Sharon Hart, University of Sheffield, for administrative support.

25
26 Members of the PANDAs Advisory Group (Alicia O'Cathain, Hina Kanabar, Hugh

27
28 McCulloch, Maxine Johnson, Michelle Horspool, Mick Taylor, Sue Beveridge, Mary

29
30 MacKinnon).

31
32 Members of the Sheffield Diabetes UK Group

33
34
35
36
37
38 Particular thanks to all those doctors, nurses and people with diabetes for their contributions

39
40 without whom it would not, of course, have been possible to undertake the PANDAs trial.
41
42
43
44

45 46 **References**

- 47
48 1. Diabetes UK. Diabetes in the UK 2011/2012: Key statistics on diabetes.
49 <http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2011-12.pdf>
50 (accessed on 12 March 2012)
- 51
52 2. Diabetes.co.uk. Cost of Diabetes. <http://www.diabetes.co.uk/cost-of-diabetes.html>
53 (accessed on 12 March 2012)
- 54
55 3. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: Newer
56 agents. London: NICE, 2009.
57
58
59
60

- 1
- 2
- 3 4. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared
- 4 with conventional treatment and risk of complications in patients with type 2 diabetes
- 5 (UKPDS 33). *Lancet* 1998;**352**:837-53.
- 6
- 7 5. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulphonylurea,
- 8 metformin, or insulin in patients with type 2 diabetes mellitus: progressive
- 9 requirement for multiple therapies (UKPDS 49). *JAMA* 1999;**281**:2005-12.
- 10
- 11 6. Fitzgerald JT, Vijan S, Stuart N. Insulin therapy and patient attitudes at two VA centers.
- 12 *Diabetes* 2000;**49**:A445.
- 13
- 14 7. Lauritzen T, Scott A. Barrier to insulin therapy in type 2 diabetes: a qualitative focus group
- 15 research among patients, GPs and diabetologists. *Eur Union Gen Pract Clin J*
- 16 2002;**3**:33-40.
- 17
- 18 8. Jeavons D, Hungin AP, Cornford CS. Patients with poorly controlled diabetes in primary
- 19 care: healthcare clinicians' beliefs and attitudes. *Postgrad Med J* 2006;**82**:347-50.
- 20
- 21 9. Paling J. Strategies to help patients understand risks. *BMJ* 2003;**27**:745-8.
- 22
- 23 10. Siriwardena AN. Clinical guidelines in primary care: a survey of general practitioners'
- 24 attitudes and behaviour. *Br J Gen Pract* 1995;**45**:643-7.
- 25
- 26 11. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or
- 27 screening decisions. *Cochrane Database Syst Rev*. 2011;Issue 10. Art. No.:
- 28 CD001431.
- 29
- 30 12. Colwell B, Mathers N, Ng CJ, et al. Improving recruitment to primary care trials: some
- 31 lessons from the use of modern marketing techniques. *Debate and Analysis Paper*
- 32 *BJGP*. 2012; 62(602): 496-498. doi: 10.3399/bjgp12X654759.
- 33
- 34 13. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions:
- 35 the new Medical Research Council guidance. *BMJ* 2008;**337**:979-83.
- 36
- 37 14. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. *Science*
- 38 1981;**211**:453-8.
- 39
- 40 15. O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering
- 41 hormone therapy after menopause: decision support framework and evaluation.
- 42 *Patient Educ Couns* 1998;**33**:267-79.
- 43
- 44 16. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;**15**:25-
- 45 30.
- 46
- 47 17. Janis IL, Mann L. *Decision making: a psychological analysis of conflict, choice and*
- 48 *commitment*. New York: Free Press, 1977.
- 49
- 50 18. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res*
- 51 1997;**29**:21-43.
- 52
- 53 19. Davidson BJ, Degner LF, Morgan TR. Information and decision making preferences of
- 54 men with prostate cancer. *Oncol Nurs Forum* 1995;**22**:1401-8.
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 20. Kremer H, Ironson G. Measuring the involvement of people with HIV in treatment
4 decision making using the Control Preference Scale. *Med Decis Making* 2008;**28**:899-
5 908.
- 6
7 21. Brehaut JC, O'connor AM, Wood TJ, et al. Validation of a decision regret scale. *Med*
8 *Decis Making* 2003;**23**:281-92.
- 9
10 22. Kinmonth AL, Woodcock A, Griffin S, et al. Randomised controlled trial of patient
11 centred care of diabetes in general practice: impact on current wellbeing and future
12 disease risk. *BMJ* 1998;**317**:1202-8
- 13
14 23. DAFNE Study Group. Training in flexible, intensive insulin management to enable
15 dietary freedom in people with type 1 diabetes: dose adjustment for normal eating
16 (DAFNE) randomized controlled trial. *BMJ* 2002;**325**:746-51.
- 17
18 24. Campbell MK, Elbourne DR, Altman DG for the CONSORT Group. CONSORT
19 statement: extension to cluster randomised trials *BMJ* 2004;**328**:702-8.
- 20
21 25. Elwyn G, O'Connor A, Stacey D, et al. International Patient Decision Aids Standards
22 (IPDAS) Collaboration. Developing a quality criteria framework for patient decision
23 aid: online international Delphi consensus process. *BMJ* 2006;**333**:417-19.
- 24
25 26. Légaré F, O'Connor AM, Graham ID, et al. Primary health care professionals' views on
26 barriers and facilitators to the implementation of the Ottawa Decision Support
27 Framework in practice. *Patient Educ Couns* 2006;**63**:380-90.
- 28
29 27. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating
30 research into action for diabetes insulin starts project. *Diabetes Care* 2010;**33**:733-35.
- 31
32 28. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance:
33 barriers to insulin use *Diabetes Education* 2008;**34**:511-17.
- 34
35 29. Auvinen A, Vornanen T, Tammela TL, et al. A randomized trial of the choice of
36 treatment in prostate cancer: design and baseline characteristics. *BJU Int*.
37 2001;**88**:708-15.
- 38
39 30. Murray E, Davis H, Tai SS, et al. Randomised controlled trial of an interactive
40 multimedia decision aid on benign prostatic hypertrophy in primary care. *BMJ*
41 2001;**323**:493-6.
- 42
43 31. Cochrane Library. Cochrane Inventory of Patient Decision Aids.
44 <http://decisionaid.ohri.ca/cochinvent.php> (accessed on 12 March 2012)
- 45
46 32. Bradley A, Brown I, Ng CJ, et al. Decision aids in patients with type 2 diabetes
47 considering treatment options: Qualitative analysis of consultations and interviews
48 from the PANDAs study. *Diabet Med* 2011;**2**(S1)8:118.
- 49
50 33. O'Cathain A, Thomas, K. J. Evaluating decision aids--where next? *Health Expect*
51 2004;**7**:98-103.
- 52
53 34. O'Donnell S, Cranney, A., Jacobsen, M. J., et al. Understanding and overcoming the
54 barriers of implementing patient decision aids in clinical practice. *J Eval Clin*
55 *Practice* 2006;**12**:174-81.
- 56
57
58
59
60

- 1
2
3 35. O'Connor AM, Wennberg JE, Legare F, et al. Toward the 'tipping point': decision aids
4 and informed patient choice. *Health Aff (Millwood)* 2007;**26**:716-25.
5
6 36. O'Connor AM, Bennett CL, Stacey D, et al. Decision Aids for people facing health
7 treatment or screening decisions. *Cochrane Database Syst Rev* 2009;Issue 3. Art. No.:
8 CD001431.
9
10 37. Wagner EH. Chronic disease management: what will it take to improve care for chronic
11 illness? *Eff Clin Pract* 1998;**1**:2-4.
12
13 38. Mathers N, Roberts S, Hodkinson I, et al. Care Planning: Improving the Lives of People
14 with Long Term Conditions. UK: Royal College of General Practitioners, 2011.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title:

Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices – a cluster randomised controlled trial (PANDAs) in General Practice.

Authors

Nigel Mathers¹ MD. PhD. FRCGP.

Chirk-Jenn Ng² MBBS. [MMed \(Family Medicine\)](#). PhD.

Michael J Campbell³ BA. MSc. PhD. CStat.

Brigitte Colwell⁴ BA.

Ian Brown⁵ BSc. PhD. RN.

Alastair Bradley⁶ MB ChB. LLB. MRCGP.

¹ Professor of Primary Medical Care, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

² Associate Professor, Department of Primary Care Medicine, Faculty of Medicine Building, University of Malaya, 50603 Kuala Lumpur Malaysia.

³ Professor of Medical Statistics, School of Health and Related Research, University of Sheffield, 30 Regent Street, Sheffield S1 4DA, UK.

⁴ Research Associate, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

⁵ Senior Lecturer, Centre for Health and Social Care Research, Sheffield Hallam University, Montgomery House, 32 Collegiate Crescent, Sheffield, S10 2BP, UK.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

⁶ NIHR In-Practice Training Fellow, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK

Corresponding Author: Professor Nigel Mathers, Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox House, Northern General Hospital, Herries Road, Sheffield S5 7AU. Email: n.mathers@sheffield.ac.uk

For peer review only

ARTICLE FOCUS:

- Does the use of the PANDAs decision aid in general practice improve decision quality and glycaemic control in people who are making treatment choices about their type 2 diabetes mellitus (T2DM) treatment, including whether or not to start insulin?

KEY MESSAGES:

- Patient decision aids provide evidence-based information about treatment options, help patients to clarify their values and guide them systematically to make an informed decision.
- The use of the PANDAs decision aid by doctors and nurses in usual NHS general practice with people who have T2DM and are making treatment choices reduces decision conflicts and improves knowledge, realistic expectations and patients' involvement in decision making.
- HbA1c levels were reduced in both groups at six months when compared to baseline (0.24% controls and 0.37% intervention) with a non-significant mean difference between the two groups of 0.351, $p=0.117$).

STRENGTHS AND LIMITATIONS

- This study was underpowered to detect a minimally, clinically important difference in glycaemic control between the two groups due to slow recruitment.
- There was no blinding in this study due to the nature of the intervention which may have influenced the outcome assessment.
- This was a pragmatic trial and there may have been variations in how the decision aid was used in different General Practices which may have diluted the effect of the study.

Abstract**Objective**

To determine the effectiveness of a patient decision aid (PDA) to improve decision quality and glycaemic control in people with diabetes making treatment choices using a cluster RCT.

Design

A cluster randomised controlled trial.

Setting

49 general practices in UK randomised into intervention (n=25) and control (n=24).

Participants

General Practices: Inclusion criteria: > 4 medical partners; list size > 7000; and a diabetes register with > 1% of practice population. 191 Practices assessed for eligibility, 49 Practices randomised and completed the study.

Patients: People with T2DM taking at least two oral glucose-lowering drugs with maximum tolerated dose with an HbA1c greater than 7.4% (IFCC HbA1c >57mmol/mol) or advised in the preceding six months to add or consider changing to insulin therapy. Exclusion criteria: currently using insulin therapy; difficulty reading or understanding English; difficulty in understanding the purpose of the study; visual or cognitive impairment or mentally ill. 182 assessed for eligibility, 175 randomised to 95 intervention and 80 controls, 167 completion and analysis.

Intervention

Brief training of clinicians and use of PDA with patients in single consultation.

Primary Outcomes

Decision quality (decisional conflict scores, knowledge, realistic expectations and autonomy) and glycaemic control (glycosolated haemoglobin, HbA1c).

Secondary Outcomes

1
2
3 Knowledge and realistic expectations of the risks and benefits of insulin therapy and diabetic
4 complications.
5
6

7 **Results**

8
9 Intervention Group: lower total decisional conflict scores (17.4 v 25.2, $p<0.001$); better
10 knowledge (51.6% v 28.8%, $p<0.001$); realistic expectations (risk of ‘hypo’, ‘weight gain’,
11 ‘complications’; 81.0% v 5.2%, 70.5% v 5.3%, 26.3% v 5.0% respectively, $p<0.001$); and
12
13
14
15
16 were more autonomous in decision making (64.1% v 42.9%, $p=0.012$).
17

18 No significant difference in the glycaemic control between the two groups.
19

20 **Conclusions**

21
22 Use of the PANDAs decision aid reduces decisional conflict, improves knowledge, promotes
23 realistic expectations and autonomy in people with diabetes making treatment choices in
24
25
26
27
28 general practice.
29

30
31
32 **ISRCTN Trials Register Number** 14842077
33

34 **Data sharing statement:** There are no additional data available
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Diabetes mellitus is a growing health problem in England with a total of 2.4 million people (5.5% of population) living with the disease in 2011.¹ Diabetes currently accounts for 10% of all NHS expenditure.² However, overall diabetes control is less than satisfactory. In 2008/2009, 67% of people with T2DM achieved a glycosolated haemoglobin (HbA1c) of less than 7.5% (IFCC HbA1c 58 mmol/mol).³

The UK Prospective Diabetes Study (UKPDS) has established the importance of maintaining good blood glucose control in patients with T2DM. For every 1.0% increase in HbA1c, there is an increase, in risk, of 14% for myocardial infarction, 21% for diabetes-related deaths and 37% for micro-vascular complications.⁴ In the same study, it was reported that only 25% were able to achieve good glycaemic control with monotherapy after 9 years of the trial. Most patients will require combination therapy, including insulin, 5-10 years after diagnosis.⁵

Currently, the NICE guidelines recommend a combination of metformin and insulin secretagogues in those who have inadequate blood glucose control with monotherapy. In those in whom dual therapy has been unsuccessful, either insulin or a thiazolidinedione should be added to optimise glycaemic control.³ Frequently, this poses a clinical dilemma for both patients and healthcare providers; both parties need to agree which next treatment option to pursue and this includes whether or not to start insulin therapy. However, patients may be fearful of needles and the side effects of insulin (e.g. hypoglycaemia); they need to acquire new skills; change their daily routine and address the challenge of glucose monitoring.⁶

Similarly, doctors may be hesitant to prescribe insulin due to their own lack of relevant skills, time pressures, and a fear of increasing the risk of side effects.^{7,8} In this category of patients, the decision making process is a complex one. Studies have shown that patients usually make

1
2
3 decisions based on emotions such as trust, rather than on the information given by their
4
5 healthcare providers.⁹ For their part, doctors do not necessarily follow evidence-based
6
7 guidelines¹⁰ and it was in this context that the PANDAs decision aid was developed to
8
9 facilitate shared decision making between clinicians and patients when making decisions
10
11 about the treatment of their diabetes at this stage of their illness. The development of the
12
13 PANDAs decision aid will be described elsewhere.
14
15

16
17
18 Patient decision aids are tools that provide evidence-based information about treatment
19
20 options, help patients to clarify their values and guide them systematically to make an
21
22 informed decision. Patient decision aids have been shown to improve knowledge, realistic
23
24 expectations, value-decision concordance and patient involvement in decision making.¹¹
25
26
27

28
29 The primary research question was “Does the use of the PANDAs decision aid improve
30
31 decision quality in patients with T2DM who are making a decision whether or not to start
32
33 insulin in general practice?”.
34
35
36

37
38 The study focussed on people with T2DM who had poor glycaemic control (HbA1c
39
40 >7.4mmol/l or IFCC HbA1c >57 mmol/mol) and who, despite receiving optimal oral glucose
41
42 lowering therapy, required "step-up" treatment. A cluster randomised controlled trial was
43
44 carried out to evaluate the clinical effectiveness of the decision aid on decision quality and
45
46 glycaemic control.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

The setting for this study was general practices in Sheffield, Rotherham and Doncaster with recruitment being undertaken through the National Institute for Health Research Primary Care Research Network (PCRN) and the Cutler Group of South Yorkshire Research Practices. The recruitment of practices and patients began in 2008 and the data collection ended in 2011.

Practices were invited to take part by postal invitation following a publicity campaign using a modified viral marketing technique involving sequential non-specific PANDAs post cards ('PANDAs are coming') to 'pique' interest, followed by increasingly informative flyers (Figure 1).¹²

Figure 1



1
2
3 The inclusion criteria for general practices were: > 4 medical partners; list size > 7000; and a
4 diabetes register with > 1% of practice population. The participating general practices were
5 asked to screen their computerised diabetes register for eligible patients with T2DM (aged >
6 21 years). The inclusion criteria were: people with T2DM who were taking at least two oral
7 glucose-lowering drugs with maximum tolerated dose and had a latest HbA1c greater than
8 7.4% (IFCC HbA1c >57mmol/mol) or had been advised in the preceeding six months to add
9 or consider changing to insulin therapy. The exclusion criteria were: patients who were
10 currently using insulin therapy; had difficulty reading or understanding English; had
11 difficulty in understanding the purpose of the study; had visual or cognitive impairment and
12 were mentally ill.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 The patients were contacted by a letter from their general practitioners (GPs) and invited to
28 participate in this study. If they agreed, they were sent details of the study (including the
29 information sheet) and asked to attend an appointment at their regular practice where consent
30 to the study was obtained by the researchers. Practices were incentivised to take part in the
31 trial, receiving a nominal payment to cover legitimate expenses.
32
33
34
35
36
37
38
39
40

41 **Randomisation and concealment:**

42 This was a pragmatic trial and all eligible and willing practices were randomly allocated by
43 computer to two groups: the intervention group used the PANDAs decision aid when making
44 the specified treatment choices and the control group delivered usual care. We stratified the
45 practices according to the Practice list size. Each practice was considered a cluster and all
46 patients within the cluster received either the intervention or usual care. The practices were
47 the units of randomisation, since it would have been difficult to allocate two patients in the
48 same practice to different arms of the trial. Blinding of the intervention and assessment of the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 process measures were not feasible in view of the nature of the intervention studied. A
4
5 statistician generated the random allocation sequence while a secretary who was not involved
6
7 in the research study assigned participants to either the intervention or control groups. A
8
9 researcher and a research nurse enrolled the participants into the study.
10

14 **Intervention and control groups**

15
16 This was a complex intervention comprised three components: PDA; healthcare professional
17
18 training workshop; and use of the PDA in a consultation. The development of the
19
20 intervention was based on the UKMRC framework for the development and evaluation of
21
22 complex interventions ¹³ and this will be reported in another study. The doctors and/or the
23

24
25 nurses who were primarily involved in the diabetes care of the practice attended a short
26
27 training session lasting between one to two hours on how to use the PANDAs decision aid.
28

29
30 The training topics covered included the principles of shared decision making, the importance
31
32 and clinical effectiveness of decision aids, the evidence for various treatment options for
33
34 poorly controlled T2DM and essential skills in risk communication.¹⁴
35

36
37 The patient participants were given the PANDAs decision aid (Table 1) by the researcher to
38
39 read and complete prior to the consultation in the waiting room. This was followed by the
40
41 consultation with the GP or the practice nurse facilitated by the use of the PANDAs decision
42
43 aid. In the control group, the GP and the practice nurse did not receive any training and the
44
45 PANDAs decision aid was not used. The GPs or the nurses conducted a normal consultation
46
47 with the patient.
48

49
50
51
52 Table 1: Content of the PANDAs decision aid
53
54
55
56
57
58
59
60

1
2
3
4 The PANDAs Decision Aid contains the following information in line with the
5 International Patient Decision Aid Standards criteria:
6

- 7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Information about the insulin and other treatment options
 - Reasons for starting insulin
 - The procedure of insulin injection
 - Common concerns about insulin
 - Treatment options: Make no change; lifestyle modification; insulin therapy
 2. Present probabilities of outcomes
 - The advantages and disadvantages of each option were described in words, numbers and pictures ('smiley faces')
 3. Patient value clarifications
 - A list of patients' values about the advantages and disadvantages of insulin therapy
 4. Structured guidance

Outcome measures and follow-up

Primary outcome measure:

The primary outcome measures were decisional conflict based on the Decisional Conflict Scale score,^{15 16} (immediate) used as an indicator of decision quality and glycaemic control (glycosolated haemoglobin, HbA1c) at six months.

Secondary outcome measures:

Knowledge and realistic expectations of the risks and benefits were assessed by asking the patients to indicate their perceived chance of experiencing the side effects of insulin therapy and diabetic complications.

Operational definitions of the secondary outcome measures were agreed as (1) knowledge: about the treatment option that is most effective in reducing blood glucose level and diabetic complications; (2) realistic expectations: a self-reported chance of experience hypoglycaemia, gaining weight and developing complications; (3) preference option: preferred treatment options of initiate insulin, adhere more to diabetes advice more regularly or make no change;

1
2
3 (4) participation in decision making: using the Control Preference Scale scores and (5) regret:
4
5 using the Regret Scale scores.
6
7

8
9
10 The secondary measures were other decision quality indicators (knowledge of treatment
11 options, realistic expectation, preference option, proportion undecided, participation in
12 decision making); duration of consultation; and outcome of decision making (regret and
13 persistence with the chosen option). Persistence with the chosen option is a single self-
14 reported item which the participant was asked what their treatment was six months after the
15 intervention. They were considered to be persistent with their decision if there was no change
16 in the treatment in the past six months.
17
18
19
20
21
22
23
24
25
26

27 The practice provided the baseline and six-month follow up data. Baseline data comprised:
28 practice and clinician profile, patients' socio-demography, diabetes profile (duration,
29 complication, prescription, glycaemic control), comorbidities (e.g. hypertension, coronary
30 artery disease, dyslipidaemia, chronic kidney disease); and previous T2DM education.
31
32
33
34
35

36 Immediate post-intervention data collected were: decision quality indicators and duration of
37 consultation. Six-month data comprised: HbA1c, regret score and persistence with the
38 decision.
39
40
41
42
43
44

45 **Instruments:**

46 ***Decisional conflict scale (DCS)***

47
48 The DCS measures personal perceptions of (a) uncertainty in choosing options; (b)
49 modifiable factors contributing to uncertainty such as feeling uninformed, unclear about
50 personal values and unsupported in decision making; and (c) effective decision making such
51 as feeling the choice is informed, value-based, likely to be implemented and expressing
52
53
54
55
56
57
58
59
60

1
2
3 satisfaction with the choice. It was derived from the decisional conflict construct.¹⁷ The
4
5 traditional 16-item DCS with five response categories was used in this study. There are five
6
7 subscales: ‘uncertainty subscale’; ‘informed subscale’; ‘values clarity subscale’; ‘support
8
9 subscale’; and ‘effective decision subscale’.¹⁵ The DCS has been shown to be reliable and is
10
11 correlated with the constructs of knowledge, regret and discontinuance, and has the ability to
12
13 discriminate between those who make and delay decisions. Scores lower than 25 are
14
15 associated with implementing decisions while scores exceeding 37.5 are associated with
16
17 decisional delay or feeling unsure about implementation.¹⁶
18
19
20
21
22

23 ***Control preference scale (CPS)***

24
25 The CPS aims to measure the extent to which patients prefer or are involved in decision
26
27 making during a clinical consultation. It measures the preferred or actual role in decision
28
29 making by asking a single question which contains five items: two represents active or patient
30
31 controlled role; one a shared or collaborative role; and two items represent a passive or
32
33 practitioner controlled role.¹⁸ It has proven validity and reliability in both general public and
34
35 patients with medical conditions.^{18 19} A recent study found a good inter-rater reliability and
36
37 good agreement between self and researcher ratings on Control Preference Scale.²⁰
38
39
40
41
42

43 ***Regret scale***

44
45 This scale measures ‘distress or remorse after a (health care) decision’. It is a five-item scale
46
47 with five responses (1 strongly agree to 5 strongly disagree). Regret is measured at a point
48
49 where the respondent can reflect on the effects of the decision that has been made. A score of
50
51 0 means no regret while a score of 100 means high regret. The regret scale correlates with
52
53 satisfaction with the decision, decisional conflict and overall quality of life.²¹
54
55
56
57
58
59
60

Sample size and statistical analysis (HbA1c)

Assuming an intracluster correlation coefficient of 0.047 for HbA1c²² and a cluster sample size of 5 patients per practice, with 80% power and 5% (two-sided) significance, 160 patients in each group are required to allow the detection of 0.5% (SD 1.5%) difference in HbA1c.²³ The total number of Practices required, therefore, was estimated to be 64. When using the total DCS score as the primary outcome measure and using a similar method to calculate sample size, the total number of participants needed was 86 and the total cluster size was estimated to be 17. We aimed for the larger sample size for the design of this study.

The outcome variables, were treated as continuous and we used multiple regressions with generalised estimating equations (GEE) and exchangeable correlation to allow for clustering. Multiple logistic regression with GEE was used for binary outcomes in the secondary analysis. If a patient in the intervention arm refused to use the decision aid, they were still included in the intervention group for analysis and were analysed according to the intention-to-treat principle.

Results

Study practices profile (Table 2)

Forty-nine general practices were recruited into the study. The practices in both arms of the study were well matched in terms of mean list size, mean diabetes list size, mean number of partners and practice nurses and mean Index of Multiple Deprivation Scores.

Table 2 Study practice profile (mean and range)

	Intervention	Control
Number of Practices	25	24
List Size	7,510 (3,129-20,900)	7,325 (1,974-13,500)
People with diabetes	350(96-912)	356 (143-634)
No of partners	5 (1-13)	5 (2-10)
No of practice nurses	3 (1-6)	3 (1-5)
IMD* score	30.35 (range 8.9 - 59.5)	30.20 (range 6.5 - 55)

*Index of Multiple Deprivation

Participants

182 patients were assessed for eligibility, of whom seven were excluded for not meeting the inclusion criteria (n=5), or declined to participate (n=2). 175 patients were randomised, of whom 95 were allocated to the intervention group and 80 to the control group. Six participants in the intervention group were lost to follow-up (3 died, 1 moved away and 2 withdrew their consent), and 2 participants in the control group were also lost to follow-up (1 died and 1 moved away). The results from 167 participants were analysed (89 interventions and 78 controls) (Figure 2).²⁴

Figure 2




Table 3 compares the socio-demographic and clinical profiles of patients between intervention and control groups. The mean age of the patients was 64.6 years (range 39 – 87). The patients in the intervention group and control group were broadly similar except that the patients in the intervention group were older and more likely to have coronary heart disease. In both groups the patients were more likely to consult nurses for diabetes related conditions than a doctor (mean number of consultations with nurses and GPs were 2.03 and 1.15 respectively). The mean length of the initial consultation for patients, when entering the

study, in the intervention and control groups was 15.31 and 16.95 minutes respectively (mean difference 1.67min, 95% CI 0.93 to 4.27 mins).

Table 3. Baseline patient socio-demographic and clinical information of the intervention and control groups (mean and range unless otherwise stated)

	Intervention	Control
Socio-demographic profile		
Number	95	80
Demography		
Age (years)	66 (39 – 82)	62 (42 – 87)
Male (%)	50 (52%)	46 (57%)
Duration of education (years) (SD)	12.22 (4.83) (8 – 45*)	11.49 (2.74) (2 – 22)
Ethnicity white (%)	85 (89.5%)	71 (88.8%)
Clinical profile		
Duration of diabetes (years) (SD)	8.4(4.1)(1 – 25)	7.07(3.83) (1 – 16)
HbA1c (IFCC HbA1c mmol/mol) in past 12 months (%) (SD)	8.6 {70}(1.9) (7.4 – 13.1){57-120}	8.8 {73}(0.98) (7.5 – 11.5){58-102}
Number with diabetic complications (%)		
Coronary Heart Disease	29/93 (31.1)	13/80 (16.2)
Peripheral vascular disease	3/93 (3.22)	3/80 (3.75)
Stroke	8/93 (8.6)	5/80 (6.25)
Retinopathy	20/93 (21.5)	10/80 (12.5)
Nephropathy	5/93 (5.37)	10/80 (12.5)
Neuropathy	5/93 (5.37)	3/80 (3.75)
Number with co-morbidities (%)		
Hypertension	58/93 (62.3)	43/80 (53.75)
Dyslipidaemia	52/93 (55.9)	38/80 (47.5)
Health Service Utilisation		
Number of diabetes-related visits to the general practice in the past 6 months (SD)		
General Practitioners	0.92 (1.13) (0-5)	1.41 (1.68) (0-11)
Nurse	2.15 (1.84)	1.89 (1.36)
Number of diabetes-related visits to the hospital in the past six months (SD)		
Length of consultation (min)	15.31 (2 – 39)	16.95 (5 – 45)

**** Self-report (this figure includes self taught continuing education outwith a formal educational programme).**

Decisional Conflict

The mean difference between the intervention and the control groups on the total score for decisional conflict was -7.72 (95% CI -12.5 to -2.97). The distribution of decisional conflict sub-scores are shown in Table 4. The total and subscores for every decisional conflict domain, apart from the support sub-score, were significantly lower in the intervention group. The difference in uncertainty, informed, value clarity and effective decision subscores between the intervention and control groups remained statistically significant after adjusting for differences in age, education and gender.

Table 4: Comparison of decisional conflict scores between the intervention and control groups (0=no decisional conflict, 100=maximum decisional conflict).

Subscore	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	95% CI p value
Uncertainty	20.1 (16.6)	29.4 (20.8)	-9.29	-8.72	-14.9 to -2.53 p=0.006
Informed	18.1 (13.3)	26.0 (16.6)	-7.65	-8.69	-13.3 to -4.10 p<0.001
Values Clarity	16.7 (13.9)	26.7 (18.2)	-9.74	-9.84	-14.8 to -4.84 p<0.001
Support	17.4 (13.1)	20.8 (15.3)	-3.41	-3.66	-8.58 to 1.25 p=0.144
Effective Decision	16.1 (14.4)	23.3 (15.2)	-9.70	-9.80	-16.8 to 2.75 p=0.006
Total Score	17.4 (12.6)	25.2 (14.9)	-7.67	-7.72	-12.5 to -2.97 p<0.001

* adjusted for clustering, insulin initiation, age, gender and education level

Glycosolated Haemoglobin (HbA1c)

Table 5 shows the HbA1c levels for both the intervention and the control groups at six months. HbA1c levels reduced in both groups at six months compared to baseline (0.24% in the control group and 0.37% in the intervention group). The mean difference in the HbA1c level at 6 months between the two groups was 0.351 (95%CI -0.088 to 0.789, p=0.117) after adjusting for age, education, gender, baseline HbA1c, insulin status and clustering.

Table 5: The effect of the PANDAs decision aid on HbA1c at 6 months

Intervention	Control	Mean	Mean	95% CI
--------------	---------	------	------	--------

		difference in HbA1c unadjusted	difference in HbA1c adjusted*	
8.64 (SD 1.37)	8.40 (SD 1.31)	0.244	0.351	-0.088 to 0.789

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering.
P=0.117

Secondary outcomes:

Knowledge

A comparison of the proportions of patients who answered the 'knowledge' questions correctly between the intervention and the control groups showed there were more patients in the intervention group who answered the questions correctly compared to those who received 'usual care'. (Table 6)

Table 6: Secondary outcomes: Knowledge and realistic expectations (Questions answered correctly)

	Intervention Decision Aid	Control Usual Care	Unadjusted Odds Ratio	Adjusted ⁺ Odds Ratio (95% CI)	ICC	p value
Knowledge						
Number	95	80				
Which choice has the greatest chance of lowering your blood sugar?	49 (51.6%)	23 (28.8%)	2.63	1.31 (1.14 to 1.50)	0.071	<0.001
Which choice has the greatest chance of lowering your complications?	29 (30.5%)	23 (28.8%)	1.09	1.20 (0.07 to 19.05)	0.202	0.90
Realistic expectations						
If you take insulin, about how many times might you experience 'hypos' in a year?	77/95 (81.0%)	4/75 (5.2%)	<u>75.9</u>	[^] —	-	<0.001 _*
If you take insulin, about how much more weight might you gain in a year?	67/95 (70.5%)	4/75 (5.3%)	<u>42.5</u>	[^] —	-	<0.001 _*
Out of 100 people like you who take insulin, how many may get complications in five years?	25/95 (26.3%)	4/80 (5%)	<u>6.8</u>	[^] —	-	<0.001 _*

⁺ adjusted for clustering, insulin initiation, age, gender and education level

[^] Numbers answering correctly in the control group were too few to control for clustering.

* Chi-squared p value

Realistic expectations

Patients who used the decision aid had significantly more realistic expectations about the side effects of insulin therapy compared to those who did not (Table 6). Almost all patients in the intervention group, compared to those of the control group, knew correctly their risk of hypoglycaemia (81.0% vs 5.2%, $p < 0.001$) and weight gain (70.5% vs 5.3%, $p < 0.001$). More people knew their risk of complications in the intervention group if they were to take insulin, although most still got it wrong (26.3% vs 5.0%, $p < 0.001$).

Preferred option

Table 7 shows that the preferred choices of patients in the intervention and control groups were similar after consultation.

Table 7: Preferred choices of patients in intervention and control groups post-consultation

	Make No Change	Follow the diabetes advice more regularly	Start insulin	I am not sure	Total
Control	33 (42.3.8%)	29 (37.1%)	9 (11.5%)	7 (9%)	78
Intervention	32 (34.7%)	38 (41.3 %)	17 (18.4%)	5 (5.4%)	92
Total	65	67	26	12	170

($\chi^2_3 = 2.88$, $p = 0.410$)

Proportion undecided

Table 8 shows that patients in the intervention group were over 3 times more likely to change from undecided to decided than in the control group, although, this was not statistically significant ($P = 0.15$).

Table 8: Comparison of the proportion of patients who remained undecided between the intervention and control group immediately after intervention

	Intervention	Control	OR	95%CI
Undecided (pre-consultation)	<u>23</u>	<u>14</u>		
Undecided (post-consultation)	<u>8*</u>	<u>9*</u>		
<u>Odds in favour of changing: undecided (pre) to decided (post)/ decided (pre) to undecided (post)</u>	<u>18/3**</u>	<u>11/6**</u>	3.27	0.69 to 16.3 (p=0.15)

* This figure of 8 patients includes 5 who remained 'undecided' post consultation and includes 3 patients who moved from 'decided' pre consultation to 'undecided' post consultation. Similarly for the 9 'undecided' post consultation patients in the control group, 3 remained 'undecided' and 6 had moved from 'decided' to 'undecided'.

**This ratio means that a total of 18 patients changed from 'undecided' to 'decided' in the intervention group and that 3 moved in the opposite direction (ie a net total of 15 patients [18 – 3] had 'decided' post consultation). In the control group the corresponding numbers were 11 and 6 (ie a net total of 5 patients [11 – 6] had 'decided' post-consultation).

Participation in decision making

There were significant differences in patients' decision making role between the intervention and control groups (p=0.012 Chi square) (Table 9). It may be seen that a smaller proportion of patients in the intervention group described their decision about their diabetes treatment as "passive" or "collaborative".

Table 9: Decision making roles of patients in the intervention and control groups, post consultation with their doctor/nurse

	How did you make your decision about your diabetes treatment? (n = 169)			
	Passive	Collaborative	Autonomous	Total
Control	16 (21%)	28 (36%)	33 (43%)	77 (100%)
Intervention	8 (9%)	25 (27%)	59 (64%)	92 (100%)

($X^2=8.9$, df=2, p=0.012)

However, patients in the intervention arm were more likely to demonstrate autonomy in their decision making about their treatment compared to the control group (64% compared to 43%). Further analysis showed that an individual patient was 1.23 (95% CI 1.05 to 1.44, $p=0.008$) times more likely to make an 'autonomous' decision using the PANDAs decision aid when the intervention and control groups are compared, allowing for age and gender.

Regret and persistence with decision

Table 10 shows that there was no difference at 6 months in the regret scale, but that patients in the intervention group were rather more likely to persist with their chosen option.

Table 10: Comparison of the decision Regret Score and persistence with chosen option between the intervention and usual care groups after six months

	Intervention	Control	Mean difference unadjusted	Mean difference adjusted*	p value
Regret Score	44.63	44.57	0.06	0.22 (-2.48 to 2.93)	0.872
Persistence with chosen option	68.1%	56.3%	1.65 [†]	1.17 [^] (1.00 to 1.36)	0.041

* adjusted for age, education, gender, baseline HbA1c, insulin status and clustering

[†]Crude odds ratio

[^]Adjusted odds ratio

Acceptability

Most of the PDA users found the PDA useful. When asked about their opinion of the PDA, 83.2% (n=88), 86.3% (n=89), 86.3% (n=89) and 88.4%(n=90) thought that the PDA had helped them: to recognize that a decision needs to be made; know that the decision depends on what matters most to them; think about how involved they wanted to be in the decision; and prepare to talk to the nurse or doctor about what mattered most to them', respectively.

Discussion

The PANDAs decision aid was designed to facilitate decision making between clinicians and their patients with T2DM who were taking at least two oral glucose-lowering drugs at maximum tolerated dose, had a high HbA1c level and were considering future treatment options including the introduction of insulin. Its evaluation was based on the IPDAS recommendations²⁵ and the use of the ODSF Framework.²⁶ The PANDAs trial provides good evidence not only for the clinical effectiveness of decision aids in usual NHS general practice but also for the utility and feasibility of use by both nurses and doctors. In addition, the PANDAs decision aid itself and its use were both effective and acceptable to people with diabetes making treatment choices during clinical consultations.

Decision quality

The findings from the PANDAs trial support the results of other studies which have evaluated the clinical effectiveness of decision aids^{11 15} in demonstrating an improvement in decision quality when a decision aid is used in clinical consultations.

Decisional conflict scores, for example, when adjusted for age, education and gender were significantly lower in the intervention group post consultation when compared to the controls, apart from the support sub-score. It is interesting to note that the support sub-score in the intervention group was not significantly lower than the control group - this may be the result of a 'ceiling effect' since patients in both the intervention and control groups may already have been receiving very good diabetes care from their general practices.

Other indicators of decision quality used in the study also demonstrated an improvement when PANDAs was used in consultations – there was, for example, a highly significant

1
2
3 difference in the knowledge of people which particular treatment choice had the greatest
4
5 chance of lowering blood sugar in those who used the decision aid - although this was not the
6
7 case when the chance of insulin in lowering complications was considered - here no
8
9 difference in knowledge was observed. Some patients believe that insulin itself causes
10
11 complications as a result of misperception^{27 28} and this may explain why knowledge did not
12
13 improve in the intervention group. However, highly significant differences were observed
14
15 between the intervention and control groups in all the three domains of realistic expectations
16
17 ['hypos', weight gain and complications] supporting the notion that the PANDAs decision
18
19 aid ensured that people were fully informed about the potential risks of each option when
20
21 making their treatment choices.
22
23
24
25
26

27
28 As far as autonomy was concerned, patients in the intervention arm were more likely to make
29
30 an autonomous decision using PANDAs when the intervention and control groups were
31
32 compared allowing for both age and gender. This is consistent with the findings of other
33
34 studies.^{29 30}
35
36
37

38
39 These findings of an improvement in decision quality when a decision aid is used in clinical
40
41 consultations in other conditions and contexts are also supported by a large number of other
42
43 studies.^{23 31}
44
45
46

47 **Decisional Outcomes**

48
49 The glycaemic control improved in both groups six months after the intervention although no
50
51 significant difference in glycaemic control was observed between the two groups. Some GPs
52
53 in the study expressed concern at the start of the trial that glycaemic control could deteriorate
54
55 in some patients in the intervention group as a result of them choosing not to start insulin.
56
57
58
59
60

1
2
3 Further study is necessary to confirm this as this study did not have sufficient power to detect
4
5 the difference in glycaemic control.
6
7

8
9
10 Treatment decisions made using a decision aid should, of course, be ones that are both
11 informed and value-based, and the PANDAs intervention was focussed on the process of
12 decision making rather than the outcomes of those decisions. It is therefore important to note
13 that PANDAs was not designed to persuade people to start treatment with insulin but to help
14 them make an informed treatment decision which was consistent with their values and
15 wishes.
16
17
18
19
20
21
22
23
24

25 Indeed, there was reduced decisional conflict within the intervention group compared to the
26 control and the decisions which were made were far more likely to be autonomous in nature
27 rather than passive. Participants in the intervention group were also significantly more likely
28 to persist with their chosen option at 6 months. This supports the hypothesis that people who
29 use a decision aid such as PANDAs are more likely to make an informed and value-based
30 decision and are therefore more likely to persist with their treatment choice. Concordance
31 with agreed treatment is, in turn, more likely to lead to better health outcomes and quality of
32 life.
33
34
35
36
37
38
39
40
41
42
43
44

45 No significant difference was observed on the regret scale scores and although people in the
46 intervention group were over three times more likely to change from undecided to decided
47 [ie come to a treatment decision after their consultation] in the control group, this difference
48 was not statistically significant.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Finally, no significant difference was observed in the preferred choices [ie the treatment
4 decision they came to] of the two groups although a higher proportion of people in the
5 intervention group did choose to initiate insulin. However it is important to note that the use
6 of a decision aid is not intended to produce a particular outcome but to support the patient
7 making a treatment choice based on their knowledge and values. These findings are also
8 consistent with current understanding of the anticipated decisional outcomes when a decision
9 aid such as PANDAs is used in clinical consultations to make treatment choices.³¹
10
11
12
13
14
15
16
17
18
19

20 **Impact on Clinical Practice**

21
22 The results of the PANDAs trial demonstrate that the use of the decision aid in usual general
23 practice by both practice nurses and GPs, provided the patient has the opportunity to
24 complete their individualised decision aid prior to their consultation, does not require
25 significant additional consultation time. Given the potential benefits of improved adherence
26 to treatment choices and an improved therapeutic relationship between clinicians and their
27 patients, this is likely to make the use of the decision aid acceptable to all parties in general
28 practice, although, its use may require some initial ‘investment’ in consultation time. In
29 particular, both clinician and patient satisfaction with their consultations, as well as the
30 healthcare provided and received, are both likely to be increased. A further potential
31 advantage is that the decision aid could be used by other clinical members of the primary care
32 team (eg healthcare assistants) potentially increasing the consultation time available to
33 doctors and nurses for other patients. However, the efficient use of the decision aid in
34 consultations may in part be attributed to the familiarity of the clinicians with the decision aid
35 as a result of the brief training clinicians received at entry to the trial. In addition, this may
36 also be due to the process by which the decision aid was developed with the active
37 involvement of both clinicians and people with diabetes to ensure that it was as ‘user
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 friendly' as possible. This involvement of users in the development of the decision aid and a
4
5 process evaluation of its use in the consultation by both parties has been described
6
7 elsewhere.³²
8
9

10 11 **Health service utilisation**

12
13 The PANDAs trial was a pragmatic one reflecting the reality of primary care diabetes clinics
14
15 which are mainly run by practice nurses. The mean number of consultations with the nurses,
16
17 for example, was greater than the mean number of consultations with the GPs and within the
18
19 intervention group patients were more likely to use the PANDAs decision aid with the
20
21 practice nurse than the GP. At baseline the distribution of the mean number of diabetes
22
23 related general practice visits was different in the intervention and control groups with the
24
25 practice nurses providing more clinical care to people with diabetes in the former reflecting
26
27 different patterns of care in the different practices.
28
29
30
31
32
33

34 **Patient decision aids**

35
36 The PANDAs decision aid is one of the few decision aids which focus on decision making in
37
38 chronic diseases, which take place over several consultations. According to the latest
39
40 Cochrane Decision Aid Inventory, 10 decision aids have been developed for diabetes.³¹ Four
41
42 decision aids focus on insulin treatment, of which two are for children, one for adults
43
44 deciding on premixed insulin and one for insulin initiation in T2DM (PANDAs decision aid).
45
46 However, unlike PANDAs, none have been developed for making treatment decisions about
47
48 glycaemic control.
49
50
51
52
53

54 Although decision aids have positive effects on many aspects of the decision making process,
55
56 there remains a large gap in the literature on how decision aids fare "in the real world".
57
58
59
60

1
2
3 O’Cathain and Thomas (2004) conducted a pragmatic trial of decision aid in a maternity ward
4
5 and found that health professional were not making use of the available decision aids,
6
7 although they reported that they approved of them. The reasons for not using them included
8
9 ‘disagreement’ with the available decision aids, lack of resources, perceived patients’
10
11 reluctance to participate and unwillingness to change their “routine care”.³³ O’Donnell,
12
13 Cranney et al, classified the barriers to the use of decision aids in the clinical situation under
14
15 three categories – the nature of the decision aid itself, the attitudes of patients and healthcare
16
17 professionals and organisational barriers such as institutional culture and commitment, time
18
19 constraint and costing.³⁴
20
21
22
23
24

25 A number of authors have proposed various strategies to facilitate such use of decision aids in
26
27 different clinical settings.³⁵ The effectiveness of these proposed strategies has not yet been
28
29 formally evaluated. The PANDAs trial however found the decision aid to be highly
30
31 acceptable to both clinicians and people with diabetes in NHS general practice – a detailed
32
33 process evaluation of its use can be found elsewhere. This report identifies some of the key
34
35 challenges to its widespread implementation in NHS general practice.
36
37
38
39

40 However, most studies of decision aids have not shown an increase in the level of satisfaction
41
42 with the decision making process or the decision itself. This may be another example of the
43
44 ‘ceiling effect’ whereby the satisfaction with the service or consultation was already high
45
46 before the intervention. It has also been observed that people tend to report satisfaction after
47
48 they have made the decisions because they tend to “rationalise” and adapt quickly to
49
50 uncertain events.³⁶ Moreover, the effect of decision aids on quality of life and health
51
52 outcomes indicators which are commonly used in health technology assessments, have yet to
53
54 be proved. More plausible intermediate outcomes, such as concordance with treatment and
55
56
57
58
59
60

1
2
3 health service utilisation, could be used as alternative indicators to evaluate the use of
4
5 decision aids.
6
7

8
9
10 General practice is a unique healthcare setting where multidisciplinary teams provide holistic,
11
12 comprehensive and continuity of care to people in the community. Practitioners usually have
13
14 an established relationship with their patient and an appreciation of their medical and
15
16 psychosocial background as well as their associated multi-morbid conditions. This puts them
17
18 in a very good position to advise patients on their treatment options. The use of decision aids
19
20 to facilitate treatment choices in general practice fits well with the adoption of a Care
21
22 Planning model for long-term conditions. This model of care, developed by the Diabetes UK
23
24 Year of Care Programme and recently adopted as a professional standard by the RCGP, is a
25
26 good way of ensuring that patients with diabetes are both fully informed and fully involved in
27
28 decisions about their care by supporting their “empowerment” and facilitating the
29
30 “activation” of people with long-term conditions.^{37 38}
31
32
33
34
35

36 **Implications for research and clinical practice**

37
38 For the use of patient decision aids, such as PANDAs, in routine clinical practice to become
39
40 the accepted norm, the new GP clinical commissioning groups will need to be aware of the
41
42 benefits of the use of such aids to ensure that decision aids become a professional standard in,
43
44 for example, newly commissioned pathways for a long-term condition such as diabetes.
45
46 Investment will also be necessary for the development and the continuing evaluation of
47
48 decision aid use, as well as for the training of all members of the multidisciplinary team in the
49
50 importance and in the practical use of decision aids in primary care. Both the patient’s
51
52 experience and patient/clinician satisfaction with the care received and provided is likely to
53
54 be much improved if this professional standard is adopted by commissioning groups.
55
56
57
58
59
60

Conclusions

The use of the PANDAs decision aid by health care professionals in usual NHS clinical practice with T2DM patients who are making treatment choices in general practice improves decision quality by reducing decisional conflict, improving knowledge and promoting realistic expectations but has no demonstrable effect on glycaemic control.

Patient autonomy however is strengthened by the use of the decision aid and longer term clinical outcomes are likely to be improved. A larger trial of the PANDAs decision aid will be necessary to determine if biomedical parameters are improved when the decision aid is used in normal NHS practice.

Strengths and limitations of this study

The study failed to achieve its planned sample size as a result of recruitment difficulties. The reasons for this were the increase in availability of new oral and injectable glucose lowering drugs (e.g. GLP1 agonists, exenatide) which were not available at the start of the project, significant staff changes in 2008/9 and the reluctance of practices to participate in the study because of a potential H1N1 flu pandemic in summer 2009. As a result each practice was only able to identify 3-5 eligible patients for inclusion in the trial. It proved impossible to secure a funded time-extension to the study and as a result recruitment ceased at 175 participants. This meant that the study was underpowered to detect a difference of 0.5% in HbA1c between the two groups. The original recruitment period was 12 months but because of the problems surrounding recruitment outlined above, recruitment was extended to 20 months. There was also some evidence of inadvertent recruitment bias with 95 participants allocated to the intervention group and 80 to the control group. This is an important and well recognised consequence of a cluster RCT design and is probably the result of the PANDAs practices being more likely to recruit participants to the trial. There were some differences in

1
2
3 baseline characteristics between the intervention and the control and these were included in
4
5 an analysis which explored how the estimates of the treatment effect changed when baseline
6
7 differences were controlled for.
8
9

10
11
12 **Contributorship statement:**

13
14 **Substantial contribution to conception and design, acquisition of data or analysis and**
15
16 **interpretation of data:**

17
18 NM, CJN, MCJ, BC, AB, IB
19

20
21 **Drafting the article or revising it critically for important intellectual content:**

22
23 NM, CJN, MCJ
24

25
26 **Final approval of the version to be published:**

27
28 NM, CJN, MCJ, BC, AB, IB

29
30 NM is the guarantor.
31
32

33
34 This article presents independent research funded by the National Institute for Health
35
36 Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference
37
38 Number PB-PG- 0906-11248), ISRCTN National Trials Register Number 14842077 and the
39
40 Sheffield Health and Social Care NHS Foundation Trust. The views expressed are those of
41
42 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
43
44
45

46
47 All authors have completed the Unified Competing Interest form at

48
49 www.icmje.org/doi_disclosure.pdf and declare that (1) NM, CJN, MC, BC, IB, AB have
50
51 support from the University of Sheffield for the submitted work; (2) NM, CJN, MC, BC, IB,
52
53 AB have no relationships with any companies that might have an interest in the submitted
54
55 work in the previous 3 years; (3) their spouses, partners or children have no financial
56
57
58
59
60

1
2
3 relationships that may be relevant to the submitted work; and (4) NM, CJN, MC, BC, IB, AB
4
5 have no none-financial interests that may be relevant to the submitted work.
6
7

8
9
10 “The Corresponding Author has the right to grant on behalf of all authors and does grant on
11
12 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
13
14 Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and
15
16 any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our
17
18 licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).”
19
20

21 22 23 24 25 **Acknowledgements**

26
27 Ethical permission to conduct the study was received from the North Sheffield Local
28
29 Research Ethics Committee (07/Q2308/53).
30

31
32 Expert specialist advice was received from Professor Simon Heller, University of Sheffield.
33

34 We thank Ms Rachel Dwyer for research support, and Dr Robert Dixon, Sheffield Care Trust,
35
36 Mr Robert Glendenning and Mr Ian Brown for managerial support.
37

38 Ms Sharon Hart, University of Sheffield, for administrative support.
39

40 Members of the PANDAs Advisory Group (Alicia O’Cathain, Hina Kanabar, Hugh
41
42 McCulloch, Maxine Johnson, Michelle Horspool, Mick Taylor, Sue Beveridge, Mary
43
44 MacKinnon).
45

46
47 Members of the Sheffield Diabetes UK Group
48
49

50
51
52 Particular thanks to all those doctors, nurses and people with diabetes for their contributions
53
54 without whom it would not, of course, have been possible to undertake the PANDAs trial.
55
56
57
58
59
60

References

1. Diabetes UK. Diabetes in the UK 2011/2012: Key statistics on diabetes.
<http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2011-12.pdf>
(accessed on 12 March 2012)
2. Diabetes.co.uk. Cost of Diabetes. <http://www.diabetes.co.uk/cost-of-diabetes.html>
(accessed on 12 March 2012)
3. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: Newer agents. London: NICE, 2009.
4. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;**352**:837-53.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). *JAMA* 1999;**281**:2005-12.
6. Fitzgerald JT, Vijan S, Stuart N. Insulin therapy and patient attitudes at two VA centers. *Diabetes* 2000;**49**:A445.
7. Lauritzen T, Scott A. Barrier to insulin therapy in type 2 diabetes: a qualitative focus group research among patients, GPs and diabetologists. *Eur Union Gen Pract Clin J* 2002;**3**:33-40.
8. Jeavons D, Hungin AP, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians' beliefs and attitudes. *Postgrad Med J* 2006;**82**:347-50.
9. Paling J. Strategies to help patients understand risks. *BMJ* 2003;**27**:745-8.
10. Siriwardena AN. Clinical guidelines in primary care: a survey of general practitioners' attitudes and behaviour. *Br J Gen Pract* 1995;**45**:643-7.
11. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2011;Issue 10. Art. No.: CD001431.
12. Colwell B, Mathers N, Ng CJ, Bradley A. Improving recruitment to primary care trials: some lessons from the use of modern marketing techniques. *Debate and Analysis Paper BJGP*. 2012; 62(602): 496-498. doi: 10.3399/bjgp12X654759.
13. Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:979-83.
14. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. *Science* 1981;**211**:453-8.
15. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. *Patient Educ Couns* 1998;**33**:267-79.

16. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;**15**:25-30.
17. Janis IL, Mann L. *Decision making: a psychological analysis of conflict, choice and commitment*. New York: Free Press, 1977.
18. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res* 1997;**29**:21-43.
19. Davidson BJ, Degner LF, Morgan TR. Information and decision making preferences of men with prostate cancer. *Oncol Nurs Forum* 1995;**22**:1401-8.
20. Kremer H, Ironson G. Measuring the involvement of people with HIV in treatment decision making using the Control Preference Scale. *Med Decis Making* 2008;**28**:899-908.
21. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. *Med Decis Making* 2003;**23**:281-92.
22. Kinmonth AL, Woodcock A, Griffin S, Spiegel N, Campbell MJ. Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. *BMJ* 1998;**317**:1202-8.
23. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. *BMJ* 2002;**325**:746-51.
24. Campbell MK, Elbourne DR, Altman DG for the CONSORT Group. CONSORT statement: extension to cluster randomised trials *BMJ* 2004;**328**:702-8.
25. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aid: online international Delphi consensus process. *BMJ* 2006;**333**:417-19.
26. Légaré F, O'Connor AM, Graham ID, Saucier D, Côté L, Blais J, et al. Primary health care professionals' views on barriers and facilitators to the implementation of the Ottawa Decision Support Framework in practice. *Patient Educ Couns* 2006;**63**:380-90.
27. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. *Diabetes Care* 2010;**33**:733-35.
28. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use *Diabetes Education* 2008;**34**:511-17.
29. Auvinen A, Vornanen T, Tammela TL, Ala-Opas M, Leppilähti M, Salminen P, et al. A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics. *BJU Int*. 2001;**88**:708-15.

- 1
2
3 30. Murray E, Davis H, Tai SS, Coulter A, Gray A, Haines A. Randomised controlled trial of
4 an interactive multimedia decision aid on benign prostatic hypertrophy in primary
5 care. *BMJ* 2001;**323**:493-6.
6
7 31. Cochrane Library. Cochrane Inventory of Patient Decision Aids.
8 <http://decisionaid.ohri.ca/cochinvent.php> (accessed on 12 March 2012)
9
10 32. Bradley A, Brown I, Ng CJ, Colwell B, N. M. Decision aids in patients with type 2
11 diabetes considering treatment options: Qualitative analysis of consultations and
12 interviews from the PANDAs study. *Diabet Med* 2011;**2**(S1)8:118.
13
14 33. O'Cathain A, Thomas, K. J. Evaluating decision aids--where next? *Health Expect*
15 2004;**7**:98-103.
16
17 34. O'Donnell S, Cranney, A., Jacobsen, M. J., Graham, I. D., O'Connor, A. M., Tugwell, P.
18 Understanding and overcoming the barriers of implementing patient decision aids in
19 clinical practice. *J Eval Clin Practice* 2006;**12**:174-81.
20
21 35. O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW, Sepucha
22 KR, et al. Toward the 'tipping point': decision aids and informed patient choice.
23 *Health Aff (Millwood)* 2007;**26**:716-25.
24
25 36. O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, et al. Decision Aids
26 for people facing health treatment or screening decisions. *Cochrane Database Syst*
27 *Rev* 2009;Issue 3. Art. No.: CD001431.
28
29 37. Wagner EH. Chronic disease management: what will it take to improve care for chronic
30 illness? *Eff Clin Pract* 1998;**1**:2-4.
31
32 38. Mathers N, Roberts S, Hodkinson I, Karet B. Care Planning: Improving the Lives of
33 People with Long Term Conditions. UK: Royal College of General Practitioners,
34 2011.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The
University
Of
Sheffield.

School
Of
Medicine
& Biomedical Sciences.

Practice Information Sheet

Study Title: 'PANDAs': Patient Decision Aids for Type 2 Diabetes
Protocol Ref: ZH25
Version: V6-06-08-2009

Part 1 tells you the purpose of this study and how your practice will be involved if you take part.

Part 2 gives you more detailed information about the conduct of the study.

Part 1

We would like to invite your practice to take part in a research study. This study will find out whether a patient decision booklet is useful for people with type 2 diabetes who need to make decisions about their diabetes treatment.

Before you decide whether your practice should participate, you need to understand why the research is being done and what it would involve. Please take time to read the following information carefully; talk to others about the study if you wish.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

1. What is the purpose of the study?

It is sometimes difficult for patients with Type 2 diabetes to make decisions about the treatment of their illness, especially when it involves taking additional medications or changing to another medication. Informed decision-making not only requires them to know the risks and benefits of the treatment, it also depends on how they feel and think about the treatment. Sometimes, they may not have had opportunity to discuss this information in detail with their doctor or nurse.

A Patient Decision Aid is a simple booklet which contains useful information on diabetes and its treatment. It also explores what patients feel and think about these treatments. It has been used widely to help people to make decisions about their specific illnesses, for example the menopause or a prostate problem.

So the purpose of this study is to find out whether using a patient decision aid before the GP's/Nurse's consultation will improve the quality of patients' decision-making and, eventually, their blood sugar control.

2. Why have I been invited?

Your practice is thought to have at least 1% of its practice population on a practice diabetes register.

3. Do I have to take part?

The participation of your practice is entirely voluntary and it is up to you to decide. We will describe the study and go through this information sheet with you when we visit your surgery if you invite us to do so. We will then ask you to sign a consent form to show you have agreed to take part.

4. What type of study is this?

This is a "Cluster Randomised Trial" in which practices which have consented to participate will be randomly allocated for their participating patients to be given the Patient Decision Aid or to the control group of practices in which normal diabetic practice will be followed.

5. What will happen to my practice if I take part?

If you agree to take part in this study, all GPs and one or two nurses in your practice will be given a *PANDAs* Training Package and the nurses will receive a brief training session at your practice, based on the package. If your practice has been randomised to the Patient Decision Aid, the package will be distributed immediately and this training will take place straightaway. Otherwise the package and training will be offered to your practice at the end of the study, if you wish to opt for this.

However the researchers will, before randomisation, have assisted the practice manager and nurses in how to identify eligible patients based on the following inclusion and exclusion criteria:

Inclusion criteria:

Patients with type 2 DM aged ≥ 21 who

- are taking the maximally tolerated dose of oral glucose-lowering drugs AND have a latest HbA1c $\geq 7.5\%$ throughout the last six months

OR

- have been advised to add or change to insulin therapy but declined previously AND have a latest HbA1c $\geq 7.5\%$.

Exclusion criteria:

Patients who:

- have a latest HbA1c $\geq 11\%$ unless they have previously declined insulin

- are currently using insulin therapy

- have chronic debilitating illness (including mental illness, visual or cognitive impairment)

- have difficulty understanding English or are unable to read or are without essential reading glasses at the time of consent

Your eligible patients will need to attend your normal clinic twice within six months for the purposes of the study.


1 A total of 446 people with type 2 diabetes will be invited to participate in the study
2 and up to 15 would be recruited from your practice until May 2009.


3
4
5 During the first visit, the researcher will go through the Participant Information Sheet
6 with patients. If they agree to participate, the researcher will ask them to sign a
7 consent form, and then to answer a questionnaire (10 minutes).
8

9
10 Depending on which treatment group your practice is put into, they will either receive
11 the Patient Decision Aid followed by a consultation with their GP/Practice Nurse or
12 just the consultation without the Patient Decision Aid. Going through the Patient
13 Decision Aid will take 15 minutes. After the consultation, all patients will be asked to
14 fill in another questionnaire (10 minutes).
15

16 During the second visit six months later, patients will be asked to answer a
17 questionnaire and a blood sample will be taken to assess their blood sugar level (5
18 minutes).
19

20 **Visit 1**



Visit 2**6. Expenses and payment**

The practice will receive £1,700 for set-up costs, including recruitment of the first consenting patient and then £50 per consenting patient thereafter, to compensate for costs of the time of all practice staff involved (practice manager, GPs, nurses and clerical officers)

At the end of the second visit, your patients will be given a £15 shopping voucher to compensate for the time they have taken to participate in this research.

7. What will the practice have to do?

A one-hour training session will be held at your practice for nurses (and GPs if they wish) on how to use the Patient Decision Aid. For practices in the intervention group this will be given immediately after the practice consents. For practices in the Control group this training will be available on request at the end of the trial.

Each practice will identify 15 eligible participants from the diabetes register and invite them to participate by telephone or mail.

Patients will attend a normal scheduled appointment at a diabetes clinic or a specially allocated appointment if the practice is willing. This appointment will, for practices in the intervention group, be after the proposed date for practice training and no later than 30 June 2009, the proposed closing date for recruitment of patients.

In the intervention group, the participants will use the Patient Decision Aid with the Nurse's assistance.

A questionnaire will be completed for each patient, but the researchers will administer that at your practice.

The GP or Nurse will then counsel the participants as in usual practice.

There will be a follow-up visit at 6-months to check the participants' HbA1c.

Your patients will be required to attend your clinic twice in six months during the study.

During their first visit, they will have to read the Patient Decision Aid, and answer a questionnaire before and after their routine consultation with the Doctor/Nurse. During the second visit, they will have to answer a questionnaire and a blood sample will be taken.

8. What is the procedure that is being tested?

We are testing the use of the Patient Decision Aid, which is a booklet containing evidence-based information about diabetes and its treatment options. It also contains questions which explore their ideas, concerns and values regarding the treatment. So far, more than 500 Patient Decision Aids have been developed in the world for various medical conditions to help patients with their decision-making. It is used to supplement GP- or nurse-led consultations .

9. What are the possible disadvantages and risks of taking part?

The Patient Decision Aid contains information about the possible side effects of different treatment options. Some people may feel anxious after reading this information. However, practice staff and/or the researchers will be able to answer any queries or concerns patients may have during and after the study.

10. What are the possible benefits of taking part?

Previous research on other medical conditions has shown that the use of Patient Decision Aids has helped people to make better-informed decisions about their treatments.

11. What happens when the research study stops?

The practice will continue to provide usual medical care.

12. What if there is a problem?

Any complaint about the way patients have been dealt with during the study or any possible harm they might suffer will be investigated. The detailed information on this is given in Part 2.

13. Will participation of patients in the study be kept confidential?

Yes. We will follow ethical and legal practice and all information about patients will be handled in confidence. The details are included in Part 2.

14. Is the purpose of this study educational?

Yes. Part of the data from this research will be used for a PhD study.

**This completes Part 1.
If the information in Part 1 has interested your practice
and you are considering participation, please read the
additional information in Part 2 before making any
decision.**

Part 2**15. What if relevant new information becomes available?**

Sometimes we get new information about the intervention being studied. If this happens, the researcher will tell the practice and then the study patients and discuss with them whether they should continue in the study. If patients decide not to carry on, they will be told that their care will be continued by your practice. If they decide to continue in the study, the researcher may ask them to sign an updated consent form.

If the study is stopped for any other reason, we will tell the practice and study patients. The practice will then continue the care of the study patients. The researchers will also keep practices and study patients informed of any new alternative treatment available for their diabetes care.

16. What will happen if patients don't want to carry on with the study?

Patients can withdraw from the study without giving a reason and without it affecting their care. The practice and its patients are also welcome to keep in contact with us to let us know of progress. Information already collected may still be used. Any stored blood samples that can still be identified as yours will be destroyed if you wish.

17. What if there is a problem?

If patients have a concern about any aspect of this study, they should ask to speak to the researchers who will do their best to answer their questions (Contact Brigitte Colwell/Rachel Dwyer at: 0114 271 5824/0114 226 9773 OR Professor Nigel Mathers at: 0114 271 5922). If they remain unhappy and wish to complain formally, they can do this through the NHS Complaints Procedure. Details can be obtained from the GP or the local Primary Care Trust.

In the event that something does go wrong and patients are harmed during the research and this is due to someone's negligence, then patients may have grounds for a legal action for compensation against the NHS but may have to pay their legal costs. The normal National Health Service complaints mechanisms will still be available to study patients.

18. Will patients' participation in this study be kept confidential?

Only the GP/Practice Nurse will have access to patients' medical records. All information collected will be coded and anonymised. The information we have collected as paper copies will be stored under lock and key, while the electronic data can only be accessed with a secure password. Only the researchers, sponsors, regulatory authorities and Research & Development auditors will have access to the identifiable data.

The data we collect will be used only for the purpose of this research; if data were to be used for future studies, further Research Ethics Committee approval will be sought. The data will be kept for 20 years according to the Medical Research Council guidelines.

1 All information which is collected about patients during the course of the research
2 will be kept strictly confidential, and any information about patients which leaves
3 the surgery will have their name, telephone and address removed so that they
4 cannot be recognised.
5
6

7 **19. Involvement of the practice**

8
9 Patients will be told that the practice has been informed about their participation
10 in this study.
11

12 **20. What will happen to any samples patients give?**

13
14 The blood sample patients give will be used to check their HbA1c as part of their
15 routine care.
16

17
18 The blood sample will be collected and sent to a standard laboratory through the
19 surgery. Only the researchers, GPs/Practice Nurse and the laboratory staff will
20 have access to the blood results. An appointment will be arranged by the practice
21 to provide feedback regarding patients' blood results.
22
23

24 **21. What will happen to the results of the research study?**

25
26 The results of this study will be published in medical journals. A summary of the
27 results will be sent to the practice and to study patients by post and you and they
28 will be invited to attend a public seminar.
29
30

31 Patients will not be identified in any report, publications or presentation without
32 seeking their full consent.
33

34 **22. Who is organising and funding the research?**

35
36 Sheffield Health and Social Research Consortium is the sponsor of this study and
37 the Department of Health will be funding it. Patients will be told that the practice
38 will be compensated for its costs of including them in this study.
39
40

41 **23. Who has reviewed the study?**

42
43 This study has been reviewed and given favourable opinion by North Sheffield
44 NHS Research Ethics Committee and scientifically reviewed by Sheffield Health
45 and Social Research Consortium as well as the Research for Patient Benefit
46 funding stream of the National Institute for Health Research. Research
47 governance approval on behalf of Sheffield Primary Care Trust has been given by
48 Sheffield Health and Social Research Consortium.
49
50

51 **24. Further information and contact details.**

52 *General Information about research*

53
54 Patients and the practice can visit the following web site to obtain more general
55 information about research:
56

57 INVOLVE – Promotes public involvement in the NHS: <http://www.invo.org.uk>
58

59 National Electronic Library for Health:
60

1 <http://www.library.nhs.uk/trials>

2
3
4 *Specific information about this research project*

5
6 Ms Brigitte Colwell
7 Academic Unit of Primary Medical Care
8 University of Sheffield
9 Sam Fox House
10 Northern General Hospital
11 Herries Road
12 Sheffield
13 S5 7AU

14
15
16 Tel: 0114 2715824
17 Fax: 0114 2422136
18 Email: b.colwell@sheffield.ac.uk

19
20
21 *Advice to your patients as to whether they should participate*

22
23 Rachel Dwyer
24 Academic Unit of Primary Medical Care
25 University of Sheffield
26 Sam Fox House
27 Northern General Hospital
28 Herries Road
29 Sheffield
30 S5 7AU

31
32
33 Tel: 0114 2269773
34 Fax: 0114 2422136
35 Email: rachel.dwyer@sheffield.ac.uk

36
37
38 *Who should patients approach if unhappy with the study*

39
40 *The Chief Investigator:*
41 Professor Nigel Mathers
42 Academic Unit of Primary Medical Care
43 University of Sheffield
44 Sam Fox House
45 Northern General Hospital
46 Herries Road
47 Sheffield
48 S5 7AU

49
50
51 Tel: 0114 2715922
52 Fax: 0114 2422136
53 Email: n.mathers@sheffield.ac.uk

54
55
56 OR

57
58
59 Using the NHS Complaint Procedures, which you can obtain from the surgery or your
60 local NHS Primary Care Trust. You can visit the following web site for more details:
<http://www.nhs.uk/England/AboutTheNhs/ComplainCompliment.cmsx>



The
University
Of
Sheffield.

School
Of
Medicine
& Biomedical Sciences.

Participant Information Sheet

Study Title: Patient Decision Aid for Type 2 Diabetes
Protocol Ref: ZH25
Version: V3-22/04/07

Part 1 tells you the purpose of this study and what will happen to you if you take part.

Part 2 gives you more detailed information about the conduct of the study.

Part 1

We would like to invite you to take part in a research study. This study will find out whether a patient decision booklet is useful for people with type 2 diabetes who need to make decisions about their diabetes treatment.

Before you decide whether to participate, you need to understand why the research is being done and what it would involve. Please take time to read the following information carefully; talk to others about the study if you wish.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

1. What is the purpose of the study?

It is sometimes difficult to make decisions about the treatment of your illness, especially when it involves taking additional medications or changing to another medication. Informed decision-making not only requires you to know the risks and benefits of the treatment, it also depends on how you feel and think about the treatment. Sometimes, you may not have had opportunity to discuss this information in detail with your doctor or nurse.

A Patient Decision Aid is a simple booklet which contains useful information on diabetes and its treatment. It also explores what you feel and think about these treatments. It has been used widely to help people to make decisions about their specific illnesses, for example menopause or prostate problem.

Therefore, the purpose of this study is to find out whether using a patient decision aid before the GP's/Nurse's consultation will improve the quality of your decision-making and, eventually, your blood sugar control.

2. Why have I been invited?

Your GP/Practice Nurse has read through your medical notes and they found that your blood sugar is not well controlled. You might need a change in your treatment and this will involve you making a decision what you want to do to improve your blood sugar control.

A total of 446 people with type 2 diabetes will be invited to participate in the study.

3. Do I have to take part?

Your participation is entirely voluntary and it is up to you to decide. We will describe the study and go through this information sheet with you when you attend the clinic. We will then ask you to sign a consent form to show you have agreed to take part. You are free to withdraw at any time, without giving a reason. This would not affect your treatment or the standard of care you receive.

4. What type of study is this?

This is a "Randomised Trial". Sometimes we don't know which way of treating patients is best. To find out, we need to complete different treatments. We put people into groups and give each group a different treatment. The results are compared to see if one is better. To try to make sure the groups are the same to start with, patients from each practice are put into a group by chance.

5. What will happen to me if I take part?

If you agree to take part in this study, you will attend your normal clinic twice within six months. These visits, as far as possible, will coincide with your routine follow-up.


During the first visit, the researcher will go through the Participant Information Sheet with you. If you agree to participate, the researcher will ask you to sign a consent form, followed by answering a questionnaire (10 minutes).

Depending on which treatment group you are put into, you will either receive the Patient Decision Aid followed by a consultation with your GP/Practice Nurse or just the consultation without the Patient Decision Aid. Going through the Patient Decision Aid will take 15 minutes. After the consultation, you will be asked to fill in another questionnaire (10 minutes).


Six months later you will be contacted by a member of the PANDAs research team, prior to being sent a postal questionnaire for you to complete and return to us. We will also need a recent blood sugar level reading, which might mean that you will need to visit your practice to have this done.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Visit 1



Visit 2



6. Expenses and payment

When we have received your completed questionnaire, you will be sent a £15 shopping voucher to compensate for the time you have taken to participate in this research.

7. What will I have to do?

You are required to attend your clinic twice in six months during the study.

During the first visit, you will have to read the Patient Decision Aid, and answer a questionnaire before and after your routine consultation with the Doctor/Nurse. During the second visit, you will have to answer a questionnaire and a blood sample will be taken.

You should not participate in this research if you are currently involved in other drug studies, or have been in the past one-year.

8. What is the procedure that is being tested?

We are testing the use of the Patient Decision Aid, which is a booklet containing evidence-based information about diabetes and its treatment options. It also contains questions which explore your ideas, concerns and values regarding the treatment. So far, more than 500 Patient Decision Aids have been developed in the world for various medical conditions to help patients with their decision-making. It is used to supplement consultations with the doctors and nurses.

9. What are the possible disadvantages and risks of taking part?

The Patient Decision Aid contains information about the possible side effects of different treatment options. Some people may feel anxious after reading this information. However, your GP or nurse as well as the researchers will be able to answer any queries or concerns you may have during and after the study.

10. What are the possible benefits of taking part?

Previous research on other medical conditions has shown that the use of Patient Decision Aids has helped people to make better-informed decisions about their treatments.

11. What happens when the research study stops?

Your GP/Practice Nurse will continue to provide medical care for you.

1
2
3
4
5
6
7
8
9

12. What if there is a problem?

Any complaint about the way you have been dealt with during the study or any possible harm you might suffer will be looked into. The detailed information on this is given in Part 2.

13. Will my taking part in the study be kept confidential?

Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. The details are included in Part 2.

14
15
16
17
18
19
20
21
22
23

14. Is the purpose of this study educational?

Yes. Part of the data from this research will be used for a PhD study.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This completes Part 1.
If the information in Part 1 has interested you and you
are considering participation, please read the additional
information in Part 2 before making any decision.

Part 2**15. What if relevant new information becomes available?**

Sometimes we get new information about the intervention being studied. If this happens, the researcher will tell you and discuss whether you should continue in the study. If you decide not to carry on, your care will be continued by your GP. If you decide to continue in the study, the researcher may ask you to sign an updated consent form.

If the study is stopped for any other reason, we will tell you and your GP will continue your care. We will also keep you informed of any new alternative treatment available for your diabetes care.

16. What will happen if I don't want to carry on with the study?

You can withdraw from the study without giving a reason and without affecting your care. You are also welcome to keep in contact with us to let us know your progress. Information already collected may still be used. Any stored blood samples that can still be identified as yours will be destroyed if you wish.

17. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions (Contact Ms Brigitte Colwell at: 0114 2715824 OR Professor Nigel Mathers at: 0114 2715922). If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from the GP or the local Primary Care Trust.

In the event that something does go wrong and you are harmed during the research and this is due to someone's negligence, then you may have grounds for a legal action for compensation against the NHS but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you.

18. Will my taking part in this study be kept confidential?

Only your GP/Practice Nurse will have access to your medical records. All information will be coded and anonymised. The information we have collected as paper copies will be stored under lock and key, while the electronic data can only be accessed with a secure password. Only the researchers, sponsors, regulatory authorities and Research & Development auditors will have access to the identifiable data.

The data we collect will be used only for the purpose of this research; if data were to be used for future studies, further Research Ethics Committee approval will be sought. The data will be kept for 20 years according to the Medical Research Council guidelines.

1 All information which is collected about you during the course of the research will
2 be kept strictly confidential, and any information about you which leaves the
3 surgery will have your name, telephone and address removed so that you cannot
4 be recognised.
5
6
7

8 **19. Involvement of the General Practitioner/Family doctor (GP)**
9

10 Your GP has been informed about your participation in this study.
11
12

13 **20. What will happen to any samples I give?**
14

15 The blood sample you give will be used to check for your sugar control (HbA1c).
16 This is part of your normal routine care.
17
18

19 The blood sample will be collected and sent to a standard laboratory through the
20 surgery. Only the researchers, GPs/Practice Nurse and the laboratory staff will
21 have access to the blood results. An appointment will be arranged by the practice
22 to provide feedback regarding your blood results.
23
24

25 **21. What will happen to the results of the research study?**
26

27 The results of this study will be published in medical journals. A summary of the
28 results will be sent to you by post and you will be invited to attend a public
29 seminar.
30
31

32 You will not be identified in any report, publications or presentation without
33 seeking your full consent.
34
35

36 **22. Who is organising and funding the research?**
37

38 The Sheffield Health and Social Research Consortium is the sponsor of this study
39 and the Department of Health will be funding the research. Your healthcare
40 providers will be paid for including you in this study.
41
42
43
44

45 **23. Who has reviewed the study?**
46

47 All research in the NHS is looked at by an independent group of people, called a
48 Research Ethics Committee to protect your safety, rights, well-being and dignity.
49 This study has been reviewed and given favourable opinion by North Sheffield
50 Local Research Ethics Committee.
51
52
53
54
55
56
57
58
59
60

24. Further information and contact details.

General Information about research

You can visit the following web site to obtain more general information about research:

INVOLVE – Promotes public involvement in the NHS: <http://www.invo.org.uk>

National Electronic Library for Health:
<http://www.library.nhs.uk/trials>

Specific information about this research project

Ms Brigitte Colwell
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715824
Fax: 0114 2715915
Email: b.colwell@sheffield.ac.uk

Advice as to whether you should participate

Ms Brigitte Colwell
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715824
Fax: 0114 2715915
Email: b.colwell@sheffield.ac.uk

Who you should approach if unhappy with the study

Professor Nigel Mathers
Academic Unit of Primary Medical Care
University of Sheffield
Sam Fox House
Northern General Hospital
Herries Road Sheffield
S5 7AU

Tel: 0114 2715922
Fax: 0114 2715915
Email: n.mathers@sheffield.ac.uk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

OR

Using the NHS Complaint Procedures, which you can obtain from the surgery or your local NHS Primary Care Trust. You can visit the following web site for more details:
<http://www.nhs.uk/England/AboutTheNhs/ComplainCompliment.cmsx>

For peer review only